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ABSTRACT 
D-lactic acidosis (DLA) is a disease associated with D-lactatemia, acidosis and 
neurological signs.  However, these associations are ill-defined.  Bacterial fermentation in 
the intestine causes increasing D-lactic acid concentrations in the body.  Therefore, DLA 
is reported secondary to gastrointestinal diseases, such as short bowel syndrome, 
gastroenteritis or diarrhea.  Despite intestinal origin, sudden D-lactatemia is often a result 
of impaired D-lactate metabolism in the body. 
Aims of this work were to determine: 1) Influence of the presence of D-lactate or 
acidity on neurological disturbances; 2) Effectiveness of parenteral NaHCO3 therapy in 
correcting cerebrospinal acidity and DLA; 3) Prevalence of DLA in diarrheic lambs and 
fecal D-lactate thresholds; 4) Effectiveness of malate in preventing DLA.   
The methodological tools consisted of animal models (calves and lambs): 1) 
Advanced surgical procedure in calves for long-lasting atlanto-occipital catheterizations; 
2) Intravenous infusions of acids to experimentally induce acidosis; 3) Intravenous 
NaHCO3 therapies; 4) Sampling of cerebrospinal fluid (CSF), blood, urine and feces from 
experimental / treated calves or diarrheic lambs for blood gas analysis, and D-lactate 
separation by chromatography.  
D-lactate entered the central nervous system (> 2 mmol/L) from the circulation 
following experimentally induced D-lactatemia (> 5 mmol/L) and was responsible for 
neurological disturbances which correlated (r = 0.9, P < 0.05) with both CSF and serum 
D-lactate concentrations.   A zenith of neurological disturbances, ataxia was evident when 
D-lactate concentration exceeded 12 mmol/L (CSF) and 26 mmol/L (serum), however, a 
nadir of acidosis (pH 6.9) caused by HCl infusions produced only mild neurological 
disturbances (P < 0.05).  Therapeutic NaHCO3 infusions did not result paradoxical CSF 
acidosis, but supportive in correcting (P < 0.05) acidosis (ΔpH + 0.11) and D-lactatemia in 
calves.   
In lambs, metabolic acidosis following a range of mild to severe diarrhea was 
observed with a corresponding range of D-lactate concentrations in both serum (< 
0.05−24.0 mmol/L) and feces (< 0.05−31.0 mmol/L).  D-lactate was absorbed into the 
circulation when the fecal D-lactate concentration exceeded 10.2 mmol/L (threshold).   
In calves, moderate oral use of malate produced a > 50% (P < 0.05) decrease in 
fecal and serum D-lactate concentrations suggesting prebiotic properties to prevent DLA.   
This dissertation answers the critical questions about the onset of neurological 
signs in D-lactic acidosis, and advances the current knowledge on the metabolism of D-
lactate, the prevention and treatment of acidosis. 
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"Not everything that counts can be counted, and not 
everything that can be counted counts." 
 
~~~ Albert Einstein (1879-1955) ~~~. 
 
   
  
 
 
 1 
  
 
1 INTRODUCTION 
1.1 Rationale 
Bacterial fermentation in the gastro-intestinal system (rumen or colon) produces D-
lactic acid which is responsible for D-lactic acidosis (DLA), a disease common in humans and 
animals.  DLA is found secondary to gastrointestinal diseases in monogastrics with short 
bowel syndrome, gastroenteritis or other diarrheic diseases.  Ruminants are also vulnerable to 
DLA related to the above pathological conditions during calf-hood and with grain over-
feeding at any age.  DLA is associated with nervous symptoms and the severity of the disease 
depends on the concentration of D-lactate found in blood.  Onset of clinical metabolic DLA 
occurs when the serum levels of D-lactic acid are greater than 2 mmol/L (Ewaschuk et al. 
2002).  Biologically significant D-lactate accumulations in the body are often subsequent to a 
combination of impaired metabolism and excretion.  The mechanism(s) for neurological 
disturbances in DLA are not clear and may be due to direct neurotoxic effects of D-lactate; 
although other compounds may also be important. 
Diarrhea is a common neonatal disease in many animals and human and has strong 
association with other complications.  Viral diarrhea is the main cause of concern in neonatal 
calves in many countries.  Juvenile diarrhea is a significant problem in humans, as well as in 
animal agriculture, and can cause death in infants.  With the occurrence of dehydration due to 
diarrhea, or any other cause, excretion and elimination of D-lactic acid is impeded and 
acidosis aggravated.  The cause of death may be a result of dehydration, high anion gap, 
acidosis or D-lactic acid toxicity.  Therefore the control of DLA is very important to minimize 
the lethal metabolic acidosis in infants regardless of the species.  Research experiments 
conducted on DLA seem to be rather limited (Ewaschuk et al. 2005; Petersen 2005). 
Since the therapeutic use of antibiotics in diarrhea (and acidosis) has some 
controversial aspects, a better therapeutic approach could be to use probiotics or prebiotics.  
These could reduce the risk of development of antibiotic resistant bacteria.  One aim in this 
thesis is to identify probiotic and prebiotic methods of controlling D-lactic acid production in 
the calf gut, particularly in calves with a damaged gastrointestinal tract.  Manipulating the gut 
microbial flora by introducing competitive inhibitors of D-lactic producers, feeding microbes 
that utilize lactate or providing compounds such as malic acid (C4H6O5) which enhances the 
removal of lactate are approaches which which could be used to control D-lactic acid 
production.  Consideration of renal clearance is also very important, as it permits the effects of 
dehydration, which are usually associated with diarrhea, on D-lactic acid clearance and in 
predisposing to lethal acidosis to be determined.  The study findings would inform the 
treatment of diseased humans and animals, improve the prognosis for cases of diarrhea and 
gastroenteritis, and prevent the onset of DLA in susceptible humans and animals. 
DLA is mainly a consequence of poor gastrointestinal health and dysbiosis.  When 
the rumen or colon microbial environment is disturbed due to the entry of highly fermentable 
food materials, bacterial fermentation results in excessive production of D-lactic acid. Hence 
enteropathies, diet, species, and age predispose to the occurrence of DLA.  Prevention and 
treatment approaches are case dependant; history, nutrition, age and the type or nature of 
   
  
 
 
 2 
  
 
gastrointestinal disease should all be taken into consideration.  Dietary management is key to 
prevention of DLA. Correct, quick diagnostic procedures (serum D-lactate concentrations) and 
appropriate treatment strategy (depending on the case) to reduce neurological signs will be 
useful to avoid life threatening sequalae.  There are a number of clinically oriented case 
studies (Lorenz and Vogt 2006; Petersen 2005; Uribarri et al. 1998).  However, controlled 
experimentation is limited.  Therefore, further investigations are needed to understand the 
mechanism of neuropathy, and to investigate novel possibilities for control, prevention and 
treatment. The mechanisms resulting in neurological signs, metabolism of D-lactate in the 
body compartments, effective treatment and control measures for DLA are yet to be 
discovered. 
 
1.2 Hypothesis 
This research project tested the following hypotheses. 
 
• Experimental model studies: 
 
I.       Increasing serum D-lactate (D-lactatemia) increases cerebrospinal fluid (CSF) D-lactate 
and correlates with neurological depression. 
II. Rapid bicarbonate infusion to correct acute acidosis may produce paradoxic CSF 
acidemia. 
 
•            Clinical studies: 
 
III. D-Lactate in feces, serum and urine may be increased in lambs with diarrhea. 
IV. Malate reduces lactate producing bacteria and increases lactate-utilizing bacteria in the 
hind gut, and hence reduces D-lactate in feces (gut) and serum, and protects calves against 
DLA. 
 
1.3 Objectives 
  The objectives of this research project are mentioned under each study. 
 
• Experimental model studies: 
 
I. Mechanistic (metabolism) acid infusion study 
This study investigated the effect of different acids including DL-lactic acid (DL-
LA), L-lactic acid (L-LA) and hydrochloric acid (HCl) on blood, CSF, and neurological 
manifestation / depression.  The specific objectives were   
1) To determine and compare the influence of acidosis and D-lactatemia on blood and CSF 
parameter changes. 
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2) To determine whether neurological disturbances are caused by increased acidity or by D-
lactate accumulation in serum and CSF. 
 
II. Short term therapeutic infusions of bicarbonate and the effect on CSF acid-base 
status [Pradoxic bicarbonate therapy trial] 
This study investigated paradoxic acidosis in CSF during systemic acid infusions, 
and paradoxic acidity in CSF with rapid and slow rate bicarbonate treatment of acidemia. The 
specific objectives were: 
1) To determine the effect of rapid versus slow NaHCO3 therapy on CSF acidosis in 
experimentally induced acidosis by DL-lactic acid (DL-LA) or hydrochloric acid (HCl). 
 
• Clinical studies: 
 
III. Incidence of D-lactic acidosis in diarrheic lambs 
This study investigated the incidence of DLA in diarrheic lambs in the University 
Sheep Barn.  
1) To determine the incidence of fecal D-lactic acidosis and prevalence of metabolic acidosis 
secondary to diarrhea in lambs. 
 
IV. Use of sodium malate as a prebiotic to prevent D-lactic acidosis 
This study investigated the optimal use of sodium malate (food grade) administered 
orally to reduce D-lactate concentrations in calf feces, blood and urine.  The specific 
objectives were 
1) To determine the ability of malate to reduce D-lactate concentrations in fecal, urine and 
blood matrices. 
2) To determine the effect of malate on blood pH, bicarbonate (HCO3-), base excess, gasses, 
hemoglobin (Hb), chloride (Cl-) and cations (Na+, K+, Ca++) 
3) To evaluate the calves for signs of toxicity. 
4) To determine an appropriate oral dose for beneficial responses in calves. 
 
1.4 Structure of thesis 
This dissertation on D-lactate metabolism and control of acidosis is a multifaceted 
research study that investigates several aspects of DLA using experimental mechanistic model 
studies and clinical therapeutic studies.  The study had many phases including the surgical 
preparation of experimental animal models, acid infusion experiments, neurological 
examinations, sample collections from calves, acidosis correction by an alkali, laboratory 
analyses, a clinical exploration of DLA in lambs, and a therapeutic approach with prebiotic in 
calves.  
Chapter 2 is a review of literature. The review begins with a general overview of 
acidosis providing a basis for understanding metabolic acidosis, lactic acidosis and DLA.  
Chemistry of lactic acid, formation, metabolism and elimination are discussed as a 
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pathophysiological basis for understanding DLA connected to gastrointestinal ailments. 
Analytical procedures leading to diagnosis are also detailed.  
Two experimental model investigations; D-lactate neurotoxicity and effective use of 
bicarbonate therapy are presented in Chapter 3.   
Chapter 4 consisted of clinical studies of the incidence of lamb DLA and prebiotic 
use in control of DLA. 
Chapter 5 contains an overall discussion of the major findings of this research and 
the future scope for related work. 
The conclusions of my overall study are that D-lactate produces neurotoxicity when 
its concentration increases in the body.  The common alkali, NaHCO3 infusion therapy is safe 
in the treatment of DLA and metabolic acidosis.  Short term lamb diarrhea did not cause DLA.  
An appropriate dose of malate can be fed to avoid the onset of DLA in calves.  
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2 LITERATURE REVIEW 
2.1 Acidosis, lactic acidosis and D-lactic acidosis: An overview 
Acidosis is increased H+ ion (proton) concentration in the body (Evans 1986; Fall 
and Szerlip 2005; Kreisberg 1980; Owens et al. 1998; Robergs et al. 2004; Stern 1994).  It 
may be a result of excessive production of protons, impaired elimination of protons or 
excessive loss of bicarbonate.  Metabolic acidosis is diagnosed based on an increased base 
excess, which is accompanied by decreased blood bicarbonate, and possibly an increased 
anion gap (Berchtold et al. 2005; Bongaerts et al. 1997; Ewaschuk et al. 2005; Fall and 
Szerlip 2005; Uribarri et al. 1998).  Acidemia means abnormal acidity of the blood; it can 
be measured by analyzing a venous or arterial blood sample for pH and commonly used 
marker for acidosis.  The major parameters used to quantify acidosis are arterial blood pH, 
bicarbonate, base excess, carbon dioxide (PCO2), oxygen (PO2) and anion gap (Astrup et al. 
1966; Gossett et al. 1990; Omole et al. 2001; Patra et al. 1993).  Blood electrolytes and 
serum organic acids may be helpful in diagnosing the type of acidosis which may in turn be 
useful in selection of treatment (Severinghaus 2002; Zwart et al. 1987).  Acidosis can be 
found in many body fluids or tissues. Assessment of acidosis in peritoneal and 
cerebrospinal fluids is clinically useful.  Measuring organic acid concentrations in the 
blood helps identify the cause of acidosis.  Acidosis may cause many deleterious effects on 
the body tissues and systems.  
Acidemia is a common problem in humans and animals (Editorial. 1990; Evans 
1985; Ewaschuk et al. 2002; Ewaschuk et al. 2005; Gossett et al. 1990).  In diarrheic 
calves, the severity of acidemia correlates with neurological depression (Gentile et al. 
2004; Naylor 1989).  Lactic acidosis is a specific form of metabolic acidosis containing 
elements of acidemia and hyperlactatemia.  Lactatemia means high lactate concentrations 
found in the blood.  Propionate concentrations are increased in propionic acidemia and keto 
acidosis (Benoist et al. 2003; Robergs et al. 2004).  
L-lactic acidosis most frequently occurs during strenuous exercises, or due to 
hypoxia (Robergs et al. 2004; Stern 1994).  L-lactate concentrations are increased in lactic 
acidosis in the body compartments.  An impaired activity of lactate dehydrogenase enzyme 
activity is a rare cause of L-lactic acidosis.  L-lactate may also result from intestinal 
bacterial production (Crichlow and Chaplin 1985; Ewaschuk et al. 2003; Omole et al. 
2001).  
In contrast to L-lactic acidosis, D-lactic acidosis (DLA) is characterized by D-
lactatemia and acidemia (Ewaschuk et al. 2005; Uribarri et al. 1998).  D-lactate usually 
comes from an intestinal source (Bongaerts et al. 1997; Uribarri et al. 1998), but may rarely 
result from endogenous glyoxalase pathway activity in the body at a sub-clinical level in 
patients with type II diabetes, ketoacidosis, or genetic metabolic disorder (Ewaschuk et al. 
2005; Thornalley 1988).  DLA is a cause of an elevated anion gap (Ewaschuk et al. 2003; 
Ewaschuk et al. 2005; Omole et al. 2001; Uribarri et al. 1998).  Within the body D-lactic 
acid is ionized to protons and D-lactate.  Mammals do not metabolize D-lactate as fast as 
L-lactate (Borba et al. 2004; Cammack 1970; Ewaschuk et al. 2005; Tubbs 1965; Uribarri 
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et al. 1998).  Accumulation of D-lactic acid directly leads to acidification of the blood and 
other body fluids causing acidemia and acidosis, and is considered a distinct form of 
metabolic acidosis (Bongaerts et al. 1997; Hove and Mortensen 1995; Petersen 2005).  The 
main clinical characteristic of DLA is neurological disturbances (Dunlop and Hammond 
1965; Ewaschuk et al. 2004; Petersen 2005; Uribarri et al. 1998); signs such as slurred 
speech and incoordination are commonly found (Petersen 2005; Uribarri et al. 1998).  DLA 
may be incompletely diagnosed as acidosis, metabolic acidosis or even lactic acidosis. 
 
2.2 Chemistry of lactic acids 
2.2.1 Structure and properties 
Lactic acid, or 2 –hydroxypropanoic acid was first reported in 1780 by a Swedish 
chemist, Scheele who isolated it from milk (Chahal 1990; Ewaschuk et al. 2002).  There 
are two enantiomers (optic isomers or stereoisomer) of lactic acid naturally present due to 
its asymmetric C2 atom (∝ hydroxy radical).  Threfore, Lactic acid is the simplest 
hydroxycarbnoxylic acid which exists as two enantiomers.   
 
 
 
 
Figure 1. Lactic acid enantiomers; L (+, S)- and D (-, R)- lactic acid optic isomers (Chahal 
1990; Chahal and Starr 2006).  L-lactic acid is the more common form and is produced by 
body tissues under hypoxic conditions or by bacterial fermentation mainly in the gastro-
intestinal tract.  In conary, the D- form is mainly formed by bacterial fermentation hence 
the main source of D-lactate to the mammalian body is exogenous; from gastro-intestinal 
tract bacterial fermentation (Editorial. 1990; Haschke-Becher et al. 2000; Petersen 2005; 
Uribarri et al. 1998).  
 
L (levo, +, S) lactic acid D (dextro, -, R) lactic acid  
H 
C 
OH
C 
C 
H
C
HO
C 
C
H H 
H 
HO O O OH 
H 
H 
H 
   
  
 
 
 7 
  
 
When a molecule has a hypbridized (SP3) atom with four different chemical 
moieties attached, it is called a chiral molecule and exists two molecular forms that are 
non-superimposable mirror images of one another, similar to human hands, and named 
optical isomers.  They have the ability to rotate light in different directions; the clockwise 
rotation is dextrorotatory (D, −, R) and anticlockwise is levarotory (L, +, S).  Therfore, 
these lactiac acid enantiomers are called the L (+, S) and D (−, R) forms (Figure 1).  Both 
enantiomers indicated similar physical and chemical properties; colorless, odorless, 
extremely hydroscopic and water soluble with a pK of 3.86 (Borba et al. 2004, Buglass et 
al. 2003, Chahal et al. 2006, Omole et al. 1999).  At physiological pH (7.4), both D- and L-
lactic acid are almost completely dissociated into lactate isomers and protons (De Vrese et 
al. 1990; Ewaschuk et al. 2005; Robergs et al. 2004). 
L-lactic acid which is the common form is produced by body tissues under 
hypoxic conditions or by bacterial fermentation in the body; gastro-intestinal tract, vagina 
or other infected tissues.  The D- form is mainly acquired from exogenous sources and is 
either ingested or produced by certain bacteria in the gastro-intestinal tact, vagina or other 
infection sites (Editorial. 1990; Connolly et al. 2005, Haschke-Becher et al. 2000; Hove et 
al. 1999, Petersen 2005; Uribarri et al. 1998). 
 
 
 
 
Figure 2. L-lactic acid production (endogenous) in body tissues; the conversion of 
pyruvate to L-lactate, (a reversible reaction) is catalyzed by L-lactate dehydrogenase 
enzyme with NADH as a cofactor in cytosol (McClendon et al. 2005). 
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2.2.2 Endogenous production 
Endogenous lactate production is by the conversion of pyruvate (C3H4O3) to 
lactate (C3H5O3) catalyzed by lactate dehydrogenase with NADH as a cofactor (Figure 2) 
(McClendon et al. 2005).  This occurs in a variety of tissues including the muscles and 
erythrocytes, particularly under hypoxic conditions secondary to poor tissue perfusion, to 
generate NAD and allow glycolysis to continue.  This type of endogenous production is 
exclusively L-lactate.  
 
 
 
 
Figure 3. Glyoxalase pathway; the generation of D-lactic acid occurs in mitochondria 
(Thornalley 1988). 
 
In mammalian cells D-lactate can be formed via the glyoxalase system (Figure 3).  
It is a ubiquitous reaction, but produces physiologically insignificant quantities of D-lactic 
acid (Thornalley 1988).  Endogenous production of D-lactate from pyruvate by mammalian 
D-lactate dehydrogenase is yet to be understood (Flick and Konieczny 2002). 
 
2.2.3 Exogenous or gastrointestinal production 
Exogenous production of lactic acid is by anaerobic bacterial (mainly gram-
positive) fermentation (Figure 4) (Bongaerts et al. 1997).  Both D- and L-lactate are found 
in many fermentation products including pickles, beer, wines and yogurt (Buglass and Lee 
2003; Fall and Szerlip 2005; Uribarri et al. 1998).  Bacterial fermentation in the 
glyoxalase I 
glyoxalase II 
hemithioacetal 
glutathione 
D-lactic acid 
Water 
methylglyoxal 
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gastrointestinal tract (rumen or colon) is the main cause and source of D-lactic acid 
(Editorial. 1990; Hove and Mortensen 1995; Omole et al. 2001; Uribarri et al. 1998).  Some 
Lactobacilli species (L. acidophilus, L. buchneri and L. fermenti and Escherichia coli) are 
capable of producing D-lactic acid (Hove et al. 1999; Ku et al. 2006).  
 
 
 
 
Figure 4. Exogenous DL-lactic acid (DL-LA) generated by bacteria in the gastrointestinal 
tract by fermenting dietary carbohydrates (Bongaerts et al. 1997; Hove et al. 1999). 
 
The main sites of gastrointestinal production in mammals, are the colon and, in 
ruminants, the rumen (Dunlop and Hammond 1965; Editorial. 1990; Ewaschuk et al. 2005; 
Petersen 2005; Uribarri et al. 1998).  D-lactate is usually detected at very low levels in the 
body fluids (Petersen 2005; Uribarri et al. 1998).  Mild overproduction of D-lactic acid 
may not be unusual. In patients with gastrointestinal diseases elevated D-lactate 
concentrations are frequently present in serum and urine even in the absence of acidosis 
(Bongaerts et al. 1995; Thurn et al. 1985; Zhang et al. 2003).  In some high D-lactatemia 
cases, alteration of the flora probably occurred following dietary changes (Puwanant et al. 
2005) or ingestion of Lactobacillus acidophilus (Ku et al. 2006; Mack 2004; Oh et al. 
1979) and in others following antibiotic administration (Coronado et al. 1995).  
 
 
2.2.3.1 Colon 
The colon is the main site of fermentation for D-lactic acid production in 
monogastrics or non-ruminants (human, canine, feline, and swine) and an important site in 
pre-ruminants (calves, kids and lambs).  
The monogastric digestive tract contains over 400 different bacterial species and 
more than 1014 microbes (Luckey 1972).  This is approximately 10 times the total number 
of individual cells in the human body (1013) and approximately 100 times the population of 
bacteria on human skin (1012).  There are more than 200 different species of bacteria in the 
carbohydrate pyruvate DL-lactate 
Bacterial (mixed acid) fermentation 
(Lactobacillus, E. coli, etc) 
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colonic flora of a single individual, the total population of which is about 1012-14 bacterial 
cells (Luckey 1987; Simon and Gorbach 1984; Simon and Gorbach 1986). 
In pre- and non-ruminants, the maldigestion and malabsorption of carbohydrate in 
the small intestines leads to an increased passage of carbohydrates to the colon intensifying 
subsequent fermentation by colonic bacteria to produce L- and D-lactic acid (Editorial. 
1990; Hove and Mortensen 1995; Uribarri et al. 1998).  
The presence of a dense bacterial flora in the colon facilitates the production of D-
lactic acid. Stool cultures from D-lactatemic cases have invariably shown a marked 
predominance of Gram-positive anaerobes such as species of lactobacillus (Lactobacillus 
acidophilus and Lactobacillus fermentum > 1012 cfu/g feces); these are known to produce 
D-lactic acid in vitro (Bongaerts et al. 1997; Kaneko et al. 1997).  Other potential D-lactic 
acid producers are Escherichia coli (1010 cfu/g feces) and Citrobacter freundii.  
Lactobacilli produce not only D-lactate dehydrogenase but also DL-lactate racemase 
(Figure 4), which could potentially explain interconversion of D- and L-lactate (Hove and 
Mortensen 1995). 
  
2.2.3.2 Rumen 
The rumen facilitates the fermentation of crude fiber and is the largest 
compartment of the fore stomach (complex stomach) of ruminants. It has been referred to 
as a large fermentation vat containing cud and over 400 microbial species particularly gram 
negative anaerobic bacteria (Russell and Rychlik 2001).  The rumen provides the 
environment for fermentation and the surface area for absorption of its products. Proper 
composition of feed (especially crude fiber) is important for the process of ruminal 
digestion and optimal health of the animal (Crichlow and Chaplin 1985; Kleen et al. 2003; 
Russell and Rychlik 2001).  Ruminal acidosis and lactic acidosis in cattle and other 
ruminants are most commonly found subsequent to imbalanced feeding, which is 
unfortunately a too frequent occurrence in modern intensive farming.  Specifically when 
fiber level in the feed is low and soluble nutrients, particularly carbohydrate are high, 
ruminal fermentation leads to ruminal acidosis.  DLA in ruminants has been found after 
over-feeding of grain or soluble carbohydrate (Crichlow and Chaplin 1985; Dunlop and 
Hammond 1965; Ewaschuk et al. 2005; Gentile et al. 2004; Kleen et al. 2003).  Over-
feeding may occur as an accident or deliberate farm practice.  
Ruminal D- and L-lactic acid levels were found to be as high as 100 mmol/L in 
healthy ruminants; presumably half of this racemic lactic acid is D- lactic acid (Dunlop and 
Hammond 1965; Ewaschuk et al. 2005; Owens et al. 1998).  Both D- and L-lactic acid are 
absorbed effectively by the rumen mucosa (Dunlop and Hammond 1965; Owens et al. 
1998).  Ruminal lactic acidosis is a common disease in both feedlot and dairy cattle in 
many parts of the world.  
A part of D-lactic acid produced in either rumen or colon is further utilized by 
ruminal microflora to produce less harmful or beneficial compounds to the host such as 
short chain fatty acids (Piva et al. 2002; Shimomura and Sato 2006).  Propionate produced 
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from lactate in the presence of malate has been shown by a few workers (Evans and Martin 
1977; Martin and Streeter 1995; Martin et al. 1999). 
 
2.2.4 Estimation of D-lactic acid production  
Estimation of the likely rate of D-lactic acid production in the average fed human 
individual has value in helping determine whether a defect in body D-lactate metabolism 
plays a role in the pathogenesis of DLA.  In 1998 Uribarri and coworkers (Uribarri et al. 
1998) estimated that D-lactic acid production in healthy humans was 87 mmol/h, applying 
the following assumptions:  
The daily caloric intake is 3,000 calories.  
a) 50% of the calories ingested are absorbed in the small intestine and the other 50% 
is delivered to the colon.  
b) 50% of the daily caloric intake comes from 1 big meal such as dinner.  
c) 50% of the entire caloric intake is in the form of carbohydrates.  
All the carbohydrates delivered to the colon are converted by bacteria to L- and 
D-lactate in equal proportions.  
In this case, if 1,500 calories are ingested during dinner, and 750 calories are 
delivered to the colon, 375 calories will be as carbohydrates and 375 as some other 
nutrients.  These 375 calories would come from 94 g of carbohydrates, which could then 
produce 522 mmol of D-lactate and 522 mmol of L-lactate.  If we further assume that 522 
mmol of D-lactate was produced over a 6 h period, the production rate will be lower than 
100 mmol/h (Oh et al. 1985).  Soluble and insoluble carbohydrate, fiber (neutral detergent, 
acid detergent, and acid insoluble) and other nutrients in the diet may have an effect on 
colonic acid production which may lead to excessive D-lactic acid production (DeGregorio 
et al. 1982; Editorial. 1990; Ferguson et al. 1981; Hove and Mortensen 1995; Uribarri et al. 
1998). 
 
2.2.4.1 Lactate concentrations  
D-lactate can be found in many different body fluids.  However, the origin of this 
D-lactate is normally by gastrointestinal fermentation.  In general serum D-lactate 
concentrations are negligible, and sometimes undetectable, because gastrointestinal lactate 
is utilized by luminal bacteria for many other biochemical pathways such as fatty acid 
synthesis (Hove et al. 1999; Simon and Gorbach 1984; Uribarri et al. 1998).  There may not 
be excess lactate available for uptake and absorption.  Although serum D-lactate levels may 
be very low (< 2 mmol/L) in healthy individuals under normal physiological status, in 
certain situations serum D-lactate concentrations can elevate to over 10 mmol/L.  In a 
human case of severe accidental propylene glycol ingestion, the serum D-lactate 
concentration was found to be 110 mmol/L (Jorens et al. 2004).  
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Peritoneal and cerebrospinal values are reported in some cases.  They are not 
consistently similar to serum levels (Benoist et al. 2003; Fine 1989; Petersen 2005; Uribarri 
et al. 1998).  In a European study healthy juvenile urinary D-lactate concentrations were 
shown to be correlated to ethnicity and diet (Haschke-Becher et al. 2000). 
Serum L-lactate concentration is the most common and meaningful measurement 
of L-lactate status.  However, (whole) blood L-lactate is reported by many clinical 
chemistry laboratories.  Serum L-lactate increases during strenuous exercise, hypoxic 
conditions, ischemia, tissue necrosis, metabolic disorders, gastro intestinal diseases, and 
drastic dietary changes.   
Baseline serum L-lactate levels in human as well as in other domestic mammals 
range from 0.5 to 3 mmol/L (Kreisberg 1980; Minniti et al. 2001; Omole et al. 1999).  In 
other body fluids lactate concentrations may be different (Ewaschuk et al. 2004; Fine 1989; 
Haschke-Becher et al. 2000; Shimomura and Sato 2006; Yasuda et al. 1993).  
Cerebrospinal fluid contains similar concentrations of lactate to serum in normal animals, 
however, the relationship changes in disease.  Fecal and urinary D-lactate concentrations (> 
10 mmol/L) are always higher than blood concentrations in clinical cases.  Urinary values 
are also typically reported relative to creatinine (mmol of D-lactate per mol of creatinine) 
because it indicates the renal function and excretion (Connor et al. 1983; Haschke-Becher 
et al. 2000). 
Fermented fruits and vegetables such as pickles, sauerkraut, yogurt, wines and 
other foodstuff contain both L- and D-lactic acid ranging from 2–15 mmol/L (Buglass and 
Lee 2003; Fall and Szerlip 2005; Ohmori and Iwamoto 1988).  Lactated Ringer’s solution 
and peritoneal dialysate also contain racemic mixtures of both isomers (Anderson et al. 
1997; Chan et al. 1994; Fine 1989; Uribarri et al. 1998). 
 
2.2.5 Metabolism of D-lactic acid in the body 
High D-lactate uptake and absorption into the circulation were found in many 
studies (Fine 1989; Flemstrom 1979; Frenning 1972; Owens et al. 1998; Poole and 
Halestrap 1993).  D-lactate can be transported via proton dependent mono-carboxylic 
transporters-1 (MCT-1) in the colon and rumen (Muller et al. 2002; Poole and Halestrap 
1993).  Absorbion of large amounts of D-lactate can create a crisis for a normal healthy 
individual because mammals are not biologically equipped with an efficient mechanism to 
deal with D-lactate elimination (Giesecke and Von-Wallenberg 1985; Oh et al. 1985).  
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Figure 5. L- and D- lactate metabolism; L- isomer is converted to pyruvate by L-lactate 
dehydrogenase (v = ~50 µmoles/min per cm3) enzyme in the cytosol (mainly in the liver) 
and bacteria (Nakae et al. 1997).  D-lactate is converted to pyruvate by D-2 (α)–hydroxy 
acid dehydrogenase (v = 5-20 µmol/min per mL) in mitochondria (Cammack 1975).  D-
lactate dehydrogenase (v = 15±17 nmol/min per mg), a peripheral membrane 
dehydrogenase in bacteria is also capable of this conversion (Cammack 1969; De Bari et al. 
2002; Dym et al. 2000).   DL-Lactate recemase (v = ~0.1 µmol/min per mL) mainly in 
bacteria can covert L-lactate to D- isomer and vise versa (Hiyama et al. 1968). 
 
Metabolism of D-lactate in mammals requires D-2 (∝)-hydroxy acid 
dehydrogenase, which converts D-lactate to pyruvate (Cammack 1969). The conversion of 
D-lactic acid to pyruvate by D-2 (∝)-hydroxy acid dehydrogenase is slower than the 
conversion of L-lactic acid to pyruvate by L-lactate dehydrogenase (Figure 5).  Vmax of L-
lactate dehydrogenase reported to be 5 to 97 µmol/min per cm3 in different tissues (Nakae 
et al. 1997).  D-2 (∝)-hydroxy acid dehydrogenase (v = 5-20 µmol/min per mL) is present 
in the mitochondria in the liver and kidney of several animal species including humans, but 
not in as high quantities as L-lactate dehydrogenase in mammalian cells (Cammack 1969; 
L-lactate  
pyruvate  
D-lactate  
L-lactate dehydrogenase 
(mammalian / bacteria) 
D-2(α)-hydroxy acid dehydrogenase 
 (mitochondria) 
D-lactate dehydrogenase 
 (bacteria) 
   
  
 
 
 14 
  
 
Cammack 1970; Cammack 1970; Ewaschuk et al. 2005; Tubbs 1965; Yasuda et al. 1993).  
Therefore, in normal physiology D-lactate metabolism is several times slower than the L-
lactate metabolism.  D-2 (∝)-hydroxy acid dehydrogenase is a non-specific flavoprotein 
and is active over a limited pH range.  This enzyme can utilize all D-2 (∝)-hydroxy acids 
including D-lactate as its substrates (Cammack 1969; De Bari et al. 2002; Tubbs 1965; 
Uribarri et al. 1998).  Mammalian D-lactate dehydrogenase (v = 15±17 nmol/min per mg) 
was found in the muscle mitochondria recently (De Bari et al. 2002; Flick and Konieczny 
2002).  However, its impact on D-lactate metabolism in mammalian body is not well 
understood (Flick and Konieczny 2002).  Normal subjects metabolize D-lactate and D-
lactic acid equally well despite the fact that the former tends to increase the blood pH and 
the latter decreases it.  Mainly based of renal excretion, healthy humans can metabolize D-
lactate at a rate greater than 100 mmol/h with only a modest increase in serum 
concentration (Oh et al. 1985). 
 
2.2.5.1 Elimination of D-lactate from the body  
D-lactate elimination from the blood was rapid in experimental studies but not 
consistent in clinical case reports (Lorenz et al. 2005; Petersen 2005; Uribarri et al. 1998).  
Infused or injected D-lactate exhibited an exponential decay (first order kinetics) in calf 
experiments (Lorenz et al. 2005).  D-lactate clearance from blood occurs at least in part 
through renal excretion (Connor et al. 1983; Ewaschuk et al. 2004; Jørgensen and Sheikh 
1984; Oh et al. 1985; Ullrich et al. 1982b).  Previous studies show that serum L-lactate is 
cleared through two independent processes: Hepatic removal follows second order kinetics 
while extrasplanchnic removal is linearly related to serum concentration (Naylor et al. 
1984).  D-lactate may also be taken up by hepatic and extrahepatic tissue (Naylor et al. 
1984); mitochondrial uptake and utilization is promoted by malate (De Bari et al. 2002).  
However, this hepatic metabolism is slow and the main route of excretion is renal (Connor 
et al. 1983; Jørgensen and Sheikh 1984; Oh et al. 1985; Ullrich et al. 1982b). 
 
2.2.5.2 Excretion 
The main route of elimination of D-lactate from the mammalian body is urinary 
excretion (Jørgensen and Sheikh 1984; Oh et al. 1985; Ullrich et al. 1982a; Yasuda 1988).  
The renal clearance of both D and L-lactic acids are apparently similar (Connor et al. 1983; 
Jørgensen and Sheikh 1984; Yasuda 1988). 
As renal excretion is a major root of elimination of D-lactate, urine contains D-
lactate.  Urinary concentrations fluctuate; although serum D-lactate levels may be low or 
undetectable, urine may contain detectable or high levels of D-lactate. 
D-lactate transport in kidney tubules occurs via diffusion and excretion via a 
monocarboxylate transporter 1 (MCT1) (Ewaschuk et al. 2004; Haschke-Becher et al. 
2000; Jørgensen and Sheikh 1984; Ullrich et al. 1982a).  Since renal excretion of D-lactate 
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is effective in healthy individuals (Jørgensen and Sheikh 1984; Oh et al. 1985), it is the 
major factor in reducing serum D-lactate levels (Connor et al. 1983; Ewaschuk et al. 2004; 
Neale et al. 2005; Ullrich et al. 1982a) in normal physiology. 
 
2.3 D-lactic acidosis; a secondary complication 
DLA is a disease condition caused by the accumulation of D-lactic acid in the 
body (Dunlop and Hammond 1965; Ewaschuk et al. 2004; Petersen 2005; Uribarri et al. 
1998).  A metabolic crisis starts not only because of increased H+, but slow metabolism of 
ionized D-lactate in the mammalian body (Borba et al. 2004; Cammack 1970; Ewaschuk et 
al. 2005; Tubbs 1965; Uribarri et al. 1998).  Therefore, accumulation of D-lactic acid 
directly leads to D-lactic acidemia and D-lactatemia, and is considered a distinct form of 
metabolic acidosis (Bongaerts et al. 1997; Hove and Mortensen 1995; Petersen 2005).  
DLA is associated with gastrointestinal diseases and neurological signs (Hingorani and 
Chan 2001; Perlmutter et al. 1983; Petersen 2005; Puwanant et al. 2005; Uribarri et al. 
1998).  However, the mechanism linking neurological signs and DLA is not well 
understood (Editorial. 1990; Ewaschuk et al. 2005; Lorenz 2004b; Petersen 2005; Uribarri 
et al. 1998).  Therefore, treatment and control are usually focused on the primary 
gastrointestinal disease. 
 
2.3.1 Clinical manifestation of D-lactic acidosis 
2.3.1.1 General clinical signs 
The main clinical manifestation of DLA is neurological impairment (Hingorani 
and Chan 2001; Petersen 2005; Uribarri et al. 1998).  General clinical symptoms and signs 
common to many gastrointestinal diseases can be observed in many DLA cases since DLA 
is often secondary to gastrointestinal diseases.  Some of the observed non specific clinical 
signs are abdominal pain, flatulence, loss of appetite, dehydration, vomiting, semisolid 
feces or diarrhea, fever, headache, debilitation, weakness and many others linked to the 
primary disease (Bongaerts et al. 1995; Hove and Mortensen 1995; Petersen 2005; 
Puwanant et al. 2005; Uribarri et al. 1998).  Further, many of these general clinical signs 
are similar regardless of the species, sex or age of the patient. 
 
2.3.1.2 Neurological signs 
Neurological signs in patients with high serum D-lactate concentrations include 
weakness, drunken appearance, altered mental status, dizziness, dysarthria, disorientation 
or confusion, sleepiness, memory loss, behavioral changes, vision disturbances, slurred 
speech, incoordination and ataxia (Carr et al. 1982a; Catlin 1982; Petersen 2005; Thurn et 
al. 1985; Uribarri et al. 1998).  Comparable neurological signs are observed in continuous 
ambulatory peritoneal dialysis patients receiving DL-lactate solutions (Anderson et al. 
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1997; Chan et al. 1994).  Many of these signs resemble alcohol intoxication (Handley and 
Ward-Smith 2005; Hudson et al. 1990; Uribarri et al. 1998).  Calves who received 
intravenous hypertonic sodium DL-lactate infusions also showed neurological symptoms 
with vision disturbances and abnormal gate (Lorenz 2004b). 
In general, neurological signs often appear in the later phase of a primary disease, 
and are associated with acute increase in blood D-lactate concentration (Petersen 2005; 
Uribarri et al. 1998). 
 
2.3.2 Prevalence of D-lactic acidosis 
DLA is commonly found in humans and cattle.  Cat and dog cases are also 
reported (Fine 1989; Packer et al. 2005).  Rodents are also susceptible according to certain 
studies (Giesecke and Fabritius 1974; Giesecke and Von-Wallenberg 1985; Ohmori and 
Iwamoto 1988).  Other species have yet to be investigated.  Under-reporting and inaccurate 
or premature diagnosis may have played a role in masking certain cases, so current 
statistics are in doubt (Petersen 2005).  North America and Europe share a larger number of 
case reports than the other regions.  Therefore, the current incidence data is indirectly 
associated with the availability of diagnostic facilities. 
In humans, short bowel syndrome (SBS) causes the highest number of DLA case 
reports (Petersen 2005; Uribarri et al. 1998).  Other gastrointestinal diseases and digestive 
disorders were also responsible for a few cases (Christopher et al. 1990; Jorens et al. 2004; 
Petersen 2005; Uribarri et al. 1998). DLA was found in cases of calf diarrhea with a 
relatively high prevalence (Ewaschuk et al. 2003; Lorenz 2004a; Omole et al. 2001).  Grain 
overfeeding and ruminal acidosis is the major cause of DLA in cattle (Dunlop and 
Hammond 1965). 
Human DLA cases over a wide range of ages from a few months to over 60 years 
old were reported all over the globe beginning in 1970.  Young children and neonates were 
more susceptible (Bongaerts et al. 2000; Perlmutter et al. 1983; Puwanant et al. 2005).  
Although humans have the highest incidence, the total number of cases in the literature is 
less than 100.  Interestingly, these numbers have more male cases than females (Uribarri et 
al. 1998).  
A large number of DLA cases were diagnosed and reported from the early 1980s 
to 2000s.  Therefore, predisposing factors for DLA have gradually become apparent.  
Although sex does not have a proven association in causing DLA, more males (> 62%) are 
affected than females (Neale et al. 2005; Oh et al. 1985; Uribarri et al. 1998). 
According to case reports, 99% of DLA cases have serum D-lactate 
concentrations higher than 2 mmol/L.  Over 90% of cases have serum D-lactate higher than 
5 mmol/L, and over 20% have serum D-lactate over 10 mmol/L.  Therefore, in most cases 
(70%) serum D-lactate lies between 5 to 10 mmol/L.  Few cases have levels higher than 20 
mmol/L.  Urinary D-lactate values in these cases were inconsistent and fluctuated, 
however, the values were higher than 20 mmol/L (Bongaerts et al. 1995; Haschke-Becher 
et al. 2000; Perlmutter et al. 1983; Uribarri et al. 1998; Zhang et al. 2003).  
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The reported incidence of human DLA is higher than that in animals because 
human patients are subjected to a more thorough investigation than animals.  Even in 
humans many neurologically affected patients were not correctly diagnosed or perhaps 
misdiagnosed.  Therefore, the possible incidence of DLA may be higher than the present 
presumption (Petersen 2005).  The majority of human cases are reported in young children 
and some in adults.  This statistical observation suggests that the body can improve its 
capability to metabolize D-lactate with maturity (Cammack 1969; Cammack 1970; Flick 
and Konieczny 2002; Tubbs 1965).  
Lambs and other animal neonates have not been well investigated for the 
occurrence of DLA. 
 
2.3.3 Etiology of D-lactic acidosis 
Overwhelming evidence from humans and many different animal species supports 
the association between gastrointestinal disease and DLA.  Some of these predisposing 
gastrointestinal diseases are short bowel syndrome (Caldarini et al. 1996; Hudson et al. 
1990; Oh et al. 1979; Puwanant et al. 2005; Zhang et al. 2003), active inflammatory bowel 
disease, enteritis (Hove and Mortensen 1995), diarrhea (exudative, secretary or osmotic) 
(Ewaschuk et al. 2003; Ewaschuk et al. 2004; Omole et al. 2001) exocrine pancreatic 
insufficiency (Packer et al. 2005), propylene glycol ingestion (Christopher et al. 1990; 
Jorens et al. 2004) indiscriminate eternal feeding, indiscriminate oral antibiotic use 
(Coronado et al. 1995), and lactose intolerance in human and non ruminant animals 
(Ewaschuk et al. 2005; Petersen 2005; Uribarri et al. 1998).   
The mechanism of DLA has been described by many authors in relation to the 
following areas (Uribarri et al. 1998): 
a) Microbial over growth and D-lactic acid production in the gastrointestinal tract,  
b) Absorption of D-lactate or D-lactic acid from the intestines (or rumen) into the 
circulation causing elevation in serum D-lactate levels,  
c) Onset of clinical symptoms in relation to serum D-lactate or D-lactic acid and 
metabolic impairment in elimination.  
Although there is evidence associating D-lactatemia and neuropathy, the direct 
pathways which link D-lactatemia to encephalopathy or neurological disturbances are not 
well understood.  
 
2.3.3.1 Primary diseases leading to D-lactic acidosis 
DLA was respectively found secondary to short bowel syndrome in human 
(monogastrics), grain over feeding in ruminants, diarrhea in calves (preruminants), 
pancreatic insufficiency in cats (monogastrics), and other gastrointestinal diseases 
(Editorial. 1990; Ewaschuk et al. 2005; Petersen 2005; Uribarri et al. 1998). 
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2.3.3.1.1 Short bowel syndrome 
The short bowel syndrome (SBS) is a disorder clinically characterized by 
malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition 
(Hudson et al. 1990; Nightingale 1995; Oh et al. 1979).  SBS is generally defined as 
malabsorption resulting from anatomical or functional loss of a significant length of the 
small intestine.  Most commonly this occurs after a surgical resection of the small intestines 
in the newborn period due to various reasons such as torsion, degeneration, necrosis or 
cancer (Nightingale 1995; Perlmutter et al. 1983).  Massive small intestinal resection 
compromises digestive and absorptive processes (Bongaerts et al. 2000; Carr et al. 1982b; 
Nightingale 1995; Perlmutter et al. 1983).  
In healthy adults, the small intestine has an average length of approximately 6 
meters.  SBS usually appears when there is less than 1.8 meters (30%) of the small intestine 
left to absorb sufficient nutrients.  Adequate digestion and absorption cannot take place, 
and proper nutritional status cannot be maintained without supportive care.  The most 
common causes of short-bowel syndrome in adults include Crohn’s disease, radiation 
enteritis, mesenteric vascular accidents, trauma, and recurrent intestinal obstruction.  In the 
pediatric population, necrotizing enterocolitis, intestinal atresia, and intestinal volvulus are 
the most common etiologic factors (Nightingale 1995).  Other conditions associated with 
short-bowel syndrome include congenital short small bowel, gastroschisis and meconium 
peritonitis (Nightingale 1995; Nightingale 2001). 
The final common etiologic factor in all causes of short-bowel syndrome is the 
functional or anatomic loss of extensive segments of small intestine so that absorptive 
capacity is severely compromised (Nightingale 1995; Nightingale 2001).  Although 
resection of the colon alone typically does not result in short-bowel syndrome, its presence 
or loss can be a critical factor in the management of patients who lose significant amounts 
of small intestine (Bongaerts et al. 2000; Hudson et al. 1990; Nightingale 1995; 
Nightingale 2001). 
Patients with intestinal resection or bypass surgery or jejunoileostomy usually 
develop DLA after a delay of several months to a few years.  This suggests that a change in 
the intestinal flora occurs during this time.  Ongoing colon acidosis may allow the over 
growth of acidophilic D-lactic acid producing bacteria (Kaneko et al. 1997).  Studies with 
stool homogenates have shown that the formation of D-lactic acid is stimulated by low pH 
and inhibited at pH > 6.5 (Caldarini et al. 1996).  
Jejunoileal bypass patients (100%) had plasma D-lactate levels greater than 0.5 
mmol/L.  Further, more than 90% (25 out of 27) had plasma D-lactate levels greater than 
5.0 mmol/L (Uribarri et al. 1998).  However, in 282 randomly chosen hospitalized patients 
with a history of gastrointestinal surgery or disease, plasma D-lactate levels were greater 
than 0.5 mmol/L only in 13 (5%).  
In 2001 Gavazzi and colleagues reported that intestinal resection followed by 
antibiotic treatment (vancomycin 1 g bid) precipitated DLA with a 9.8 mmol/L serum D-
lactate concentration (Gavazzi et al. 2001).  Oral antibiotics are one predisposing factor to 
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the onset of DLA in patients with gastroenteropathies (Coronado et al. 1995; Gavazzi et al. 
2001). 
The fact that DLA and encephalopathy has not been described with greater 
frequency in patients with malabsorption syndrome not related to a short bowel may also 
be partly explained by the limited feed intake that sometimes occurs in these other 
conditions.  In general, malabsorption syndrome is also more severe in the short bowel 
syndrome (Meier et al. 2003).  DLA in dogs was reported secondary to bowel surgeries and 
experimentally secondary to peritoneal dialysis (Arieff et al. 1982; Fine 1989; 
Westermarck and Wiberg 2003). 
DLA develops intermittently even in SBS patients and does not occur following 
every meal.  If malabsorption with increased delivery of nutrients to the colon led 
immediately to osmotic diarrhea, there might not be a sufficient amount of substrate in the 
colon to produce D-lactate (Field 2002; Lorenz and Vogt 2006; Meier et al. 2003).  Hence, 
colonic stagnation might be another important contributing factor.  
Over the last 3 decades short bowel syndrome was the most common primary 
disease predisposing patients to DLA (Carr et al. 1982a; Carr et al. 1982b; Hudson et al. 
1990; Petersen 2005; Uribarri et al. 1998).  This syndrome has accounted for more than 
half of the reported human DLA cases.  
 
2.3.3.1.2 Grain over-feeding and ruminal acidosis 
The rumen is the major site and reservoir for microbiological colonization and 
fermentation shortly after weaning of young ruminants.  The bacterial population in healthy 
rumen is over 1010 and about 80% is gram negative (Allison et al. 1975; Russell and 
Rychlik 2001).  The major rumen bacteria are Selenomonas, Clostridia, Ruminococcus, 
Fibrobacter and Megasphaera.  Apart from bacteria, the presence of a large amount of 
fungi and protozoa adds to the complexity of this biological ecosystem (Allison et al. 1975; 
Russell and Rychlik 2001). 
The consequence of overfeeding high grain or readily fermentable diets to 
ruminant is ruminal acidosis (Allison et al. 1975; Crichlow and Chaplin 1985; Gentile et al. 
2004; Kleen et al. 2003; Owens et al. 1998).  An important point is that even slightly 
overfeeding fermentable carbohydrate can cause microecological changes (Russell and 
Rychlik 2001) in the rumen leading to sub-acute ruminal acidosis (Crichlow and Chaplin 
1985; Kleen et al. 2003).  This is in agreement with the colon analogy of bacterial 
overgrowth in monogastric SBS.  
D-lactic acid is a major component in the blend of organic acids produced by 
bacteria during ruminal acidosis (Dunlop and Hammond 1965; Ewaschuk et al. 2005).  The 
concentration can be high as 100 mmol/L. Ruminal DL-LA levels increased over 300 
mmol/L in many ruminal acidosis cases; presumably half of this racemic lactic acid is D- 
lactic acid (Dunlop and Hammond 1965; Ewaschuk et al. 2005; Owens et al. 1998).  Both 
D- and L-lactic acid are absorbed effectively by the rumen mucosa into the circulation 
causing systemic acidosis (Dunlop and Hammond 1965; Owens et al. 1998).  Ruminal 
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lactic acidosis is a common disease finding in both feedlot and dairy cattle all over the 
world.  Many times these diseases were imprecisely credited to lactic acidosis because 
ruminal or serum D-lactic acid concentrations were not measured.  Some clinical signs 
reported after ruminal lactic acidosis in cattle are neurological.  They include abnormal 
gate, limping, drunken appearance, fatigue, depression, loss of appetite and sometimes 
ataxia.  
Many adult cattle DLA cases are associated with the management practice of 
grain over feeding in modern intensive feedlot and dairy farms (Dunlop and Hammond 
1965; Editorial. 1990; Ewaschuk et al. 2005; Owens et al. 1998).  
In 2004 Gentile and coworkers also reported significant and rapid elevation of serum D-
lactate in calves as a consequence of experimentally induced ruminal acidosis (Gentile et 
al. 2004). 
 
2.3.3.1.3 Diarrhea 
Diarrhea is a condition caused by a variety of gastrointestinal diseases; either it is 
infectious or non-infectious, the pathology may be malabsorptive, exudative or secretory 
(Field 2002).  During severe, chronic diarrhea the composition of the gastro-intestinal 
bacterial flora is disrupted, the mucosa damaged, and the immune system over-stimulated.  
Since pathogens generally have shorter generation times than commensals, there is a higher 
relative abundance of pathogens during diarrhea and the initial stages of intestinal recovery 
(Field 2002; Katelaris 1996).  The inflammatory reaction during enteritis and colitis can 
facilitate organic (lactic) acid uptake and absorption from the lumen into the circulation 
(Field 2002; Meier et al. 2003).  
Diarrhea is associated with malabsorption, major metabolic disturbances 
including dehydration and metabolic acidosis.  The passage of fermentable materials to the 
colon in diarrheal diseases mimics SBS causing DLA.  Neonates with diarrhea may be 
predisposed.  
Metabolic acidosis develops in the diarrheic calf as a result of the loss of 
bicarbonate via the intestinal tract and the high production of acids in the colon (Field 
2002; Lorenz 2004a; Meier et al. 2003; Omole et al. 2001).  In addition reduced tissue 
perfusion may result in L-lactic acid production, reduced renal perfusion and reduced 
excretion of hydrogen ions and acids which can exacerbate the acidosis (Field 2002; 
Schelcher et al. 1998).  Ewaschuk and coworkers in 2004 showed a linear relationship 
between serum and fecal or rumen D-lactate concentrations in diarrheic calves (Ewaschuk 
et al. 2004).  Many calf cases of DLA had diarrhea (Ewaschuk et al. 2003; Ewaschuk et al. 
2004; Lorenz 2004a; Lorenz and Vogt 2006; Omole et al. 2001).  
Diarrhea affects 4 billion people yearly worldwide.  Juvenile or neonatal diarrhea 
is a significant problem in humans causing death.  Diarrhea causes more than 12,000 deaths 
per day in children worldwide.  In North America, more than 100,000 infants and children 
are hospitalized per year as a result of diarrhea.  Patients with diarrhea and other intestinal 
diseases from developing countries may not undergo expensive diagnostic procedures, and 
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hence DLA may be under-investigated (Bhan et al. 1989; Ewaschuk et al. 2005; Field 
2002; Katelaris 1996; Ruuska and Vesikari 1991).  
Diarrhea is a major cause of morbidity and mortality in livestock.  Young calves 
are susceptible worldwide and severely affected.  Among the calf population in North 
America about 11% are affected by neonatal diarrhea with mortality close to 0.7% 
(Ewaschuk et al. 2003; Ewaschuk et al. 2004).  In 2002 Ewaschuk and coworkers reported 
over 60% correlation between anion gap and serum D-lactic acid in diarrheic calves 
(Ewaschuk et al. 2002).  
Diarrhea in lambs is considered an important constraint in sheep farming.  This 
condition is associated with considerable morbidity (2.8%) and mortality (0.7%) in 
Canadian lambs for the last few decades.  The Prairie Provinces have a greater share of 
these scouring cases than other lamb diseases (Dohoo et al. 1985).  Infectious agents such 
as bacteria, virus and cryptosporidium are responsible for 99% of lamb dysentery.  More 
than 75% of these scouring cases are due to Escherichia coli infection.  Some strains are 
known to be able to produce D-lactic acid (Bongaerts et al. 1997; Connolly et al. 2005; 
Hove et al. 1999; Petersen 2005; Uribarri et al. 1998).  An episode of lamb diarrhea reduces 
the growth of lambs permanently with about 2 kg weight loss at the age of five weeks 
(Green et al. 1998).  Diarrhea occurs at all ages of lambs and 15% to 40% of the flock may 
be affected any time, however, peak prevalence is 3 to 5 weeks of age (Green et al. 1998).  
Lambs affected with diarrhea may also be prone to DLA. 
 
2.3.3.1.4 Exocrine pancreatic insufficiency 
Exocrine pancreatic insufficiency (EPI) is the inability to digest food due to a lack 
of digestive enzymes secreted by the pancreas (DiMagno 1993).  EPI is found frequently in 
dogs, cats and also in humans afflicted with cystic fibrosis (DiMagno 1993; Steiner and 
Williams 1999; Westermarck and Wiberg 2003).  EPI is caused by a progressive loss of the 
pancreatic cells that make digestive enzymes, most commonly subsequently to pancreatic 
acinar atrophy.  The atrophy in turn can be caused by previous infections, a blocked 
pancreatic duct, or genetics.  The genetic form, which is common in dogs starts at the 
young age of about two months.  Chronic pancreatitis is the most common cause of EPI in 
humans and cats.  A loss of digestive enzymes leads to maldigestion and malabsorption of 
nutrients, which in turn resembles SBS further causing DLA. 
A cat with exocrine pancreatic insufficiency ended up exhibiting neuropathy and 
was diagnosed with DLA (Packer et al. 2005).  A high serum D-lactate (over 5 mmol/L) 
and loss of reflexes were the main characteristics of this case. 
 
2.3.3.1.5 Other causes of DLA 
The other gastrointestinal diseases and conditions that may lead to DLA are active 
inflammatory bowel disease, malabsorption syndrome, ingestion of propylene glycol, 
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colonic intubation, oral antibiotics, some probiotics and oral oxalate (Petersen 2005; 
Uribarri et al. 1998).  In 1995 Hove and coworkers (Hove and Mortensen 1995) found high 
or detectable D-lactate concentrations in patients with gastrointestinal ailments including 
active inflammatory bowel disease and malabsorption.  Patients with metabolic acidosis, 
high serum anion gap, relatively normal L-lactate concentrations and malabsorption 
following enteropathy were more likely to suffer from D-lactic academia and acidosis 
(Azhar and Beach 2002).  
The gut metabolism of propylene glycol, an agent frequently used in medications 
and food, can lead to generation of D-lactate (Christopher et al. 1990).  In cats, DLA occurs 
in experimental propylene glycol intoxication (Christopher et al. 1990) and is associated 
with central nervous depression, ataxia and weak eye reflexes, and coma. 
Floppy kid syndrome, a disease in young goats is proven to be DLA (Bleul et al. 
2006).  A lack of proper diagnostic facilities, misdiagnosis and under reporting may mask 
the incidence of DLA in animals.  Therefore, lambs and other animal neonates with 
gastrointestinal or neurological diseases needed to be investigated for DLA. 
 
2.3.4 Clinical pathophysiology 
Onset of clinical signs varies with many factors such as the type of primary 
disease, species, healthiness of the individual, and age of the patient.  Other toxins produce 
by the over growing bacteria may have a role in the initiation of clinical signs. Some of 
these substances (organic acids, formate, histamine, ethanol, tyramine, and endotoxin) may 
interfere with the intake absorption, metabolism (Cammack 1969; Cammack 1970; Tubbs 
1965), renal clearance or perhaps promote neuropathic actions of D-lactate (Cammack 
1969; Cammack 1970; Ewaschuk et al. 2005; Hudson et al. 1990; Tubbs 1965; Uribarri et 
al. 1998).  
Thiamine deficiency has been suggested to play a contributory role in the 
pathogenesis of DLA because DLA did not recur after initiation of thiamine 
supplementation.  However, thiamine deficiency has not been shown to increase production 
of D-lactate (Uribarri et al. 1998). 
Injection of 2.23 M sodium D-lactate produced ataxia, depression and a reduced 
palpebral reflex in calves within 6 h of injection (Lorenz et al. 2005).  However, the above 
experiment was criticized since the solution was hyperosmolar; therefore, some of the 
neurological signs might have been related to fluid shifts (Stampfli 2005).  Similarly, 
disagreement about whether D-lactate is directly responsible for neurological signs in 
humans exists (Laptook et al. 1988; Petersen 2005; Uribarri et al. 1998).  Human patients 
undergoing Ringer’s lactate peritoneal dialysis experienced neurological signs that 
disappeared with cessation of the lactate infusion (Anderson et al. 1997; Chan et al. 1994).  
Most of these clinical signs were acute in nature.  Researchers have assumed that elevating 
serum D-lactate levels above 3 mmol/L is the point at which the onset of neurological 
symptoms occurs (Petersen 2005; Uribarri et al. 1998).  Although gastrointestinal 
fermentation is a major cause of DLA, oral supplementation of D-lactic acid did not cause 
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clinical signs in many studies (De Vrese et al. 1990; Ding and Xu 2003; Partanen and Mroz 
1999). 
 
2.3.4.1 Impairment of D-lactate metabolism in the body  
Healthy humans can metabolize D-lactate absorbed at a rate greater than 100 
mmol/h with only a modest increase in serum concentration (Oh et al. 1985).  Therefore, 
one might argue that impaired metabolism is a prerequisite for the production of DLA.  On 
the other hand, DLA occurs when gastrointestinal fermentation is grossly excessive; 
therefore, the rate of D-lactate production could exceed the rate estimated above.  It is also 
possible that the rate of D-lactate metabolism is reduced in patients with such acidosis, not 
because of any specific metabolic defect but as the result of generalized diminution in 
metabolism due to chronic malnutrition.  If there is a specific mechanism of impaired 
ability to metabolize D-lactate, it is currently unknown.  
As the liver and kidney contain D-2 (∝)-hydroxy acid dehydrogenase, disease of 
these organs might diminish the ability to metabolize D-lactate (Cammack 1969; De Bari et 
al. 2002; Uribarri et al. 1998).  Loading rats with D-lactate over several days significantly 
increased the activity of D-2 (∝)-hydroxy acid dehydrogenase in the liver, but this increase 
was much less in rats and humans with chronic renal failure than in control animals 
(Anderson et al. 1997; Yasuda 1988; Yasuda et al. 1993).  Although renal function has 
been described in only a few patients with DLA, some degree of renal insufficiency is 
common because of volume depletion; calcium oxalate kidney stones are frequent 
complications in patients with the short bowel syndrome (Hudson et al. 1990; Oh et al. 
1985; Petersen 2005; Uribarri et al. 1998).  Unfortunately, the rate of metabolism of D-
lactate in patients with DLA has not been successfully measured.  
Oxalate is a powerful competitive inhibitor of D-2 (∝)-hydroxy acid 
dehydrogenase (Tubbs 1965).  Patients with the short bowel syndrome frequently have 
intestinal hyper absorption of oxalate, perhaps due to low intestinal pH, and it seems 
possible that high plasma and tissue levels of oxalate could inhibit enzyme activity.  Low 
pH, which also diminishes the dehydrogenase activity, could play a role in the diminished 
metabolism of D-lactate.  The effect of pH on the in vivo metabolism of D-lactate has not 
been investigated fully (Ullrich et al. 1982b; Uribarri et al. 1998).  
Another mechanism by which renal dysfunction might alter D-lactate metabolism 
is interference with renal excretion.  The renal threshold for D-lactate is low because other 
carboxylic acids including L-lactate may compete for the same transporter in reabsorption 
(Oh et al. 1985; Ullrich et al. 1982a; Ullrich et al. 1982b; Uribarri et al. 1998).  However, 
renal fractional excretion is very high (Oh et al. 1985).  Impaired renal function or volume 
depletion may decrease renal excretion of D-lactate and thereby increase plasma levels.  
Urinary secretion of D-lactic acid (5.0-30.0 mmol per creatinine mol) was correlated with 
age and ethnicity of young children (Haschke-Becher et al. 2000). 
A combination of the above evidence suggests that the development of DLA 
requires the following conditions (Petersen 2005; Uribarri et al. 1998):  
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a) Ingestion of large amounts of carbohydrate or similar substrate, 
b) Carbohydrate malabsorption with increased delivery of nutrients to the colon,  
c) Colonic bacterial flora of a type that produces D-lactic acid,  
d) Diminished colonic motility, allowing time for nutrients in the colon to undergo 
bacterial fermentation,  
e) Damage to intestinal mucosa, and  
f) Impaired D-lactate metabolism or excretion (dehydrated, debilitated or neonates). 
 
2.3.4.2 Neonates at risk 
Neonates are more susceptible to DLA. In human, DLA cases were reported in 
neonates more frequently than adults (Petersen 2005).  Neonatal DLA cases exhibited 
severe neurological symptoms and encephalopathy (Gurevitch et al. 1993).  Neonatal 
calves with diarrhea which had serum D-lactate concentration over 5 mmol/L showed 
neurological symptoms (Ewaschuk et al. 2005; Lorenz 2004b; Lorenz et al. 2005).  
Enzymatic activities in neonates are at a developing stage and may be less effective than in 
adults.  The enzyme D-2 (∝)-hydroxy acid dehydrogenase which metabolizes D-lactate 
does not exist in neonates (Cammack 1969; Cammack 1970; Flick and Konieczny 2002; 
Tubbs 1965).  Functional abilities of liver and kidney are comparatively lower in neonates 
(Connolly et al. 2005; Haschke-Becher et al. 2000; Mack 2004; Marko et al. 2004; Yasuda 
et al. 1993).  Digestion and absorption in neonates are not as efficient as in adults and 
neonates are more susceptible to enteric infections which compromise digestion and 
absorption and hence could result in a high passage of fermentable nutrients to the colon 
(Bongaerts et al. 2000; Packer et al. 2005; Puwanant et al. 2005; Uribarri et al. 1998).  All 
these factors contribute to put neonates at higher risk for D-lactate production and elevation 
in blood.  Many DLA cases in neonates are reported at the ages of 1 to 2 years.  However, 
there may be cases in infants which may not be diagnosed accurately or may not be 
available for diagnosis (Petersen 2005). 
 
2.3.4.3 Possible mechanisms of neurological manifestations  
Apart from the common clinical symptoms such as drowsiness, lethargy and 
depressed appearance, there may be specific neurological symptoms such as ataxia, slurred 
speech, nystagmus, seizures and confusion.  Three main hypotheses have been proposed to 
explain the neurological manifestations of DLA:  
a) D-lactate itself is toxic to the brain (neurotoxic),  
b) H+ or increased systemic acidosis, and  
c) Unknown compounds produced or released along with D-lactate are toxic to the 
brain. 
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Indeed, compounds such as formate, histamine, ethanol, tyramine, and endotoxin 
have been found in the rumen of cattle with DLA (Dunlop and Hammond 1965), and 
excessive urinary excretion of hydroxyphenyllactic and phenylacetic acids (Uribarri et al. 
1998) has been observed in patients with this condition.  The role that each of these 
compounds may play in causing the neurological abnormalities, is uncertain but it is clear 
that ethanol is not responsible for the symptoms.  Although the patients appear to be drunk, 
serum levels of ethanol are normal (Hudson et al. 1990).  Neonates with DLA are more 
vulnerable to neurological symptoms and encephalopathy (Gurevitch et al. 1993; Petersen 
2005; Uribarri et al. 1998).  Neonatal calves with diarrhea had neurological symptoms 
when serum D-lactate concentration exceeded 5 mmol/L (Ewaschuk et al. 2005; Lorenz 
2004b; Lorenz et al. 2005). 
D-lactate can penetrate into the central nervous system by simple diffusion and 
can thus reach high concentrations in the brain (Uribarri et al. 1998).  Recent studies also 
showed that D-lactate can cross the blood brain barrier (Aubert et al. 2005; Martin et al. 
2006; Ros et al. 2001; Tekkök et al. 2003).  Although it has been hypothesized that D-
lactate may accumulate in the brain because of the low local level of metabolizing enzyme 
(Oh et al. 1985), levels of D-lactate in the cerebrospinal fluid have been found to be similar 
to those in the blood (Benoist et al. 2003; Karton et al. 1987; Okubo et al. 2000; Uribarri et 
al. 1998).  However, CSF D-lactate levels were not well established in many cases (Benoist 
et al. 2003; Oh et al. 1985; Okubo et al. 2000; Thurn et al. 1985).  Moreover, the 
correlation between serum D-lactate levels and severity of symptoms is poor (De Vrese et 
al. 1990; Lorenz 2004b; Thurn et al. 1985).  However, Lorenz and coworkers in 2004 and 
2005 showed a correlation (70%) between serum D-lactate concentration and the degree of 
nervous symptoms (ataxia) in diarrheic calves; they also documented that D-lactate 
concentrations were higher in the less severely dehydrated calves (Lorenz 2004b; Lorenz et 
al. 2005).  They did not measure CSF lactates. 
In 1985, Thurn and coworkers (Thurn et al. 1985) found that patients with 
jejunoileal bypass reported symptoms consistent with D-lactic acid encephalopathy but 
only a few of them had high plasma levels of D-lactate, while some individuals with high 
plasma D-lactate levels did not have symptoms.  The fact that some patients present with 
encephalopathy did not have high plasma D-lactate levels strengthens the suggestion that 
the encephalopathy results from toxins which may be produced simultaneously with D-
lactic acid, or may be due to trapped D-lactate in nervous tissue.  However, CSF was not 
available to measure D-lactate levels in any or many of these encephalopathic patients. 
Acidosis itself is not likely to be responsible for neurological manifestations since 
patients with other types of acidosis of comparable or greater severity do not present with 
neurological signs (Owens et al. 1998; Petersen 2005; Uribarri et al. 1998).  Altered pH 
may have some role in the toxic effect of D-lactate or other chemicals on the brain since 
patients with DLA usually have significant metabolic acidosis.  It is also probable that D-
lactate is harmful to the central nervous system only in the presence of another metabolic 
defect, such as deficiency of certain vitamins, which might only be present in patients who 
develop the syndrome (Uribarri et al. 1998).  Interference of pyruvate metabolism by D-
lactate has been postulated based on the observation of clinical similarities between DLA 
and inherited or acquired abnormalities of pyruvate metabolism (Cross and Callaway 
1984). 
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Excessive production of D-lactate either in the colon or rumen is the beginning of 
a crisis (Giesecke et al. 1985; Hove and Mortensen 1995; Oh et al. 1985; Petersen 2005; 
Uribarri et al. 1998).  However, if D-lactic acid or D-lactate is not absorbed into the 
circulatory system, the patient may not exhibit clinical manifestation of D-lactatemia; DLA 
and neuropathy. 
Slow metabolism and the single route of elimination of D-lactate from the body 
result in accumulation of D-lactate in the blood and other body compartments.  Once the 
serum D-lactate concentration exceeds 3 mmol/L level, patients start exhibiting 
neurological signs of DLA on top of the signs of the primary disease (Chan et al. 1994; 
Hingorani and Chan 2001; Petersen 2005; Thurn et al. 1985; Uribarri et al. 1998).  In cases 
of renal and hepatic impairment, elimination of D-lactate from the body is more severely 
compromised.  The result is further accumulation of D-lactate in the body.  In extreme 
cases, with very high D-lactate concentrations (110 mmol/L), ataxia, paralysis and coma 
are seen (Christopher et al. 1990; Jorens et al. 2004; Petersen 2005; Uribarri et al. 1998).  
Therefore, impairment in D-lactate metabolism or excretion can lead to a metabolic crisis.  
Differences in blood pH in acidosis experiments conducted by few previous 
workers (De Vrese et al. 1990; Gentile et al. 2004; Laptook et al. 1988; Lorenz et al. 2005; 
Patra et al. 1993) were quite modest compared with those observed in patients with clinical 
DLA (Bongaerts et al. 1997; Ewaschuk et al. 2005; Uribarri et al. 1998; Yasuda et al. 
1993).  
 
2.3.4.3.1 D-lactate and the central nervous system  
Low pH (< 7.2) enhances L-lactate transport across the blood brain barrier 
(Oldendorf et al. 1979).  In addition to lipid mediated penetration (Oldendorf et al. 1979), 
L-lactate may be transported across the blood brain barrier by mono-carboxylic acid 
transporters (Gladden 2004; Hertz and Dienel 2005; Schurr 2006) which are reported to be 
stereo specific (Tekkök et al. 2003; Tekkök et al. 2005).  L-lactate is formed within 
nervous and muscle tissues by metabolism of glucose (Aubert et al. 2005; Gladden 2004).  
D-lactate also has the ability to rapidly pass the blood brain barrier though it may 
not be pH dependent (Oldendorf et al. 1979).  L-lactate competes with D-lactate for uptake 
from blood by cerebrospinal tissue (Tekkök et al. 2003; Tekkök et al. 2005).  
As many of the neurological signs are acute and depressive in nature, D-lactate 
may mediate these by affecting neurotransmitters or receptors.  Since glutamate and γ-
aminobutyrate (GABA) are important chemical neurotransmitters (Ge et al. 2005; Gjedde 
et al. 2002; Horikawa et al. 1996; Krnjević 2005) D-lactate may interfere with these 
transmitters to cause acute neuropathy.  D-lactate might interrupt (antagonize) the 
excitatory activities of glutamate or initiate (agonize) the inhibitory activities of GABA.  
D-lactate, unlike L-lactate, inhibits the development of an action potential in the optic 
nerve of rodents in vitro (Tekkök et al. 2003; Tekkök et al. 2005).  Neurons are not capable 
of utilizing D-lactate (Oh et al. 1985; Tekkök et al. 2003).  Cassady and coworkers in 2001 
(Cassady et al. 2001) reported an acute increase in GABA release in rodent cerebral 
cortical superfusates following topical application of D-lactate (20 mM).  Similarly, D-
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lactate in vivo may initiate GABA release which could trigger inhibitory pathways (Krause 
and Schwarz 2005; Krnjević 2005; Kuffler and Edwards 1958; McCormick and Tunnicliff 
1998) causing somnolence, depression and paresis (Waagepetersen et al. 2003).  L-lactate 
can be metabolized by neurons (Aubert et al. 2005; Gladden 2004; Schurr 2006) and can be 
exchanged with glutamate during baseline or excitation both in neurons and astrocytes 
(Gjedde et al. 2002; Hertz and Dienel 2005), thereby playing a major role in synaptic 
activity (Magistretti and Pellerin 1999; Pellerin and Magistretti 1994).  D-lactate may 
interfere with this coupling synaptic activity which is critical for excitatory pathways 
(Krnjević 2005; Magistretti and Pellerin 1999).  L-lactate is thought to be cerebro-
protective (Gladden 2004; Medina and Tabernero 2005; Ros et al. 2001; Schurr 2006) and 
can act as an energy source (Bouzier-Sore et al. 2003; Gladden 2004; Hertz et al. 2007; 
Schurr 2006).  Unlike L-lactate, D-lactate does not interfere with glutamate accumulation 
(Cassady et al. 2001) or with acetate uptake (Waniewski and Martin 1998) in nervous 
tissue cultures.  
In acute ethanol consumption, neurological depression may be caused by low 
concentrations of circulating tryptophans (Badawy et al. 1995).  However, alcohol is also 
able to interact with the GABAA receptor complex and facilitate GABA action (Gonzales 
and Hoffman 1991; Starke 1991), therefore, D-lactate may have similar actions in similar 
fashion in those receptors. 
  
2.3.5 Therapies and prevention 
Therapeutic measures in DLA vary with the type of primary disease and 
predisposing causes.  Therapeutic and prevention measures can be categorized into 
immediate (treatment) and long term (control) measures.  General therapeutic measures are 
fluid or bicarbonate therapy, peritoneal dialysis, antibiotic use, dietary management and 
many others.  Treatments basically focus on removal of clinical signs, elimination of D-
lactate, correction of acidosis, nourishing the patient and correction of microbial 
overgrowth and imbalance in the intestines.  General control measures are appropriate 
dietary management, proper use of antibiotics, and use of prebiotics or / and probiotics to 
maintain a healthy intestinal flora. 
Therapeutic management of DLA cases focuses on different strategies; clinical 
symptomatic treatments, elimination of D-lactate and acidosis, reducing D-lactate 
production and absorption in the gut, and also on preventive or control measures to avoid 
recurrence of DLA (Petersen 2005; Puwanant et al. 2005; Uchida et al. 2004; Uribarri et al. 
1998).  Many strategies are based on the fact that many DLA cases have a gastro intestinal 
link. 
  
2.3.5.1 Clinical approach to treatment 
Common approaches to the treatment of DLA use simple methods to eliminate D-
lactate from the body (Anderson et al. 1997; Mathieu et al. 1991; Puwanant et al. 2005; 
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Uribarri et al. 1998).  Bicarbonate is the most commonly used infusion to reduce acidosis 
and acidemia (Arieff et al. 1982; Booth and Naylor 1987; Cooper et al. 1990; Kasari and 
Naylor 1985; Mathieu et al. 1991; Puwanant et al. 2005).  Doses of bicarbonate, amount of 
fluid and rate of infusions administered to patients with DLA were case dependant.  The 
results were not consistent and raise many doubts about the effectiveness of these 
treatments; hence further research is needed.  Regular monitoring of renal clearance of D-
lactate is important to understand the efficacy of fluid therapy, dehydration status and renal 
health.  Faster removal of D-lactate can be achieved by peritoneal dialysis in weak patients 
with renal failure (Fine 1989; Petersen 2005).  Intermittent or continuous dialysis can be 
performed with saline.   
The next step is to minimize the production and absorption of D-lactate.  Some 
measures are alteration of diet, use of antibiotics and use of probiotics or prebiotics.  Many 
of these measures target intestinal flora to reduce D-lactic acid production (Gurevitch et al. 
1993; Narula et al. 2000; Petersen 2005; Uribarri et al. 1998).  Neomycin or kanamycin (5-
10 mg/kg body weight) and other gut acting antibiotics have been used; however, they were 
not very successful (Bongaerts et al. 2000; Bongaerts et al. 1997; Gavazzi et al. 2001; 
Hudson et al. 1990; Uchida et al. 2004).  Bongaerts and coworkers recently showed that 
yeast mediated a suppression of D-lactate production after antibiotic cocktail treatment in a 
patient with short small bowel (Bongaerts et al. 2005).  Other probiotics have also been 
used in certain cases with limited success (Chermesh and Eliakim 2006; Ewaschuk et al. 
2004; Ewaschuk et al. 2006; Katelaris 1996; Uchida et al. 2004).  The most commonly 
administered organisms were Lactococcus and Lactobacillus species which could compete 
with and inhibit D-lactic acid producers.  Feeding microbes that utilize D-lactate is another 
approach.  Prebiotics seem to be a potential treatment method which has yet to be fully 
investigated (Evans and Martin 1977; Martin and Streeter 1995; Martin et al. 1999; Passos 
et al. 2003; Vicini et al. 2003). 
 
2.3.5.2 Dietary management 
Dietary management is applied following bowel surgery (Caldarini et al. 1996; 
Hudson et al. 1990; Puwanant et al. 2005; Puwanant et al. 2005), enteritis(Vella and 
Farrugia 1998), diarrheic diseases (Ferguson et al. 1981; Pearson et al. 1978), exocrine 
pancreatic insufficiency (Packer et al. 2005), and lactose intolerance (Hove and Mortensen 
1995) to manage excessive organic acid production (DeGregorio et al. 1982) including D-
lactic acid production (Editorial. 1990; Kleen et al. 2003; Petersen 2005; Uribarri et al. 
1998).  Parental or enteral nutrition is the choice of feeding in certain cases for the high risk 
period.  Strict limitation of diet may be beneficial to avoid supplying fermentable 
compounds to the colon.  In cases of exocrine pancreatic insufficiency, the missing 
enzymes may be supplemented in the diet, or predigested food (ready made nutrients) in 
the right quantities can be fed enterally (Westermarck and Wiberg 2003).  In veterinary 
practice, such patients (dogs) are treated by supplements such as Lypex pancreatic enzyme 
capsules (VetPlus International Ltd, Lytham, United Kingdom) which contain lipase 
30000, amylase 18750 and protease 1200 Ph Eur U.  These patients are fed with low fat 
diets such as beef liver or pork pancreas extract / soup with an appropriate commercial food 
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/ products similar to Waltham® Chappie dog food (Waltham® Centre for Pet Nutrition, 
Waltham, Massachusetts, USA).  Chappie consists of protein 5.5%, oil 2.0%, ash 1.5%, 
fibre 0.4%, moisture 77.0%, copper 2mg/kg (as Cu2SO4), vitamin A 500 IU/kg, vitamin D 
150 IU/kg and vitamin E 10 mg/kg (Westermarck and Wiberg 2003). 
  
2.3.5.3 Control (and prevention) 
Control has two themes; control of recurrence in an affected patient, and control 
of occurrence (prevention) in a susceptible patient or herd. 
Bacterial overgrowth (dysbiosis) (Hove and Mortensen 1995) and decreased gut 
pH (Caldarini et al. 1996) play a major role in increasing D-lactic acid producing bacteria 
(Bongaerts et al. 2000; Bongaerts et al. 1997; Connolly et al. 2005; Hove et al. 1999).  The 
two most commonly used control approaches are to supplement the diet with live microbes 
(probiotics) or with nutritional compounds (prebiotics) that enhance the proliferation of 
favorable, non-D-lactate producing (gram negative strictly anaerobic) bacteria such as 
Selenomonas ruminantium and Megasphaera elsdenii (Martin 1998).  Probiotics (such as 
Lactobacillus strains) (Chermesh and Eliakim 2006; Ewaschuk et al. 2004; Ewaschuk et al. 
2006; Katelaris 1996; Uchida et al. 2004) and prebiotics (such as malate) (Martin et al. 
1999; Montano et al. 1999; Uchida et al. 2004) may be used in the treatment / prevention of 
DLA.  
The use of antibiotics (feed growth additives) reduces the incidence of lactic 
acidosis.  The mechanisms by which growth promoting antibiotics improve growth 
performance are not known with certainty, but may include:  
a) Nutrients are more efficiently absorbed because of a thinner small intestinal 
epithelium;  
b) Nutrients are spared due to a reduction in competing microorganisms;  
c) Microorganisms responsible for subclinical infections are reduced or eliminated;  
d) Production of growth-depressing toxins or metabolites by the gastrointestinal 
microbiota is reduced;  
e) Microbial deconjugation of bile salts is reduced.  
Growth promoting antibiotics accomplish their effect in the small intestine while 
they have some effect on the microbiota in the large intestine (Hove et al. 1999).  The 
microbiota in the hindgut of the healthy animal has a beneficial effect on the host animal 
via the fermentation of feed material that escaped digestion in the small intestine and via its 
stabilizing effects on microbial population and the mucosal structure and function 
throughout the gut.  
Since the use of antibiotics to control D-lactic acid producing bacteria is 
controversial, a better approach would be use of probiotics (Chermesh and Eliakim 2006; 
Ewaschuk et al. 2006; Katelaris 1996) or prebiotics (Martin et al. 1999; Montano et al. 
1999; Uchida et al. 2004) together with symptomatic remedies (vitamins-thiamine, 
   
  
 
 
 30 
  
 
electrolytes and fluid therapy) (Booth and Naylor 1987; Lorenz and Vogt 2006; Uribarri et 
al. 1998).  Manipulating the gut microbial flora (by Lactococcus / Lactobacillus species), 
introducing competitive inhibitors to D-lactic producers, feeding microbes that utilize 
lactate, providing prebiotic compounds such as malic acid (C4H6O5) which enhances the 
removal of lactate are approaches which could be further investigated in order to control D-
lactic acid production in the gastrointestinal tract.  Malate has the ability to modulate pH in 
its environment (Passos et al. 2003; Piva et al. 2002; Russell and Rychlik 2001).  Malate 
promotes the growth of gut bacteria that can convert lactate to propionate (Evans and 
Martin 1977; Martin 1998).  Malate has been used to reduce rumen D-lactic acid 
production in cattle (Martin 1998; Nisbet and Martin 1991; Nisbet and Martin 1994; 
Russell and Rychlik 2001).  Therefore, malate may be a potential candidate in the 
prevention of DLA.  Dietary supplements of CaCO3 and MgCl2 may potentially diminish 
intestinal production of D-lactic acid (Caldarini et al. 1996) by increasing the luminal 
rumen and colonic pH.  Ca malate may be used to gain both properties. 
Thiamine supplementation may reduce recurrence of DLA when given to 
susceptible individuals (Hudson et al. 1990; Uribarri et al. 1998).  Surgical (serial 
transverse enteroplasty) management enhanced the recovery of refractory DLA in a patient 
with short-bowel syndrome recently (Modi et al. 2006). 
 
2.4 Analysis of lactic and other organic acids 
2.4.1 Diagnosis and confirmatory tests 
Biological fluids including blood and urine are commonly analyzed for D- and L-
lactate determination (Ewaschuk et al. 2002; Ohmori and Iwamoto 1988; Okubo et al. 
2000; Omole et al. 1999; Van-Hee et al. 2004).  Blood lactate concentrations are measured 
by some modern automated analyzers (Braconnier et al. 2003; Zwart et al. 1987).  Serum 
concentrations are measured using either enzymatic assays (Buttery and Pannall 1986; 
Haschke-Becher et al. 2000; Martí et al. 1997) or chromatographic methods (Ewaschuk et 
al. 2002; Ohmori and Iwamoto 1988; Okubo et al. 2000; Omole et al. 1999; Van-Hee et al. 
2004).  
For modern automated analyzers (blood gas machines) only 0.5 ml blood sample 
is needed, however, the sample needs to be tested soon after collection (immediate fresh 
sample or analyzed within 2 h kept in ice).  Serum separated from blood can be stored at -
20 °C for years for chromatography and less than 1 mL blood sample is needed for serum 
separation. 
Stereospecific identification of D-lactate in body fluids (serum and cerebrospinal 
fluid), urine and feces is important in diagnosis and treating DLA.  High performance 
liquid chromatography (HPLC) is preferred for accurate quantifications (Ewaschuk et al. 
2002; Minniti et al. 2001; Okubo et al. 2000; Omole et al. 2001) to the other methods such 
as enzymatic procedure (Buttery and Pannall 1986; Haschke-Becher et al. 2000; Martí et al. 
1997). 
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2.4.2 Measuring lactates 
Modern automated blood analyzers measure blood gases, lactate, electrolytes, 
hemoglobin, lactate and glucose (Severinghaus 2002).  Lactate measurement is based on 
spectrophotometry (reflective photometry) or enzymatic assay (lactate oxidase) and usually 
express total lactates in mmol(s) per liter (mmol/L) of blood.  
Enzymatic methods are interfered by certain compounds including sodium fluoride, 
acetaminophen and potassium oxalate.  HPLC systems are accurate, precise, repeatable, 
and have negligible interference from contaminants (Ohmori and Iwamoto 1988; Omole et 
al. 1999).  The HPLC method is also applicable to a variety of biological fluids (and 
extracts). 
 
2.4.3 Measuring L- and D-lactates using HPLC 
Measurement of D-lactate in body fluids using HPLC system was established by 
Omole and coworkers (Omole et al. 1999) in 1999.  Both L- and D-lactates are separately 
eluted in the chromatogram and can be quantified relative to known standards. Venous 
blood (3 mL) is collected, allowed to coagulate for 20 min and serum separated by 
refrigerated centrifugation (IEC Centra-7R Refrigerated Centrifuge; International 
Equipment Company, Needham Heights, Massachusetts, USA) at 1000 RCF for 30 min. 
Serum is stored at -20 °C. D- and L-lactate concentrations measured from 0.2 mL serum 
sample using an HPLC system (Waters 600 HPLC pump, 486 UV detector and 786 Ultra 
WISP auto-injector, Millenium32 v.4 software; Waters, Mississauga, Ontario, Canada).  
For the separation of D- and L-lactic acid a stereoselective 3 μm ODS (octadecyl Silane) 
packed (50 mm × 4.6) analytical ligand exchange column coated with N,N-dioctyl- alanine 
(ChiralPak MA+; Chiral Technologies Inc., Exton, Pennsylvania, USA) is employed 
(Omole et al. 1999).  A Guard-Pak Precolumn Module containing an ODS (octadecylsilyl) 
cartridge (Waters Guard-Pak™ precolumn; Waters, Mississauga, Ontario, Canada) insert is 
placed serially just before the analytical column to reduce the risk of obstruction, to limit 
interfering substances and enhance elution capability. Internal standard is a 2 mmol/L 
malonic acid solution.  The mobile phase is a 2 mmol/L copper sulfate in 1% acetonitrile. 
The flow rate for the mobile phase is 0.4 mL/min and the column works at room 
temperature (25 ºC).  UV detection occurs at 236 nm wavelength. 
 
2.4.4 Measuring other organic acids using HPLC 
Measurement of organic acids in body fluids is performed using HPLC system 
(Ewaschuk et al. 2002; Omole et al. 1999) which has a nonstereoselective, reverse phase 
Shodex RSPAK KC-811 (300 mm × 8) analytical column with a KC-811 precolumn 
(Showa Denko K.K., Tokyo, Japan).  Internal standard is a 7 mmol/L adepate solution.  
The mobile phase is a 0.1% phosphoric acid in double distilled water.  The flow rate for the 
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mobile phase is 0.7 mL/min and the column temperature is maintained at 50 ºC. UV 
detection wavelength is at 236 nm.  The rest of the procedure and quantifications are 
similar to the above section (2.4.3). 
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3 EXPERIMENTAL MODEL STUDIES 
3.1 D-lactate induced neurotoxicity in a calf model 
3.1.1 Introduction 
Acidemia is a common problem in humans and other animals.  In diarrheic calves, 
the severity of acidemia correlates with neurological depression (Naylor 1989).  In humans 
with short bowel syndrome, DLA is suggested as the cause of certain neurological 
symptoms (Bongaerts et al. 1995; Bongaerts et al. 2000; Bongaerts et al. 1997; Hingorani 
and Chan 2001; Hudson et al. 1990; Oh et al. 1979; Perlmutter et al. 1983; Uribarri et al. 
1998).  Similarly, in a variety of ruminant diseases including neonatal diarrhea, ruminal 
carbohydrate overload and acidosis without dehydration syndromes, DLA occurs in 
association with functional impairment of central nervous system (CNS) including signs of 
ataxia and coma (Ewaschuk et al. 2003; Gentile et al. 2004; Jorens et al. 2004; Omole et al. 
2001; Schelcher et al. 1998).  In cats, DLA occurs in experimental propylene glycol 
intoxication (Christopher et al. 1990) and in exocrine pancreatic insufficiency (Packer et al. 
2005).  In both cases DLA is associated with CNS depression, ataxia and in one case, 
coma.  In a recent human case, accidental propylene glycol ingestion was associated with a 
very high serum D-lactate concentration (110 mmol/L), subsequent loss of CNS function 
and development of coma (Jorens et al. 2004). 
At physiological pH, D-lactic acid is almost completely dissociated (De Vrese et 
al. 1990; Ewaschuk et al. 2005).  Whether or not acidosis per se or the D-lactate anion is 
responsible for impaired CNS function is not well established.  A bolus injection of 223 
mmol sodium D-lactate in 100 mL of water produced ataxia, depression and a reduced 
palpebral reflex in calves (Lorenz et al. 2005).  However, the experiment was criticized 
since the solution was hyperosmolar with an osmotic pressure approximately 15 times that 
of plasma; therefore, some of the neurological signs might have been related to fluid shifts 
(Stampfli 2005). Similarly, there is disagreement about whether D-lactate is directly 
responsible for neurological signs in humans (Uribarri et al. 1998). 
The objectives of this study were to compare the influence of different types of 
acidosis on neurological function, and to determine whether signs are caused by either 
increased acidity or D- or L-lactate concentrations. 
   
  
 
 
 34 
  
 
3.1.2 Materials and methods 
3.1.2.1 Experimental animals and care 
Calves for this study were obtained from the Dairy Barn of the Department of 
Animal and Poultry Sciences, University of Saskatchewan, Canada (Table 1) which had 
Holstein breed and only male calves were provided for the experiment.  The calves were 
housed indoors in the Animal Care Facility at the Western College of Veterinary Medicine, 
University of Saskatchewan.  The indoor environment was held at 22 ± 1°C, 65 ± 5% 
relative humidity, and was lit from 6:00 to 20:00 h.  Each calf was housed in a 2.0 × 1.5 m2 
pen. Flooring was a 3 cm thick rubber mat covered with approximately 4 cm of wood 
shavings. 
Clean water was freely available to these calves through automatic water bowls 
fixed to the walls.  The stalls were cleaned twice a day.  The calves were offered alfalfa hay 
and fed milk replacer (20 - 20 - 20 Wet Nurse™, green tag; Prairie Micro-Tech Inc., 
Regina, Saskatchewan, Canada) twice a day.  Milk replacer solution was made on a 20% 
v/v basis and fed at 2.5 - 3.0 L a meal.  The calves were weighed (Norac Instaweigh™ 
Instrumentation Animal Scale; Norac Weighing and Control Systems, Norac International 
Inc., Saskatoon, Saskatchewan, Canada) on the arrival to the Animal Care Facility, and 
prior to the catheterization (Table 1).  The latter weight was used for dosage calculations. 
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Table 1. Calf information and order of infusion of DL-lactic acid (DL-LA), hydrochloric 
acid (HCl), L-lactic acid (L-LA) and saline 
 
Calf ID 
Body weight (kg)
 
Age (d) 
Order of infusions 
 DL-LA    HCl    L-LA    Saline 
648588504 62 35 2 NA 1 NA
287348803502 68 41 4 2 3 1
8648585501 64 34 NA 1 NA NA
8648583499 77 47 1 2 3 4
8648582498 88 37 NA NA 1 2
277634660 75 30 1 4 3 2
8648573489 55 17 1 4 3 2
8648572488 68 15 1 NA NA 2
Total number of 
infusions   6 5 6 6
Mean  ± se 69.6 ± 3.6 32.0 ± 3.9  
 
NA= not available (infusion not performed). 
 
3.1.2.2 Catheterization 
Calves were catheterized with indwelling jugular intravenous, ear arterial, and 
atlanto-occipital CSF catheters (Cox and Littledike 1978; De Craene et al. 1997; Jones and 
Robinson 1981).  All surgeries were performed in the Department of Large Animal Clinical 
Science, Western College of Veterinary Medicine, University of Saskatchewan.  The calves 
were premedicated with intravenous hydromophone at 0.1 mg/kg, sometimes in 
combination with metatomidine at 7 μg/kg or medetomidine at 4 μg/kg, induced with a 
combination of ketamine at 2 to 6 mg/kg and diazepam at 0.1 to 0.5 mg/kg, intubated and 
maintained under gaseous isoflurane anesthesia.  Strict aseptic technique was followed 
throughout the catheter placement procedure. 
  
3.1.2.2.1 Atlanta-occipital CSF catheter 
A spinal Tuohy needle (18 G, 9 cm) from a freshly opened epidural kit (Mila 
International Inc., Florence, Kentucky, USA) was inserted into the subarachnoid space 
(cisterna magna, site confirmed by needle ‘pop’ and aspiration of CSF).  The catheter (20G, 
9203 wire reinforced, closed end) was threaded 10 to 15 cm into the space, the needle 
withdrawn, and a sampling adaptor and cap attached to the open end of the tube.  The 
catheter was fixed in place with a butterfly tape and sutures near the skin-catheter interface.  
The sampling tip was closed with an infusion cap, wrapped in sterile gauze soaked in 
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chlorhexidine acetate 1% (Hibitane® Veterinary Ointment; Wyeth Animal Health, Division 
of Wyeth Canada, Guelph, Ontario, Canada) and placed in a sterile plastic bag. 
  
3.1.2.2.2 Jugular intravenous catheters   
A sterile catheter was made using sterile vinyl tube (Dural Plastics and 
Engineering, Auburn, Australia) with an inner diameter of 1 mm and a length of 45 cm.  
The catheter was inserted through a needle into the jugular vein.  The catheter was placed 
25-30 cm into the vein (depending on the calf body weight) so that the tip lay in the 
anterior vena cava.  The sampling end was tunneled subcutaneously (5-6 cm) to reduce the 
possibility of thrombophlebitis.  Both jugular veins were catheterized; one catheter was 
used for infusion and the other for venous blood sampling.  The entire neck was covered 
with sterile dressing to protect the three catheters.  Pockets in the dressing allowed access 
to the catheters. 
 
3.1.2.2.3 Ear arterial catheter  
A freshly opened arterial catheter (22-G [0.9 mm] × 25 mm length, BD InsyteTM; 
Becton Dickinson, Infusion Systems Inc., Sandy, Utah, USA) was placed in the ear artery 
on the dorsal surface of one of the ears for arterial sampling. 
 
3.1.2.3 Post surgical care 
The post surgical rest period was a minimum of 4 days during which the 
catheterized calves were treated with an antibiotic, enrofloxacin, 5 mg/kg (Baytril® 100 
injectable solution; Bayer HealthCare, Bayer Inc., Animal Health Division, Toronto, 
Ontario, Canada) and an analgesic, ketoprofen, 3 mg/kg (Anafen® 100; Merial Canada Inc., 
500 boul. Morgan, Baie d’Urfe, Quebec, Canada) intra muscularly.  Sixteen calves were 
surgically catheterized; eight remained healthy with functioning catheters and were used 
for infusions (Table 1).  Following completion of the experiment, two calves were 
randomly euthanized using IV dose (2 mL/4.5 kg) of Pentobarbital Sodium USP 
(Euthanyl®, 240 mg/mL, Din 00141704; Bimeda-MTC Animal Health Inc, Vėtoquinol 
Canada Inc (distributor), Lavaltrie, Quebec, Canada) to confirm the location of the 
catheters at necropsy.  This was carried out to ensure that CSF was being sampled.  The 
placement of CSF catheters in surviving calves was confirmed by contrast radiology. 
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3.1.2.4 Experimental design  
The calves (n = 8) with indwelling cerebrospinal fluid (CSF), venous and arterial 
blood catheters were experimentally infused for 6 h with solutions of DL-lactic acid (DL-
LA), L-lactic acid (L-LA), hydrochloric acid (HCl) or physiological saline (NaCl) as a 
control.  The order of treatments was randomly assigned.  CSF fluid, venous and arterial 
blood were sampled over a 24 h period and concentrations for D- and L-lactic acid and 
blood gas values were determined.  Neurological assessments of the calves were also 
carried out throughout the experimental period.  The study received approval from the 
Animal Research Ethics Board of the University of Saskatchewan, and was carried out in 
accordance with the guidelines specified by the Canadian Council on Animal Care 
(Canadian Council on Animal Care 1993).  
 
3.1.2.5 Infusates and infusion protocol 
DL-LA, L-LA (Sigma-Aldrich, St. Louis, Missouri, USA), and HCl (BDH Inc. 
Toronto, Ontario, Canada) were formulated as 300 mmol/L solutions while saline (NaCl; 
EMD Chemicals Inc., Gibbstown, New Jersey, USA) was 150 mmol/L; pH values, mean ± 
se, for the four solutions were 2.5 ± 0.1, 2.6 ± 0.1, 1.2 ± 0.2 and 5.6 ± 0.1, respectively.   
By analysis, DL-LA contained 53% D-lactate and 47% L-lactate.  DL-LA was the 
choice of infusion instead of pure D-lactic acid due to financial circumstances.  Since bulk 
quantities (8-10 L of 300 mmol/L) of infusions needed for a calf, purchase of D-lactic acid 
in such quantities was not affordable.  All infusates were autoclaved prior to use. A 
separate experiment with three sets of solution documented a small loss in weight to 99.93 
± 0.02 % of the original weight and no loss of lactate or its isomers following autoclaving; 
for DL-lactate solutions, D-lactate concentrations, mmol/L, were 141.5 ± 1.4 and 144.7 ± 
1.1, L-lactate 146.5 ± 2.0 and 150.6 ± 1.4 pre and post autoclaving respectively. 
The eight calves randomly received intravenous infusions of DL-LA, L-LA, HCl 
or saline (Table 1) at an infusion rate of 20 mL/kg BW per hour using an automated 
infusion pump (Imed 980 volumetric infusion pump; Imed Corporation San Diego, 
California, USA) for 4 h.  Infusion was continued for a further 2 h or until venous pH 
reached 7.05.  If venous pH rose above 7.1 which was considered a typical lower point in 
acidosis, infusion was restarted.  After 12 h from the beginning of the infusion, severely 
acidotic calves were treated with 155 mmol/L NaHCO3 (Sigma-Aldrich, St. Louis, 
Missouri, USA) solution to correct blood pH and alleviate neurological disturbance.  There 
was a minimum period of 2 days between each infusion.  
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3.1.2.7 Sampling and measurements 
Samples of CSF fluid (~0.7 mL), venous (4 mL) and arterial (1 mL) blood were 
collected, and neurological assessment was performed at –1 (pre infusion), 0 (start of 
infusion), 1, 2, 3, 4, 5, 6 (completion of infusion), 7 (post infusion), 8, 10 and 24 h.  
Neurological assessment was performed by a veterinarian who was blinded to the 
type of infusion being administered.  Neurological function was scored based on the 
strength of the suck, menace (response of the integrity of the entire visual pathway), 
palpebral (sensory component-trigeminal nerve and motor component-facial nerve), tactile 
(local sensitivity along spine) reflexes, and ability to stand (Kasari and Naylor 1986; 
Lorenz 2004b; Naylor 1989).  Each item was given a score of from 0 (normal) to 2 
(severely abnormal) according to a previously published scale (Kasari and Naylor 1986).  
The values were summated to produce a total neurological score (TNS).  Calves with 
normal CNS function had scores of 0 while severely obtunded calves could have a 
maximum score of 10. 
 
3.1.2.8 Laboratory analyses 
Heparinized arterial and venous blood (1 mL each) and 0.3 mL of CSF fluid were 
placed on ice and analyzed within 40 minutes of collection for pH, bicarbonate (HCO3¯), 
base excess, partial pressure of carbon dioxide and oxygen (PCO2 and PO2) using a blood gas 
analyzer (ABLTM 5; Radiometer Medical A/S, Copenhagen, Denmark) (Severinghaus 
2002).  Hemoglobin and its oxygenation status were measured in a hemoximeter (OSM3; 
Radiometer Medical A/S, Copenhagen, Denmark) (Zwart et al. 1987).  
The remaining venous blood (3 ml) was allowed to coagulate for 20 min, and 
serum was separated in a refrigerated centrifuge (IEC Centra-7R Refrigerated Centrifuge; 
International Equipment, Needham Heights, Massachusetts, USA) at 1,000 RCF for 30 
min.  The serum and remaining CSF fluid were stored at –20°C. D- and L-lactate 
concentrations were measured from 0.1 ml of serum or CSF sample using an HPLC system 
(Waters 600 HPLC pump, 486 UV detector, 786 Ultra WISP autoinjector, and Millenium v. 
4 software; Waters, Mississauga, Ontario, Canada) as we previously described (Omole et 
al. 1999).  The sample mixed with an internal standard (2 mmol/L malonic acid) in 1:1 
vol/vol ratio was centrifuged and filtered to deproteinize via Ultrafree®-MC 5000 NMWL 
filter units (Millipore Corporation, Bedford, Massachusetts, USA) under 3000 RCF 
(AccuSpin Micro 17; Fishers Scientific,  Schwerte, Germany) for 30 min.  For the 
separation of D- or L-lactate isomer a stereoselective 3 µm ODS-packed (50 mm × 4.6 
mm) analytical ligand exchange column coated with N,N-dioctyl-alanine (ChiralPak MA+; 
Chiral Technologies, Exton, Pennsylvania, USA) was employed.  A Guard-Pak Precolumn 
Module containing an ODS (octadecylsilyl) cartridge (Waters Guard-Pak™ precolumn; 
Waters) insert was placed serially ahead the analytical column to reduce the risk of 
obstruction and to enhance elution capability.  The mobile phase was a 2 mmol/L copper 
sulfate in 1% acetonitrile.  The flow rate for the mobile phase was 0.4 mL/min and the 
column worked at room temperature (25 ºC).  UV detection occurred at 236 nm wavelength 
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(Omole et al. 1999); 20 μl aliquots of the final filtrate were injected into the HPLC system 
and a sample was run for 30 min (Ewaschuk et al. 2002). 
Infusate pH was measured using a pH meter (Beckman Ø 32 pH meter; Beckman 
Instruments Inc., Fullerton, California, USA). 
 
3.1.2.9 Statistical analysis 
Graphs and Figures were created using a spreadsheet (Microsoft Excel; Microsoft 
Corporation, Redmond, Washington, USA).  Descriptive statistics and Pearson Correlation 
Coefficients were calculated using a statistical analytical software package (SPSS statistical 
software v.13, 2005; SPSS Inc., Chicago, Illinois, USA).  Analysis of Variance (ANOVA) 
and Multivariate Analysis of Variance (MANOVA) with Repeated Measures was carried 
out using SAS statistical software (SAS/Stat® statistical software package for Windows, v. 
8.02; SAS Institute Inc., Cary, North Carolina, USA).  The significance of treatment effects 
on neurological scores, blood gas values, and serum and CSF lactates was determined by 
repeated measures analysis of variance using treatment (infusion) as the independent 
variable (Steel and Torrie 1980).  Mean values at individual time points were compared 
using the Student-Newman-Keul’s (SNK) test.  Treatment differences were also tested 
using orthogonal contrasts to compare DL-LA versus HCl, L-LA and saline.  Polynomial 
contrast was also used to deferenciate CSF and serum D-lactate concentrations.  A P value 
of ≤ 0.05 was considered to be statistically significant.  Values are reported as mean and 
standard error (mean ± se).  
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3.1.3 Results 
All infusions were continued for 6 h except for HCl which was given 
intermittently between hours 4 and 6 to maintain venous pH above 7.0 and below 7.10. 
 
3.1.3.1 Neurological assessment 
Saline had no effect on neurological score (Figure 6).  L-LA and HCl infusions 
produced mild impairments in neurological function and had no significant effect on the 
menace, tactile and palpebral reflexes at any time period (Video clip 1.).  DL-LA infused 
calves had a significantly reduced menace reflex between 1 and 10 h; the menace response 
was completely absent at 6 h, 7 h and 8 h of infusion.  Ability to stand was significantly 
inhibited by DL-LA infusion between 2 and 10 h; weakness was detected at 2 h, developed 
into ataxia at 4 h, and progressed to involuntary recumbency at 8h.  During infusions other 
than DL-LA, involuntary recumbency was only seen on one occasion, in a calf receiving L-
LA.  In DL-LA infused calves significant reductions in the palpebral and tactile reflexes 
were first detected at 3 h, increased to maximum at 7 or 8 h (Video clip 2) and slightly 
recovered by 10 h.  The suck reflex was unusual in that HCl and DL-LA similarly 
depressed this reflex; L-LA had a smaller effect (Figure 6). 
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Figure 6. Change in total neurological score [graph A] and suck reflex [graph B] during (0 
to 6 h) and after infusion of DL-lactic acid (DL-LA ), L-lactic acid (L-LA ), 
hydrochloric (HCl ) or saline ( ).  Values at 24 h returned to baseline. Repeated measures 
analysis showed significant effects of treatment (P < 0.01), time (P < 0.01), and treatment 
versus time interaction (P < 0.01).  Values at each time point that do not share a common 
letter (a, b, c or d) are statistically significant at P < 0.05 by Student-Newman-Keul’s test. 
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Video clip 1. Minimal or no neurological signs at 4 h after infusion of hydrochloric acid 
(300 mmol/L) in calves.  Mean serum D-lactate concentrations were > 0.5 mmol/L at 6 h 
and the infusion was discontinued. However, mean serum pH was > 7.1.  (Please double 
click on the middle of the media player to see the video). 
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Video clip 2. Severe neurological disturbances at 6 h after infusion of DL-lactic acid (DL-
LA, 300 mmol/L) caused paralysis to calves.  Mean serum D-lactate concentrations were > 
10 mmol/L at 6 h and the infusion was discontinued.  However, mean serum pH was > 7.2.  
(Please double click on the middle of the media player to see the video).
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3.1.3.2 Acidosis  
HCl infusion produced the most severe metabolic acidosis which reached a nadir 
at 4 h of infusion: venous blood pH 6.9 ± 0.1, bicarbonate 7.00 ± 1.45 mmol/L and BE -
23.3 ± 1.7 mmol/L. DL-LA produced a moderate metabolic acidemia.  In contrast, L-LA 
infusion resulted in little change in acidemia with blood gas values similar to those during 
saline infusion (Table 2).   
Both HCl and DL-LA infusions produced similar decreases in CSF pH, 
bicarbonate (Figure 7) and PCO2 (Table 2).  Arterial blood bicarbonate (r = 0.87), BE (r = 
0.84), and PCO2 (r = 0.78) were highly correlated (P < 0.01) with the corresponding CSF 
measurements.  However, arterial and CSF pH were only moderately correlated (r = 0.57, P 
< 0.05).  The correlations between CSF and venous blood gas measurements were not as 
strong; correlations for CSF and venous measurements of bicarbonate, PCO2 and pH were 
0.85, 0.56 and 0.46 respectively. 
  
3.1.3.3 D- and L-lactate concentrations 
Serum and CSF D-lactate were only increased by DL-LA infusion.  Venous 
serum and CSF D-lactate concentrations were highly correlated (r = 0.91, P < 0.01). 
However, changes in CSF D-lactate lagged those in serum (Table 3). 
Serum L-lactate concentrations were unaffected by HCl infusion, increased to a 
moderate extent during DL-LA infusion and were highest during L-LA infusion.  CSF L-
lactates were also highest with L-LA infusion and moderately increased with DL-LA 
infusion (Table 2).  During L-LA infusion, peak CSF L-lactate concentrations were 
attained at 6 h (11 ± 1 mmol/L) and were similar to peak serum L-lactate concentration (10 
± 1 mmol/L).  During DL-LA infusion, CSF L-lactate concentration (8 ± 1 mmol/L) 
peaked at 6 hours, and was 60% higher than serum concentration (5 ± 2 mmol/L).  During 
DL-LA infusion peak serum and CSF L-lactate concentrations were considerably lower 
than those of peak D-lactate concentrations (Table 2). 
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Figure 7. Change in cerebrospinal pH [graph A] and bicarbonate concentration [graph B] 
during (0 to 6 h) and after infusion of DL-lactic acid (DL-LA ), L-lactic acid (L-LA ), 
hydrochloric (HCl ) or saline ( ).  Values at 24 h returned to baseline. Repeated measures 
analysis showed significant effects of treatment (P < 0.01), time (P < 0.01), and treatment 
versus time interaction (P < 0.01).    
a
b
b
b
b
b b
ab
a
aaaa
a
aa
abc
a
b
bbbb
b
c
b b
a
a
aaaaaa
b
7.1
7.15
7.2
7.25
7.3
7.35
7.4
-2 0 2 4 6 8 10 12
Time (h)
C
SF
 p
H
A
b
bc
b
b
b b b b
aaa
aaaaab
c
c
c b b b b b
a
a
aaaaaa
5
10
15
20
25
30
-2 0 2 4 6 8 10 12
Time (h)
C
S
F 
bi
ca
rb
on
at
e 
(m
m
ol
/L
) B
C
SF
 p
H
C
SF
 p
H
C
S
F 
bi
ca
rb
on
at
e 
(m
m
ol
/L
)
C
S
F 
bi
ca
rb
on
at
e 
(m
m
ol
/L
)
   
  
 
 
 46 
  
 
Table 2. Effects of DL-LA, L-LA, HCl, or saline infusions on arterial, venous and 
cerebrospinal fluid blood gas values, and cerebrospinal fluid and venous-serum lactate 
concentrations 
 Infusions P- value 
DL-LA* L-LA* HCl Saline 
Serum 
D-lactate, mmol/L 23.5±0.7 1.1±0.2 (0.01)† 0.9±0.1 (0.01)† 0.6±0.1 (0.01)† <0.01 
L-lactate, mmol/L 4.5±0.4 8.5±0.5 (0.02) 1.7±0.2 (0.12) 1.8±0.1 (0.01) <0.01 
Venous blood 
pH 7.21±0.02 7.33±0.02 (0.01) 7.05±0.02 (0.01) 7.35±0.01 (0.01) <0.01 
BE, mmol/L -11.1±1.0 0.4±0.9 (0.01) -18.6±1.0 (0.01) 1.7±1.0 (0.01) <0.01 
HCO3-, mmol/L 15.6±0.6 25.3±0.9 (0.01) 10.1±0.5 (0.04) 26.5±0.9 (0.01) <0.01 
PCO2 , mm Hg 40.3±1.4 48.0±1.9 (0.01) 34.2±1.7 (0.75) 49.7±1.5 (0.01) 0.03 
PO2, mm Hg 44.3±1.2 39.5±1.8 (0.69) 41.4±2.3 (0.35) 36.4±1.3 (0.02) 0.32 
Hemoglobin, g/L 82.9±9.2  74.1±6.5 (0.54) 85. 7±8.9 (0.80)ƈ 75.6±7.8 (0.39) 0.82 
Arterial blood 
pH 7.26±0.02  7.38±0.02 (0.01) 7.08±0.02 (0.01) 7.41±0.01 (0.01) <0.01 
BE, mmol/L -11.1±1.1 -3.0±0.9 (0.01) -20.2±0.9 (0.01) 2.8±1.6 (0.01) <0.01 
HCO3-, mmol/L 14.3±0.1 20.9±1.1 (0.01) 7.4±0.7 (0.01) 26. 6±1.9 (0.01) <0.01 
PCO2 , mm Hg 32.8±1.7 36.8±1.7 (0.07) 25.2±1.9 (0.01) 44.1±2.9 (0.01) <0.01 
PO2, mm Hg 107.1±5.3 105.0±7.2 (0.25) 120.2±5.5 (0.68) 95.3±6.9 (0.25) 0.04 
Hemoglobin, g/L 71.8±10.0 62.3±6.7 (0.41) 74.5±9.1 (0.69) 61.8±13.3 (0.33) 0.71 
CSF 
D-lactate , mmol/L 14.8±3.8 0.2±0.1 (0.01) 0.2±0.1 (0.01) 0.04±0.01 (0.01) <0.01 
L-lactate, mmol/L 6.9±1.2 10.7±0.8 (0.04) 3.8±1.0 (0.08) 3.4±0.5 (0.01) <0.01 
pH 7.24±0.04 7.29±0.02 (0.01) 7.20±0.06 (0.33) 7.29±0.02 (0.01) 0.170 
HCO3-, mmol/L 18.3±0.9 22.5±0.9 (0.01) 16.3±1.8 (0.55) 24.2±1.7 (0.01) <0.01 
PCO2, mm Hg 44.9±2.5 49.5±2.5 (0.02) 43.4±3.9 (0.75) 53.3±1.9 (0.05) 0.07 
PO2, mm Hg 80.9±1.6 73.2±3.8 (0.67) 81.7±3.5 (0.51) 83.1±2.9 (0.35) 0.82 
 
* Values are mean ± se for data collected between 1 and 7 h of infusion. 
† P-values shown in parenthesis were determined for values between 1 and 7 h of infusion 
inclusive by Repeated Measures MANOVA (over-all P-value) and orthogonal contrast 
comparison for DL-LA versus L-LA, HCl or saline. 
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3.1.3.4 Removal of D-lactate from the body compartments 
Following cessation of infusion, serum D-lactate concentrations declined in an 
exponential fashion with time (r = 0.98, P < 0.01).  Removal of D-lactate from CSF was 
slower, and more gradual than from serum (Figure 8).  CSF removal was constant over the 
12 h post-infusion period while removal from serum declined with time and correlated (r = 
0.73, P < 0.01) with serum D-lactate concentration. 
  
3.1.3.5 Correlation of neurological disturbances with changes in blood 
and CSF chemistry 
CSF and serum D-lactate concentrations strongly correlated (P < 0.01) with all 
neurological scores except for the strength of the suck reflex (Table 3).  Although DL-
lactate concentrations in the CSF and serum also strongly correlated with neurological 
signs, L-lactate concentrations correlated weak (Table 3).  
The suck reflex was affected similarly by both DL-LA and HCl infusions (Figure 
6) and was better correlated with CSF bicarbonate, BE or pH than with CSF D-lactate 
concentration (Table 3).  Arterial or CSF pH or bicarbonate correlated weakly with other 
reflexes and with total neurological score (Table 3). 
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Figure 8. Change in serum ( ) and cerebrospinal fluid ( ) D-lactate concentration during 
(0 to 6 h) and after infusion of DL-LA.  Values at 24 h returned to baseline.  There was no 
change in serum or CSF D-lactate concentrations from baseline during infusion of saline, 
HCl or L-LA (data not shown).  At all time points from 1 to 10 h inclusive D-lactate 
concentrations in serum and CSF were significantly higher with DL-LA than saline, HCl or 
L-LA infusion.  Repeated Measures (polynomial contrast) and SNK showed significant 
statistical differences (P < 0.05).  Values at each time point that do not share a common 
letter (a or b) are statistically significant at P < 0.05. 
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Table 3. Correlation of total neurological score (TNS), menace, palpebral, tactile, stand 
and suck with individual CSF and blood parameters 
Parameter TNS Menace Palpebral Tactile Stand Suck
CSF D-lactate 0.86* 0.85* 0.88* 0.81* 0.88* 0.34* 
CSF L-lactate 0.22* 0.21* 0.11NS 0.07NS 0.17† 0.38* 
CSF D+L-lactate‡ 0.89* 0.87* 0.87* 0.79* 0.85* 0.53* 
CSF HCO3- -0.48* -0.35* -0.41* -0.39* -0.43* -0.57* 
CSF pH -0.37* -0.30* -0.33* -0.28* -0.30* -0.44* 
CSF PCO2 -0.25* -0.13NS -0.20* -0.22* -0.26* -0.32*
 
Serum D-lactate 0.83* 0.63* 0.56* 0.66* 0.65* 0.29* 
Serum L-lactate 0.13† -0.02NS -0.09NS -0.06NS -0.03NS 0.12NS 
Serum D+L-lactate‡ 0.85* 0.83* 0.74* 0.78* 0.81* 0.53*
 
Venous HCO3- -0.43* -0.33* -0.34* -0.36* -0.37* -0.49* 
Venous BE -0.42* -0.31* -0.31* -0.34* -0.34* -0.50* 
Venous pH -0.35* -0.23* -0.21* -0.25* -0.26* -0.44* 
Venous PCO2 -0.26* -0.23* -0.30* -0.27* -0.26* -0.39*
 
Arterial HCO3- -0.42* -0.34* -0.29* -0.30* -0.36* -0.57* 
Arterial BE -0.40* -0.32* -0.27* -0.29* -0.34* -0.56* 
Arterial pH -0.33* -0.26* -0.19† -0.24* -0.29* -0.49* 
Arterial PCO2 -0.28* -0.19† -0.23* -0.15 NS -0.21† -0.48* 
 
Correlations (r) are calculated using all values obtained between from -1 to 24 h inclusive 
for all four infusions, number of calves = 8.  ‡ indicates total of D and L isomer 
concentration (mmol/L). 
* and † indicate statistically significant correlation at P < 0.01 and < 0.05 respectively. 
NS indicates not significant at P = 0.05. 
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3.1.4 Discussion  
D-lactic acidosis has been associated with neurological dysfunction in a variety of 
species including humans, cattle, cats and dogs (Jorens et al. 2004; Packer et al. 2005; 
Petersen 2005; Uribarri et al. 1998).  The reported signs in humans include slurred speech, 
loss of reflexes, abnormal gate, ataxia, paresis, and sometimes coma.  In calves (Lorenz et 
al. 2005) and cats (Packer et al. 2005) impairment of palpebral and menace reflexes have 
been reported in association with other neurological signs.  While clinical studies have 
consistently shown an association between D-lactate concentration and neurological 
disturbances a causal link has not been established (Hudson et al. 1990; Jorens et al. 2004; 
Packer et al. 2005; Petersen 2005; Uribarri et al. 1998; Zhang et al. 2003).  In many of 
these studies, other parameters, such as acidemia were also associated with CNS 
impairment. In this study, severe acidemia and mild impairments of neurological function 
were induced by HCl infusion alone whereas DL-LA infusion produced severe 
neurological derangements (Figure 6).  These derangements are similar to those reported 
clinically and include ataxia, decreased palpebral and menace reflexes.  These severely 
affected calves became ataxic, developed involuntary recumbency (Video clip 2) and 
appeared comatose.  This toxicity is independent of changes in blood or CSF pH because 
HCl infusion produced a more severe metabolic acidosis and a similar CSF acidosis but 
only small changes in neurological function (Video clip 1).  Toxicity is also unrelated to 
the L-LA component of the DL-LA infusion as infusion of pure L-LA produced a more 
marked L-lactatemia but had only small effects on neurological function.  Thus, D-lactate 
was the neurotoxic agent in this study. The majority of the infused D-lactic acid would 
dissociate into D-lactate and hydrogen ions in the blood stream.  The conclusion that D-
lactate is neurotoxic is supported by the high correlation between CSF D-lactate 
concentrations and neurological disturbances (Table 3).  A secondary role for L-LA cannot 
be completely excluded, as this was also infused and DL-lactate concentrations also had 
strong correlations with neurological scores (Table 3).  However, this inference that D-
lactate is neurotoxic is consistent with earlier work in which signs of ataxia, somnolence 
and impaired palpebral reflexes developed following hypertonic sodium D-lactate injection 
in calves (Lorenz et al. 2005).  This study also indicates that D-lactate, not hypertonicity as 
some have proposed (Stampfli 2005), is the toxic agent.  D-lactate may be transported into 
neurons with either sodium or hydrogen ions via Na+- or H+-monocarboxylate transporters 
(Martin et al. 2006; Shimozono et al. 1998).  Hence, either D-lactate or D-lactic acid may 
be the toxic agent intracellularly. 
In previous experiments, oral administration of DL-LA did not significantly 
influence humans physiologically or pathologically (De Vrese et al. 1990).  This lack of 
effect can be explained by the much smaller amounts of DL-LA administered, a maximum 
of 12.8 mmol/kg0.75 of racemic DL-LA per day.  The total dosage administered in the 
present experiment was 8 times higher.  Consequently, plasma D-lactate did not exceed 1 
mmol/L in the previous experiment whereas we obtained peak serum concentrations of 
around 36 mmol/L.  Clinical reports of neurological dysfunction suggest that D-lactate 
concentrations have to be at least 3 mmol/L before clinical signs are seen (Uribarri et al. 
1998). 
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In the present study the suck reflex (Figure 6) was correlated more strongly with 
CSF bicarbonate, base excess and pH than with CSF D-lactate concentration (Table 3).  
Similarly, clinical studies in calves have noted that ataxia and loss of the palpebral reflex 
are correlated with D-lactate concentrations whereas the strength of the suck reflex is 
correlated with acidemia (Lorenz 2004b).  Taken together, this work suggests that acidemia 
depresses the suck reflex but is not responsible for ataxia or changes in the palpebral reflex. 
In the present study, neurological depression was first observed at 2 h of DL-LA 
infusion when mean serum D-lactate was 16 ± 1 mmol/L which is higher than the serum D-
lactate concentrations of about 3 mmol/L reported in some clinical cases (Uribarri et al. 
1998).  Previous studies in this laboratory established that diarrheic calves with 
neurological depression have serum D-lactate concentrations as high as 26 mmol/L 
(Ewaschuk et al. 2004; Omole et al. 2001).  The serum D-lactate concentrations in this 
infusion study are well below the serum value (110 mmol/L) reported in a patient 
intoxicated after over-ingestion of propylene glycol (Jorens et al. 2004).  Furthermore, 
these data show that it takes time for D-lactate to diffuse into the CSF.  At 1 h of infusion, 
mean serum D-lactate was 11 ± 1 mmol/L but CSF D- lactate was 2 ± 1 mmol/L.  It is 
possible that a more gradual infusion would result in greater equilibration between CSF and 
blood D-lactate concentrations with clinical signs at lower venous serum D-lactate 
concentrations. 
In the brain, astrocytes are net producers of L-lactate, because their thin processes 
are too small to accommodate mitochondria (Hertz et al. 2007; Hyder et al. 2006).  The L-
lactate is metabolized by neurons (Aubert et al. 2005; Bouzier-Sore et al. 2006; Hyder et al. 
2006; Medina and Tabernero 2005; Schurr 2006).  It has been estimated that 75% of 
neuronal oxygen consumption is accounted for by L-lactate metabolism and 25% by 
glucose metabolism (Bouzier-Sore et al. 2006).  Lactate utilization may be particularly 
important during acidemia, since low pH can inhibit phospofructokinase activity, a key 
glycolytic regulatory enzyme (Kreisberg 1980).  In neurons, uptake of L-lactate is close to 
saturation at physiologic L-lactate concentrations (Hertz and Dienel 2005).  D-lactate 
blocks the ability of isolated optic nerves to generate an action potential, probably by 
competitively blocking L-lactate entry into neurons and limiting neuronal metabolism 
(Tekkök et al. 2003; Tekkök et al. 2005).  L-lactate can act as an energy source during 
ischemia / reperfusion injury and reduces cerebral injury (Cassady et al. 2001; Ros et al. 
2001).  In contrast, D-lactate enhances neuronal injury in ischemia-reperfusion models 
(Cassady et al. 2001).  Although, D-lactate dehydrogenase is found in mammalian 
mitochondria, particularly in liver and kidney, it is poorly expressed in human brain tissue 
(Flick and Konieczny 2002).  It is therefore possible that the neurotoxic effects of D-lactic 
acid infusion observed in the present study are the result of reduced L-lactate availability 
within neurons and energy deficit.  In support of this, the serum-CSF L-lactate difference 
was slightly greater during DL-lactate infusion; this may reflect reduced neuronal removal 
of astrocyte produced L-lactate, Table 2.  Similarly, others have shown that blockade of 
neuronal monocarboxylate transporters responsible for L-lactate entry results in increased 
neuronal cell death in the developing brain (Adle-Biassette et al. 2007). 
Rapid ethanol consumption is another situation where acute neurological signs are 
observed in humans (Handley and Ward-Smith 2005).  We were impressed with the 
‘drunken’ appearance of these calves during DL-LA infusion.  In acute ethanol 
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consumption, neurological depression may be caused by low concentrations of circulating 
tryptophan (Badawy et al. 1995) or interactions with the GABAA receptor complex and 
facilitation of GABA action (Gonzales and Hoffman 1991; Starke 1991).  However, 
ethanol also has early effects on energy metabolism (Adle-Biassette et al. 2007; Juhlin-
Dannfelt 1977; Volkow et al. 2006) which may be similar to some of the actions of D-
lactate. 
In addition to lipid mediated penetration (Oldendorf et al. 1979), L-lactate may be 
transported across the blood brain barrier by mono-carboxylic acid transporters (Gladden 
2004; Hertz and Dienel 2005; Schurr 2006) which are stereo specific (Tekkök et al. 2003; 
Tekkök et al. 2005).  During DL-LA infusion, CSF L-lactate concentrations increased 
steadily and were higher than serum concentrations by a similar amount in all infusions 
(Table 2).  L-lactate was probably being formed within nervous tissue by metabolism of 
glucose and this likely contributes to the higher concentrations in CSF (Aubert et al. 2005; 
Gladden 2004).  In this study D-lactate rapidly crossed the blood brain barrier, although 
CSF concentrations were about half those of serum (Table 2).  This could be explained by 
serum L-lactate competing with serum D-lactate for uptake from blood by CSF tissue 
(Tekkök et al. 2003; Tekkök et al. 2005).  
In the present study, and in previous work (Lorenz et al. 2005), serum D-lactate 
exhibited an exponential decay.  However, CSF D-lactate removal was constant over the 
period studied suggesting that the metabolic process involved in removal was saturated. 
Mono-carboxylic transporters may remove D-lactate from CSF (Tekkök et al. 2003; 
Tekkök et al. 2005).  In contrast, D-lactate removal from blood occurs at least in part 
through renal clearance (Connor et al. 1983; Ewaschuk et al. 2004; Ewaschuk et al. 2005; 
Jørgensen and Sheikh 1984; Oh et al. 1985; Ullrich et al. 1982b).  This slow elimination of 
CSF D-lactate would explain the prolonged neurological disturbances and encephalopathy 
observed in many clinical DLA cases even after treatment has been initiated (Petersen 
2005; Puwanant et al. 2005; Uribarri et al. 1998).  Serum L-lactate elimination was not 
exponential.  Previous studies show that serum L-lactate is cleared through two 
independent processes: Hepatic removal follows second order kinetics while 
extrasplanchnic removal is linearly related to serum concentration (Naylor et al. 1984).  D-
lactate may also be taken up by hepatic and extrahepatic tissue (De Bari et al. 2002; Naylor 
et al. 1984), although some is excreted in urine (Connor et al. 1983; Ewaschuk et al. 2004; 
Ewaschuk et al. 2005; Jørgensen and Sheikh 1984; Oh et al. 1985; Ullrich et al. 1982b).  
The current understanding of the distribution of lactate enantiomers supported by this study 
is summarized in Figure 9.  
D-lactate is a potent neurotoxic agent. In acidemic calves, the majority of 
neurological signs (i.e. ataxia, and depressed menace, palpebral and tactile reflexes) are 
related to D-lactate accumulation in CSF rather than in blood or to acidosis in CSF.  
According to our observations and evaluations, this total neurological score (TNS) which 
was characterized by the above depressive signs was a state of neurological disturbance.  
Therefore we refer to TNS as neurological disturbance in the future sections of our studies. 
HCl infusion has mild depressive effects on neurological function and the suck 
reflex was similarly depressed by both DL-LA acid and HCl infusions. D-lactate 
accumulation may be responsible for the majority of clinical signs of depression and loss of 
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function in a variety of diseases including neonatal calf diarrhea and other animal and 
human syndromes characterized by DLA.  Research needs to be undertaken to determine 
the precise mechanism of neurological depression caused by D-lactate. 
 
 
 
 
Figure 9. Serum and CSF peak concentrations of lactate at 6 hours of either DL-lactic acid 
(DL-LA) or L-lactic acid (L-LA) infusions, and possible fate of D and L-lactate in serum 
and CSF. Peak mean ± se values are reported.  
٭Adopted from previous workers (Connor et al. 1983; De Bari et al. 2002; Ewaschuk et al. 
2004; Ewaschuk et al. 2005; Gladden 2004; Hertz and Dienel 2005; Jørgensen and Sheikh 
1984; Magistretti and Pellerin 1999; Medina and Tabernero 2005; Naylor et al. 1984; Oh et 
al. 1985; Oldendorf et al. 1979; Schurr 2006; Ullrich et al. 1982b). 
 % removals of L- or D-lactates from serum were calculated using a formula. 
 % removal = (amount infused  –  amount remained in serum) / amount infused × 100. 
Amount infused = infused volume of infusate × concentration in infusate.  
Amount remained in serum = concentration in serum × plasma volume. 
Plasma volume = 10% of calf body weight (Quigley et al. 1998) 
Infused volume = pump flow rate × time. 
(CSF – cerebrospinal fluid, BBB – blood brain barrier, ↑ - higher route). 
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3.2 Effects of sodium bicarbonate therapy on blood, CSF, and 
neurological status in experimentally induced metabolic and D-lactic 
acidosis 
3.2.1 Introduction 
Intravenous (IV) infusion of sodium bicarbonate (NaHCO3) is the mainstay of 
therapy for severe acidemia (Charles and Heilman 2005; Narins and Cohen 1988).  
Treatment with IV NaHCO3 solutions can alleviate potentially dangerous effects of the 
acidotic state (Narins and Cohen 1987; Naylor et al. 2006; Suzuki et al. 2002a).  However, 
there is concern that rapid NaHCO3 therapy can lead to paradoxic CSF acidosis and other 
problems (Arieff et al. 1982; Feeney-Stewart 1990; Forsythe and Schmidt 2000; Forsythe 
and Schmidt 2000; Graf and Arieff 1986).  One concern is that increased blood PCO2 can 
diffuse into the CSF, increasing CSF PCO2; which can be followed by dissociation into 
protons and bicarbonate acidifying the CSF (Figure 10) (Astrup et al. 1966; Herrera and 
Kazemi 1980; Javaheri et al. 1979).  The condition is referred to as paradoxic CSF acidosis 
because CSF pH falls as blood pH rises (Bureau et al. 1980; Javaheri et al. 1983).  The 
extent of this problem is poorly documented (Berchtold et al. 2005; Holander 1987).  
Changes in CSF pH need to be investigated during NaHCO3 therapy of metabolic acidosis 
(Berchtold et al. 2005; Herrera and Kazemi 1980; Mathieu et al. 1991) to define the nature 
and extent of this problem.  Delayed recovery of CSF pH in HCl induced acute acidosis 
regardless of NaHCO3 infusion in our previous work (see the section 3.1, Abeysekara et al. 
2007). The clinical observation that calves improve their neurological status at a slower 
rate than improvements in blood pH during therapy, and a desire to determine if NaHCO3 
could be given rapidly, making treatment more convenient were concerns which instigated 
our investigation of possible paradoxic CSF acidosis during rapid IV NaHCO3 therapy. 
The primary objective of this second study was to determine the effect of rapid 
versus slow NaHCO3 therapy on acidemia and CSF acidosis in experimentally induced DL-
LA or hydrochloric acid (HCl) acidosis.  A secondary objective was to investigate the 
effects of chronic exposure to concentrations of DL-LA that are commonly encountered in 
disease states on neurological function. 
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Figure 10. Postulated mechanism of how sodium bicarbonate infusion increases blood PCO2 
and then CSF PCO2 to reduce CSF pH and cause paradoxic CSF acidosis (Astrup et al. 1966; 
Herrera and Kazemi 1980; Javaheri et al. 1979). 
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3.2.2 Materials and methods 
This study with calves was approved by the Animal Research Ethics Board of the 
University of Saskatchewan, and was carried out in accordance with the guidelines 
specified by the Canadian Council on Animal Care. 
  
3.2.2.1 Experimental animal model 
Calves (n = 8) with indwelling venous and arterial blood and CSF catheters were 
experimentally infused with solutions of 150 mM DL-LA, or HCl.  Then the acidotic 
calves were treated with equimolar iso-osmotic NaHCO3 infusions for 4 h (rapid) or 24 h 
(slow).  The order of treatments was randomly assigned. 
  
3.2.2.2 Experimental animals and care 
Calves for this study were obtained from the Dairy Barn of the Department of 
Animal and Poultry Sciences, University of Saskatchewan, Canada.  Animal care, feeding 
and management were performed according to our previous work (chapter 3 section 
3.1.2.1, page 34) (Abeysekara et al. 2007). 
Pages 35, 36 and 36 (section 3.1.2) contain details on atlanto-occipital CSF, 
jugular (venous), and ear (arterial) catheterization, and on postsurgical care. 
 
3.2.2.5 Experimental design 
The calves (n = 8) with indwelling CSF, venous, and arterial blood catheters 
randomly received 150 mM solutions of DL-LA or HCl intravenously a rate of 20 mL/kg. 
h-1 for a period of 24 h (intermittent infusion > 12 h) or until they became severely acidotic.  
If hourly venous pH was below 7.05 the infusion was ceased until pH recovered to 7.1.  
After 25 h of acidosis the calves were intravenously treated with equimolar amounts of iso-
osmotic NaHCO3 infused over either 4 h (rapid) or 24 h (slow).  The dosage of NaHCO3 
was calculated using the venous base excess (BE) value at the end of the acidotic stage 
(Naylor and Forsyth 1986; Naylor 1987).  
Equation 1. Bicarbonate required, mmol = BE × body weight × 0.5 (factor) 
 
CSF, and venous and arterial blood were sampled over a 48 h period and 
concentrations for D- and L-lactic acid and blood gas values were determined.  
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Neurological assessments of the calves were also carried out throughout the experimental 
period.   
We ended up with four treatments; HCl followed by rapid NaHCO3 infusion 
(HCl_R), HCl followed by slow NaHCO3 infusion (HCl_S), DL-LA followed by rapid 
NaHCO3 infusion (DL-LA_R), and DL-LA followed by slow NaHCO3 infusion (DL-
LA_S). 
 
3.2.2.6 Infusates and infusion protocol 
DL-LA (Sigma-Aldrich, St. Louis, Missouri, USA), HCl (BDH, Toronto, Ontario, 
Canada) infusions, and NaHCO3 (Sigma-Aldrich, St. Louis, Missouri, USA) treatment 
were formulated as 150 mM; pH values (means ± se) for the three solutions were 2.8 ± 0.1, 
1.4 ± 0.2, and 8.6 ± 0.1, respectively.  By analysis, DL-LA solution contained 51% D-
lactate and 49% L-lactate. All infusates were autoclaved prior to use.  A separate 
experiment with three sets of solutions documented a small loss in weight to 99.95 ± 0.02% 
of the original weight and no loss of lactate or its isomers following autoclaving; for DL-
LA solutions, D-lactate concentrations were 77.5 ± 1.1 and 77.6 ± 1.1 mmol/L, L-lactate 
72.4 ± 1.3 and 72.5 ± 1.4 mmol/L pre- and post-autoclaving, respectively. 
The eight calves randomly received intravenous infusions of HCl, or DL-LA at an 
infusion rate of 20 mL·kg body wt–1·h–1 using an automated infusion pump (Imed 980 
volumetric infusion pump; Imed, San Diego, California, USA) starting at 0h for 4-8 h until 
venous pH reached 7.05; if venous pH dropped below 7.05 acid infusions were ceased until 
pH rose back to 7.1.  Once pH rose above 7.1 acid infusion was restarted and continued 
intermittently until 24 h to maintain venous pH below 7.1.  The calves were then rested for 
an hour.  At 25 h from the beginning of the acid infusion, calves were treated with 
equimolar amounts of iso-osmotic (150 mM) NaHCO3 solution in two regimens; slow, 24 h 
or rapid, 4 h to correct acidosis.  NaHCO3 infusion rates were established using volume/24 
h or volume/4 h accordingly as below. 
   
Equation 2. Slow rate = [(base excess × body weight × 0.5) ÷ 150] ÷ 24 l·h–1 
Equation 3. Rapid rate = [(base excess × body weight × 0.5) ÷ 150] ÷ 4 l·h–1. 
 
There was a minimum of 2 days rest between each infusion protocol. 
 
3.2.2.7 Sampling and measurements 
Samples of CSF fluid (~0.7 ml) and venous (~4 ml) and arterial (~1 ml) blood 
were collected, and neurological assessment was performed at acid infusion hours -25 (pre 
acid infusion), -24, -22, -20, -18, -16, -1 h (completion of acid infusion).  During NaHCO3 
therapies, the sampling and assessments were performed at 0 (start of rapid or slow 
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NaHCO3 therapy), 1, 2, 4 (end of rapid NaHCO3 therapy), 6, 8, 24 h (end of slow NaHCO3 
therapy).  
Neurological assessment was performed by a veterinarian who was blinded to the 
type of infusion being administered.  Neurological function was scored on the basis of the 
strength of the suck, menace, palpebral, and tactile reflexes and ability to stand 
(Abeysekara et al. 2007; Kasari and Naylor 1986; Lorenz et al. 2005; Naylor 1989).  Each 
item was given a score of from 0 (normal) to 2 (severely abnormal) according to a 
previously published scale (see the section 3.1.2.7).  The values were summated to produce 
a total neurological disturbance score.  Calves with normal CNS function had scores of 0, 
whereas severely obtunded calves could have a maximum score of 10. 
 
3.2.2.8 Laboratory Analyses 
See section 3.1.2.8, page 38 for details. 
 
3.2.2.9 Statistical Analysis 
Descriptive statistics, ANOVA and MNOVA with repeated measures were carried 
out using a statistical analytical software package (SPSS statistical software v. 15, 2006; 
SPSS, Chicago, Illinois, USA).  The significance of treatment effects on neurological 
scores, blood gas values, and serum and CSF lactates which were reported in Table 4, was 
determined by repeated-measures ANOVA / MANOVA with treatment (infusion and 
therapies) as the independent variable (Steel and Torrie 1980) using SAS statistical 
software (SAS/STAT statistical software package for Windows, v. 8.02; SAS Institute, 
Cary, North Carolina, USA).  Mean values at individual time points were compared using 
the Student-Newman-Keul’s (SNK) test.  Treatment differences were also tested using 
orthogonal contrasts to compare slow vs. rapid NaHCO3 therapies.  A P value of < 0.05 was 
considered to be statistically significant.  Values are reported as means ± se. 
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3.2.3 Results 
3.2.3.1 Neurological assessment and recovery 
Severe depression was found in calves with DL-LA induced acidosis (Figure 11 
and Figure 12, P < 0.05).  DL-LA infusion induced complete ataxia, recumbency and 
paralysis when serum D-lactate concentrations were > 10 mmol/L.  HCl produced mild 
impairments in neurological function (Figure 11 and Figure 12); only the suck reflex was 
affected. Serum (Figure 12, r = 0.95) and CSF D-lactate (Figure 11 and Figure 12, r = 0.98) 
concentrations strongly correlated (P < 0.05) with neurological disturbance scores.  The 
suck reflex was affected by both DL-LA and HCl infusions.  The suck reflex had stronger 
correlation with bicarbonate, base excess or pH than with D-lactate concentration.  
Alleviation of neurological disturbances was slow.  The suck reflex recovered faster with 
rapid NaHCO3 therapy and both regiments had a greater recovery in sucking than the other 
reflexes. 
Only, DL-LA calves showed marked neurological disturbances, (Figure 11 and 
Figure 12).  Both NaHCO3 therapies alleviated neurological disturbances by only 10% at 4 
h of correction despite the fact that blood pH was close to normal in calves rapidly 
corrected with bicarbonate at this time; however, a 33% improvement (Δ neurological 
score 2.0) was seen at 8h (Figure 12).  At 4, 6 and 8 h, rapid NaHCO3 therapy had a non 
significant, but numerically faster recovery from neurological disturbances compared to 
slow therapy.  Neurological disturbances recovered back to base line level by 24 h in both 
NaHCO3 therapy groups. 
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Figure 11. Blood (venous) pH [graph A], serum D-lactate concentration (mmol/l) [graph 
B], Neurological disturbance score [graph C] as affected by 150 mM hydrochloric (HCl, ) 
or DL-lactic acid (DL-LA, ) infusions. The X axis represents the time course of the 
experiment where BL is a healthy baseline sample, followed by a period where acidosis 
was induced for 24 h intermittently to produce blood pH <7.30 and >7.05.  Values at each 
time point that do not share a common letter (a or b) are statistically significant at P < 0.05. 
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Figure 12. Neurological disturbance score [graph A], serum D-lactate concentration 
(mmol/L) [graph B], CSF D-lactate concentration (mmol/L) [graph C] as affected by rapid 
or slow equimolar NaHCO3 intravenous therapies in severe acidosis induced by HCl or 
DL-lactic acid infusions respectively.  Data are presented as  for DL-LA_R,  for DL-
LA_S,  for HCl_R, and  for HCl_S.  The X axis represents the time course of the 
experiment where BL is a pre-acid infusion baseline sample, followed by a period (24 h) 
where acidosis was induced (─), and then either rapid, 4 h (----) or slow, 24 h (….) NaHCO3 
infusion. 
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3.2.3.2 Acidosis and recovery 
HCl infused calves had the most severe metabolic acidosis (Figure 11A, P < 0.05) 
which reached a nadir after 24 h of acid infusion (Figure 13), comprising venous blood pH 
7.0 ± 0.1, bicarbonate 7.0 ± 1.5 mmol/L, PCO2 32 ± 2 mmHg and BE -24 ± 2 mmol/L.  The 
lowest arterial blood values were recorded with HCl acidosis and had pH 7.05 ± 0.06, 
bicarbonate 6.8 ± 1.1 mmol/L, PCO2 26 ± 3 mmHg, PO2 86 ± 30 mmHg and base excess -20 
± 3 mmol/L.  The lowest hematocrit and hemoglobin concentrations (25 ± 6% and 76 ± 17 
g/L) also appeared with HCl induced acidosis. HCl infusion (P < 0.05) caused a drop in 
body temperature (36 ± 1 °C).  DL-LA also produced a metabolic acidemia which was 
moderate compared to the HCl infusion and had had less severe (P < 0.05) acidosis 
parameters.  
Both NaHCO3 therapies increased (P < 0.05) blood bicarbonate, pH and PCO2 
(Figure 13).  However, rapid NaHCO3 therapy corrected acidemia faster (P < 0.05) than 
slow therapy (Figure 13).  HCl acidotic calves with slow therapy had the slowest recovery 
for all blood acidosis parameters.  Arterial pH, PCO2 and other parameters were recovered 
faster (P <0.05) by rapid NaHCO3 therapy than slow therapy (Table 4).  However, no 
significant changes were found in hemoglobin concentrations or PO2 levels with time.   
After 24 h of both NaHCO3 therapies, blood pH had recovered to baseline values; 
however, blood bicarbonate and PCO2 did not recover completely (Figure 13). 
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Figure 13. Blood PCO2 (mm Hg) [graph A], bicarbonate concentration (mmol/L) [graph B], 
pH [graph C] as affected by rapid or slow equimolar NaHCO3 intravenous therapies in 
severe acidosis induced by HCl or DL-lactic acid infusions respectively.  Data are 
presented as  for DL-LA_R,  for DL-LA_S,  for HCl_R, and  for HCl_S.  The X 
axis represents the time course of the experiment where BL is a pre-acid infusion baseline 
sample, followed by a period (24 h) where acidosis was induced (─), and then either rapid, 
4 h (----) or slow, 24 h (….) NaHCO3 infusion.  
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Figure 14. CSF PCO2 (mm Hg) [graph A], CSF bicarbonate concentration (mmol/L) [graph 
B], CSF pH [graph C] as affected by rapid or slow equimolar NaHCO3 intravenous 
therapies in severe acidosis induced by HCl or DL-lactic acid infusions respectively.  Data 
are presented as  for DL-LA_R,  for DL-LA_S,  for HCl_R, and  for HCl_S.  The X 
axis represents the time course of the experiment where BL is a pre-acid infusion baseline 
sample, followed by a period (24 h) where acidosis was induced (─), and then either rapid, 
4 h (----) or slow, 24 h (….) NaHCO3 infusion. 
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Both HCl and DL-LA infusion produced decreases in CSF pH, bicarbonate and 
PCO2 (Figure 14).  Rapid NaHCO3 therapy produced a greater (P < 0.05) increase in CSF 
PCO2 (Figure 14A) and bicarbonate (Figure 14B) at 4 h in both DL-LA and HCl induced 
acidosis.  Following rapid NaHCO3 therapy in HCl acidotic calves a further decrease (Δ pH 
0.03) in CSF pH occurred at 4 h of correction.  However, DL-LA induced acidosis calves 
receiving rapid NaHCO3 therapy (Figure 14) had a faster recovery in CSF pH (P < 0.05).  
The lowest CSF pH (7.20 ± 0.02) was found when calves with HCl induced acidosis 
received rapid NaHCO3 therapy (Figure 14).  However, all acidotic calves responded to 
either NaHCO3 therapy with a ~50% pH recovery (Δ pH -0.11) at 8 h of correction (Figure 
14).  Calves with DL-LA induced acidosis had a faster recovery in CSF bicarbonate and pH 
when they received rapid NaHCO3 therapy (Figure 13, P < 0.05).  After 24 h of correction, 
CSF pH and PCO2 recovered to near baseline values.  However, CSF bicarbonate in HCl 
acidotic calves did not fully recover to the base line values (Figure 14).  All acidotic 
parameters had returned to the base line values by 48 h of correction. 
 
3.2.3.3 D and L-lactate concentrations 
Serum and CSF D-lactate (Figure 11 and Figure 12) were only increased by DL-
LA infusion. Peak CSF D-lactate concentration (11 ± 1 mmol/L) after > 12 hours of DL-
LA infusion was 15 % lower than the peak serum D-lactate concentration (13 ± 2 mmol/L).  
Venous serum D-lactate concentration was correlated (r = 0.91, P < 0.05) with CSF D-
lactate concentration.  Serum and CSF L-lactate concentrations were unaffected by HCl 
infusion (2 ± 1 and 3 ± 1 mmol/L).  CSF L-lactates (6 ± 2 mmol/L) were increased with 
DL-LA infusion and were 20% higher than the peak serum L-lactate concentration.  
However, peak serum and CSF L-lactate concentrations were lower than peak D-lactate 
concentrations (Table 4). 
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Table 4. Effects of rapid or slow NaHCO3 therapy on neurological disturbance, arterial, 
venous and cerebrospinal fluid blood gas values, and cerebrospinal fluid and venous serum 
lactate concentrations in calves with induced acidosis either by HCl or DL-lactic acid (DL-
LA) 
 DL-LA* HCl* Significance (P-value) † 
  Fast  Slow   Fast   Slow   Therapy 
and  
time  
DL-LA 
versus HCl 
Fast  
  versus 
Slow 
 
Neurological score 
 
4.4±1.2 
 
4.4±1.3 
 
1.0±0.5 
 
1.2±0.6 
 
<0.05 
 
<0.05 
 
0.18 
Serum 
D-lactate, mmol/L 6.7±1.4 7.9±1.3 0.08±0.1 0.09±0.1 <0.05 <0.05 0.07 
L-lactate, mmol/L 3.5±0.4 3.7±0.5 1.8±0.2 1.9±0.1 <0.05 0.12 0.10 
Venous blood 
pH 7.38±0.01 7.34±0.01 7.32±0.03 7.24±0.02 <0.05 <0.05 <0.05 
BE, mmol/L 2.0±0.5 -3.8±0.08 -4.0±1.0 -9.8±2.2 <0.05 <0.05 <0.05 
HCO3-, mmol/L 25.5±1.0 21.5±1.0 21.0±1.0 14.8±1.4 <0.05 0.06 <0.05 
pCO2 , mm Hg 45.0±2.0 40.0±1.5 42.2±2.5 35.2±3.9 <0.05 0.16 <0.05 
pO2, mm Hg 34.3±1.8 34.0±2.0 36.2±1.5 34.3±3.3 0.06 0.81 0.72 
Hemoglobin, g/L 69.8±4.8 71.0±7.5 71.5±7.3 72.0±4.8 0.81 0.72 0.39 
Arterial blood 
pH 7.41±0.03 7.28±0.05 7.40±0.02 7.27±0.04 <0.05 0.34 <0.05 
BE, mmol/L 1.0±2.0 -7.3±3.4 -4.8±0.8 -11.3±2.4 <0.05 0.07 <0.05 
HCO3-, mmol/L 23.0±2.5 16.0±1.5 18.0±1.5 12.4±1.5 <0.05 0.05 <0.05 
pCO2 , mm Hg 40.8±3.3 35.3±2.8 35.0±2.5 29.6±3.3 <0.05 <0.06 <0.05 
pO2, mm Hg 90.8±9.3 103.5±22.0 101.0±5.5 99.8±15.8 0.07 0.87 0.56 
CSF 
D-lactate , mmol/L 6.7±2.3 7.9±2.1 0.06±0.1 0.07±0.01 <0.05 <0.05 0.09 
L-lactate, mmol/L 6.9±1.2 10.7±0.8 3.8±1.0 3.4±0.5 <0.05 0.82 0.04 
pH 7.29±0.08 7.25±0.07 7.20±0.06 7.29±0.02 <0.05 0.06 0.08 
HCO3-, mmol/L 21.8±1.4 17.3±1.6 18.5±1.6 15.7±1.7 <0.05 0.11 <0.05 
pCO2, mm Hg 46.3±1.8 39.7±2.1 44.0±1.5 37.3±1.5 <0.05 0.13 <0.05 
pO2, mm Hg 106±17.5 90.6±5.9 89.8±3.5 83.1±6.25 0.23 0.36 0.18 
 
* Values are mean ± se for data collected at 6 h from 1 and 24 h of NaHCO3 therapy. 
†Statistically significance was determined for values between 1 and 24 h of NaHCO3 
therapy inclusive by repeated measures MANOVA for NaHCO3 therapy and time 
interaction effects, and orthogonal contrast comparison for DL-LA versus HCl infusions 
and fast versus slow NaHCO3 therapy. 
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3.2.3.4 D-lactate removal from the body 
Serum D-lactate concentrations declined following the cessation of infusion and 
the start of correction of acidemia.  Serum D-lactate removal was concentration dependant 
and had an exponential decrease.  At 10 mmol/L concentration, the rate was ~ 1.5 mmol/L. 
h-1, and at 5 mmol/L it was 0.5 mmol/L. h-1.  Rapid NaHCO3 therapy had a faster serum D-
lactate decline (Figure 12, ~57%, Δ D-lactate concentration 7.5 mmol/L in 8 h, P < 0.05).  
Slow NaHCO3 therapy had a steady serum D-lactate decline (Figure 12, ~47%, Δ D-lactate 
concentration 6.1 mmol/L in 8 h).  
CSF D-lactate concentrations did not change following cessation of infusion 
(Figure 12C, -1 to 0 h, P > 0.05) and only started to decline when bicarbonate therapy 
commenced.  Rapid NaHCO3 therapy had a faster CSF D-lactate decline (Figure 12C, 
~50%, Δ D-lactate concentration 5.5 mmol/L in 8 h, P < 0.05).  Slow NaHCO3 therapy had 
a steady CSF D-lactate decline (Figure 12, ~32%, Δ D-lactate concentration 3.5 mmol/L in 
8 h).  Regardless of the type of correction, removal of D-lactate from CSF was slower, and 
more gradual than from serum.  Although CSF D-lactate removal was not concentration 
dependant and had a constant decrease (0.1−0.3 mmol/L. h-1), NaHCO3 therapy promoted 
the decline (Table 4).  All D-lactate concentrations returned to baseline values in 24 h of 
correction.  
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3.2.4 Discussion  
Infusion of DL-LA or HCl produced profound acidemia (pH close to 7.0), a less 
severe CSF acidosis and marked clinical signs of neurological disturbance only in calves 
receiving DL-LA.  NaHCO3 therapy relieves neurological disturbances; with a trend for 
faster alleviation of neurological disturbances with rapid therapy.  
DL-LA infusion caused neurological dysfunction with severe ataxia, even though 
peak blood and CSF concentrations were lower than in our previous study (see section 
3.1.3).  Longer exposure to D-lactate in this study is a better approximation to natural DLA 
and may have allowed greater penetration of D-lactate into the neurons (Lorenz 2007; 
Petersen 2005).  The serum concentrations in the present experiment (10 mmol/L) are 
comparable to those in naturally occurring DLA in calves and humans with gastrointestinal 
diseases (Ewaschuk et al. 2004; Uribarri et al. 1998).  Deteriorating acid base parameters 
from both HCl and DL-LA infusions were once again associated with a weakened suck 
reflex (Abeysekara et al. 2007; Lorenz 2004b).  The suck reflex recovered quickly with 
both NaHCO3 therapies and rapid regimen produced a faster recovery.  In previous studies 
of calves, acidemia has been associated with a weak suck reflex (Kasari and Naylor 1986; 
Lofstedt et al. 1999; Lorenz 2004b). 
Rapid NaHCO3 therapy caused paradoxic CSF acidosis in HCl acidotic calves 
(HCl_R) where the lowest CSF pH (~7.2) was found after 4 h of rapid NaHCO3 therapy 
(Table 4 and Figure 14).  However, neurological scores were not affected by this 
paradoxical acidosis. Rapid NaHCO3 therapy caused increase in CSF PCO2 and bicarbonate 
(Figure 14) subsequent to similar increases in blood.  In agreement with Figure 10, excess 
CSF PCO2 may dissolve to form carbonic acid (H2CO3) further lowering CSF pH.  This 
would explain the drop in CSF pH in the HCl_R group.  Anions may also play a role in 
retention or elimination of H+ in CSF (Berchtold et al. 2005; Gowrishankar et al. 2007).  It 
is possible that the lack of paradoxic CSF acidosis in DL-LA calves, and the apparent 
enhancement of CSF D-lactate removal with rapid bicarbonate therapy are both the result 
of the transport or diffusion of D-lactic acid carrying D-lactate and a proton out of the CSF 
in response to therapy 
The mechanism that enhances D-lactate removal by NaHCO3 is not well 
understood. Lactate uptake (100 μmol/kg . min-1) is increased by 1 mol/L NaHCO3 
infusions in rat liver (Beech et al. 1993).  Although D-lactate may not be transported the 
same way, permeation across transporters and membranes may be enhanced (De Bari et al. 
2002; Hertz and Dienel 2005; Poole and Halestrap 1993; Ullrich et al. 1982b).  Rising 
alkalinity of blood with bicarbonate in blood does not modulate D-lactate transport via 
kidneys.  However, Na+ and PCO2 have a positive effect on D-lactate transport (Ullrich et al. 
1982b).   
In conclusion in the models of severe prolonged acidosis that we used in calves 
with HCl acidemia, rapid correction of blood pH with bicarbonate induced paradoxic CSF 
acidosis but there were no adverse clinical signs.  There appears to be no danger of 
inducing paradoxic CSF acidosis by IV NaHCO3 therapy in calves with DL-LA acidosis.  
Rapid correction of DL-LA acidosis was exceptional in that DL-lactate concentrations 
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decreased faster.  This is presumably the explanation for the absence of paradoxical CSF 
acidosis in this group.  However, these results certainly do not exclude the possibility that 
the effect of NaHCO3 therapy on cellular pH in other critical organs such as the heart may 
be deleterious.  Further research studies in animals and humans will be necessary with 
therapies focused to the type and cause of acidosis.   
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4 CLINICAL STUDIES 
4.1 Incidence of D-lactic acidosis in diarrheic lambs 
4.1.1 Introduction 
D-Lactic acidosis (DLA) is common in cases of calf diarrhea (Ewaschuk et al. 
2003; Omole et al. 2001).  It has also been described in humans, secondary to short bowel 
syndrome, propylene glycol ingestion (Christopher et al. 1990; Jorens et al. 2004) and other 
digestive disorders (Uribarri et al. 1998).  The common feature in all these cases is that D-
lactic acid originates in the gut (Uribarri et al. 1998) and is absorbed into the blood 
circulation resulting increased serum D-lactate (D-lactatemia) (Lorenz et al. 2005).  
Neurological signs (Hingorani and Chan 2001), a drop in blood pH, bicarbonate, base 
excess, and increase in anion gap (Lorenz 2004a; Omole et al. 2001) are all characteristics 
of the clinical stage of DLA (Ewaschuk et al. 2005; Uribarri et al. 1998).  
Lamb diarrhea is considered an important constraint in sheep farming.  Lamb 
diarrhea has caused considerable morbidity (2.8%) and mortality (0.7%) rates in Canada 
for last few decades; the Prairie has a greater share of these cases (Dohoo et al. 1985).  
Infectious agents such as bacteria, viruses and cryptosporidia are responsible for 99% of 
lamb diarrhea. More than 75% of cases are due to Escherichia coli infection; a bacterium 
that can produce D-lactic acid.  An episode of lamb diarrhea reduces the growth of lambs 
permanently yielding about 2 kg weight loss at the age of five weeks (Green et al. 1998).  
Diarrhea occurs at all ages of lambs and 15% to 40% of the flock may be affected in lamb 
at any age, however, peak prevalence is 3 to 5 weeks of age (Green et al. 1998).  
 Lambs affected with diarrhea may also be prone to DLA.  The objective of this 
study was to determine the incidence of DLA and prevalence of metabolic acidosis 
secondary to lamb diarrhea / dysentery / scours. 
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4.1.2 Materials and methods 
Diarrheic lambs at the University sheep barn were monitored in this study from 
January 2004 to June 2005. 
  
4.1.2.1 Severity of diarrhea and fecal score 
Diarrhea was determined and assessed by a fecal score system.  Healthy lambs 
with solid fees had a score of 0, and diarrheic lambs with watery feces had a maximum 
score of 4 (Lofstedt et al. 1999; Tzipori et al. 1981). 
  
4.1.2.2 Sampling and analyses 
Samples collected for analysis were blood, feces and urine from 27 diarrheic and 
4 healthy lambs (31 ± 12 days of age, 16 ± 8 kg).  Blood (1 mL) was drawn to a 
heparinized syringe and kept in ice (less than 1 h) until used for blood gas analyses. Venous 
blood (4 mL) from the jugular vein was collected into a serum tube; the blood was allowed 
to coagulate for 20 min, spun in a refrigerated centrifuge (IEC Centra-7R Refrigerated 
Centrifuge; International Equipment Company, Needham Heights, Massachusetts, USA) at 
1000 RCF for 30 min and the serum harvested.  Serum samples were stored in a freezer (-
20 °C) until analyzed for lactates.   
Fresh urine (~10 mL) and feces (~50 g) were collected in the morning from the 
reported diarrheic lambs.  Urination and defecation was stimulated manually by rubbing the 
groin and perineum.  Urine samples were stored in a freezer (-20 °C) until analyzed for 
lactates and creatinine.  Feces were dissolved 1 to 1 in 1% sodium ethylmercuric 
thiosalicylate (thiomerosal; ICN Biomedicals Inc., Aurora, Ohio, USA) solution (a 
bacteriostatic agent) to minimize bacterial growth and stored at -20 °C. 
  
4.1.2.2.1 Quantification of acidemia and serum electrolytes 
Blood was immediately analyzed for pH, HCO3-, base excess, hemoglobin (Hb), 
Na+, K+, Ca++, Cl-, anion gap, glucose using an ABL5 Blood Gas Analyzer (Radiometer 
Medical A/S, Copenhagen, Denmark) and an electrolyte analyzer (Braconnier et al. 2003).  
Hemoglobin was measured in an OSM3 Hemoximeter (Zwart et al. 1987). 
  
4.1.2.2.2 Lactate measurements  
D- and L-lactate concentrations in serum, urine and feces were measured using an 
HPLC system (see the section 3.1.2.8, Omole et al. 1999; Ewaschuk et al. 2002).  Serum 
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could be analyzed without dilution.  In order to achieve accurate measurement within a 
detection range (0.05–10 mmol/L), fecal and urines samples were appropriately diluted 
after identifying they contained higher concentrations of lactate.  All dilutions were 
performed using deionized water from a Milli-Q synthesis A10 (Millipore Corporation, 
Bedford, Massachusetts, USA). The lactate concentrations which were lower than 0.05 
mmol/L were considered 0 or not quantified (nq).  However, an arbitrary value of 0.04 
mmol/L was used in statistical calculations and drawings. 
Fecal sample preparation and analysis:  Samples were thawed at 4 °C and then 
shaken for 20 min on an automatic shaker (VWR DS-500E Orbital Shaker).  One gram of 
feces (or 1 mL of semisolid feces) was added to 9 mL of deionized water from a Milli-Q 
synthesis A10 (Millipore Corporation, Bedford, Massachusetts, USA) and homogenized for 
1 min, and centrifuged at 20,000×g for 30 min.  The supernatant was removed and syringe 
filtered through an Acrodisc PF (0.8/0.2 μm) filter.  Then 100 μL of filtrate were added to 
50 μL of internal standard (2 mmol/L malonic acid for stereoselective assay) and 50 μL of 
deionized water in an Ultrafree®-MC 5000 NMWL filter units (Millipore Corporation, 
Bedford, Massachusetts, USA) under 3000 RCF (AccuSpin Micro 17; Fishers Scientific, 
Schwerte, Germany) for 30 min; 20 μL aliquots of the final filtrate were injected into the 
HPLC system (Ewaschuk et al. 2002).  
Urine sample preparation and analysis:  Urine samples were diluted 1:5 (or 
appropriately) with deionized water.  Then 100 μL of diluted urine were mixed with 50 μl 
of internal standard and 50 μL of deionized water in Ultrafree®-MC 5000 NMWL filter 
units (Millipore Corporation, Bedford, Massachusetts, USA) under 3000 RCF (AccuSpin 
Micro 17; Fishers Scientific, Schwerte, Germany) for 30 min; 20 μL aliquots of the final 
filtrate were injected into the HPLC system.  Urine samples were run for 40 min because of 
late eluting peaks (Ewaschuk et al. 2002).  
 
4.1.2.2.3 Urine creatinine measurement  
The concentration of urinary creatinine was determined by high-performance 
liquid chromatography with 3-mm Chromsep ODS-2 column (Varian Inc., Mississauga, 
Ontario, Canada) and with a detection wavelength 220 of the same 486 UV detector and 
HPLC system (Waters, Mississauga, Ontario, Canada) (Smith-Palmer 2002; Yang 1998).  
Then 0.2 mL of urine was deproteinized with 1 mL acetonitrile (EMD Chemicals Inc., 
Gibbstown, New Jersey, USA), and vacuum centrifuged in an Eppendorf concentrator 5301 
(Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany) according to MacNeil et al. 2005 
((MacNeil et al. 2005).  This dried sample was mixed with 1.2 mL of deionized water, and 
then 0.2 mL of mixed sample was used analysis in the HPLC system.  Subsequent to 
calibration and quantification using Waters’ Millenium32 v 4 software, creatinine 
concentrations were determined from their peak heights in comparison to a standard linear 
curve ranging from 0.5 to 10 mmol/L creatinine (Sigma-Aldrich, St. Louis, Missouri, 
USA).  Mobile phase solution was 20 mM potassium hydrogen phosphate (Sigma-Aldrich, 
St. Louis, Missouri, USA) buffer, adjusted to a pH 5.0 with 1 M potassium hydroxide.  The 
flow rate and temperature were maintained at 0.7 mL/min and 25 ºC. 
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4.1.2.3 Lamb care 
The lambs monitored in this study were Suffolk lambs taken from the Sheep Barn, 
Department of Animal and Poultry Sciences, University of Saskatchewan, Canada.  They 
were selected on the basis of age (0-6 weeks) and health or signs of diarrhea for the control 
or diarrheic samples respectively.  All lamb handlings and management were performed 
according to the guidelines of Canadian Council on Animal Care (Canadian Council on 
Animal Care 1993).  The lambs were either housed indoors at 15 ± 5 °C room temperature 
and 55 ± 5% relative humidity in 3.0 × 2.5 m2 mobile pens made up of metal on a concrete 
floor.  The floor of these pens was bedded with 10 cm thick layer of straw.  Some lambs 
were kept outside in straw bedded yards. 
Clean water was freely available from water bowls fixed to the fence of these 
pens. Regular cleaning, watering and feeding were performed twice a day at 8.00 and 17.00 
hours.  Visual inspections for any ailments were performed at the same time by an animal 
technician 
Feeds for lambs consisted of fresh milk and alfalfa hay.  Twice a day, the lambs 
were fed 0.2-0.8 L of the milk depending on the body weight, using a bottle feeder or a 
plastic bucket.  Approximately 1 kg of second cut alfalfa hay was provided in the feeder in 
the pen for lambs to eat.  However, new born lambs were allowed to be with their mothers 
and allowed to suckle for a week before introducing them to the lamb pens.  Only severe 
cases of diarrhea were treated. Once the animal technicians observed diarrhea samples and 
an examination were collected the next morning. 
 
4.1.2.4 Statistical analysis 
Data were analyzed using SPSS v14, 2006 (SPSS Inc. 2005) and Figures were 
created using SPSS and Microsoft Excel (Microsoft Corporation Inc. 2004).  One way 
ANOVA, Student t test, frequency distributions and Pearson correlation procedures were 
performed (Steel and Torrie 1980).  Biphasic Regression (Break Point) Analysis was 
performed using SAS statistical software (SAS/STAT statistical software package for 
Windows, v. 8.02; SAS Institute Inc., Cary, North Carolina, USA. 2001).  For statistical 
purposes of Regression Analysis, parameters that were not detectable by the method used 
were assigned a value of 0, and parameters that were detectable but below the limit of 
quantitation (LOQ, 0.05 mmol/L) were assigned 0.04 mmol/L.  A P < 0.05 was considered 
statistically significant.  
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4.1.3 Results 
4.1.3.1 Diarrhea and fecal score 
Severe to moderate diarrhea was observed, however, the scouring lambs were not 
severely debilitated.  Many were active and alert and needed to be restrained for sampling.  
Fecal scores indicated 26% of mild, 67% of moderate and 9% severe diarrhea among the 
scouring lambs (Figure 15).  Fecal color changed from creamy (7%), yellow (62 %), brown 
(19%) to chocolate (2%).  Most of the moderate cases had yellow diarrhea.  Mild diarrhea 
was often chocolate or the feces were semisolid with misshapen pellets. 
 
4.1.3.2 Lactate concentrations 
The distribution of fecal D-lactate appeared normal (Figure 16), but the 
distribution of serum D-lactate concentration was skewed with many values below 0.1 
mmol/L (Figure 17).  74% of diarrheic lambs had < 0.05 mmol/L, the lowest level of 
detection with our analytical method.  In the 26% of scouring lambs with quatifiable serum 
D-lactate, mean D-lactate concentration was 0.3 ± 0.2 mmol/L. Serum D-lactate (> 0.05 
mmol/L) was not quantified in any healthy lamb (Table 5).  
Fecal D-lactate concentrations were greater (P < 0.05) in diarrheic than in healthy 
lambs, while L- lactate concentrations were marginally higher.  The D- and L- lactate 
concentrations were 9.5 ± 3.7 and 8.9 ± 2.5 mmol/L respectively (Table 5).  Diarrheic 
lambs also had higher (P < 0.05) urine D-lactate concentrations and higher serum L-lactate 
concentrations (P < 0.05). 
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Figure 15. Distribution of fecal score (severity of diarrhea, 0 to 4 score) among diarrheic 
lambs (n = 31, mean ± sd = 1.5 ± 0.8, normal distribution —). 
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Figure 16. Distribution of fecal D-lactate concentration among diarrheic lambs (n = 31, 
mean ± sd = 8.7 ± 4.0, normal distribution —). 
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Figure 17. Distribution of serum D-lactate concentration among diarrheic lambs (n = 31, 
mean ± sd = 0.08 ± 0.17, normal distribution —).  
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Table 5. Mean fecal and blood indices in diarrheic and healthy lambs 
Diarrheic lamb (n = 27) Healthy lamb (n = 4) 
Feces 
Fecal Score 1.8 ± 0.6* 0
D-lactate, mmol/L 9.5 ± 3.7* 3.9 ± 0.8
L-lactate, mmol/L 8.9 ± 2.5 6.1 ± 1.7
 
Urine 
D-lactate, mmol/mol creatinine 27.3 ± 5.2* 9.8 ± 3.4
L-lactate, mmol/mol creatinine 3.3 ± 1.7 1.5 ± 1.1
 
Serum 
D-lactate, mmol/L 0.3 ± 0.2 nq
L-lactate, mmol/L  7.2 ± 4.9* 3.7 ± 1.0
 
Blood 
pH 7.33 ± 0.03 7.38 ± 0.02
PCO2, mmHg 49.5 ± 3.6 50.49 ± 1.3
PO2, mmHg 45.2 ± 4.8 42.2 ± 0.8
Bicarbonate, mmol/L 23.0 ± 3.1 27.1 ± 0.8
Base excess, mmol/L -2.8 ± 3.8 0. 3 ± 0.5
Hemoglobin, g/L 130.3 ± 10.1 128.0 ± 1.6
Saturation of O2, % 61.5 ± 6.1 67.2 ± 2.2
Na+, mmol/L 144.0 ± 2.1 147.3 ± 1.0
K+, mmol/L 4.9 ± 0.4 4.6 ± 0.1
Ca++, mmol/L 1.4 ± 0.1 1.4 ± 0.1
Cl-, mmol/L 109.2 ± 2.7 109.5 ± 1.3
Anion gap, mmol/L  17.3 ± 3.0 11.3 ± 1.0
Glucose, mmol/L 5.4 ± 0.9 5.6 ± 0.1
 
*Statistically significant difference between diarrheic and healthy lambs at P < 0.05.  
nq = not quantified. 
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Figure 18. Break Point Analysis showing a threshold concentration for absorption when 
fecal D-lactate exceeded 10.18 mmol/L (↑) in lambs.  The regression equation for Break 
Point Analysis consists of serum D-lactate concentration (y), fecal D-lactate concentration 
(x) and a dummy variable (z), n = 31.  The equation for the estimated threshold is ‘y = - 
0.69952 + 0.06873 x + 0.69952 z - 0.06873 (x*z)’ where, z = 0 for the first line and z = 1 
for the second line.  First regresssion line (—, strait) was associated with square shape ( ) 
data points and the second regression line (----, broken) was associated with triangular ( ) 
data points.  Linear Correlation between fecal and serum D-lactate concentrations (r = 
0.75).  
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4.1.3.2.1 Fecal D-lactate threshold concentrations 
Fecal D-lactate threshold is the new finding we came across with the lamb study 
and then our previous calf data were also analyzed to find species wise associations 
(Appendix C: Diarrheic calf fecal D-lactate threshold).  
In diarrheic and healthy lambs (n = 31), threshold concentration for fecal D-
lactate absorption was 10.18 mmol/L which was estimated using Biphasic (Break Point) 
Regression Analysis (Figure 18).  The regression equation for Break Point Analysis 
consists of serum D-lactate concentration (y), fecal D-lactate concentration (x) and a 
dummy variable (z).  Therefore, the regression equation for the estimated threshold is 
shown below. 
Equation 4. y = - 0.69952 + 0.06873 x + 0.69952 z - 0.06873 (x*z)  
Dummy variable codes applied in Equation 2 are z = 0 for the fist line and z = 1 
for the second line.  Linear Correlation between fecal and serum D-lactate concentrations (r 
= 0.71).  
 
4.1.3.3 Metabolic acidosis 
Two diarrheic lambs (7.4%) had moderate metabolic acidosis, blood pH (7.18, 
7.25), HCO3- (18, 20 mmol/L), base excess (-9, -8 mmol/L) and anion gap (21, 19 
mmol/L).  Three diarrheic lambs (11%) had mild metabolic acidosis with a pH of 7.29 and 
improved other parameters.  The remainder of the diarrheic lambs (81%) had pH < 7.30 
with no signs of metabolic acidosis.  However, comparisons between diarrheic and healthy 
lambs showed a trend for numerical decrease in mean blood pH, HCO3- and Na+.  
Indicating an opposite trend, methemoglobin was slightly increased with diarrhea (Table 
5).  Weak correlations (r ≥ 0.45, P < 0.05) were also observed between several parameters. 
The only significant linear correlations are serum lactate concentration vs. blood pH, fecal 
D- and L-lactate vs. serum D-lactate (Figure 18), and fecal score vs. blood Na+ (Figure 19).   
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Figure 19. Blood sodium concentration correlated with fecal score (r = 0.51, ----regression 
line). 
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4.1.3 Discussion 
Severe calf diarrhea has resulted in mean fecal and serum D-lactate 
concentrations of 25 and 14 mmol/L respectively (Ewaschuk et al. 2003; Ewaschuk et al. 
2004).  Serum D-lactate values reported by Uribarri et al. 1998 were over 3 mmol/L 
generally in human DLA cases (Uribarri et al. 1998).  However, the present lamb data 
shows that mean serum D-lactate concentrations did not exceed 0.5 mmol/L in diarrheic 
lambs although fecal D-lactate concentrations averaged 14 mmol/L. In the following 
sections (4.2.3.1), we found similar low, but measurable serum D-lactate values in healthy, 
bucket fed calves prior the malate treatment.  However, these diarrheic lamb serum D-
lactate concentrations are clinically non-significant (< 2 mmol/L).  This may be due to a 
pathophysiological difference (Field 2002) in the processing of D-lactate absorption in 
upper intestines of sheep (Ding and Xu 2003).  Ding et al (2003) indicated that lactic acid 
absorption (~0.1 µmol/cm2.min) in sheep intestine was affected by pH, osmotic pressure 
and lactic acid concentration (Ding and Xu 2003).   
Our findings show that fecal D-lactate should be higher than ~10 mmol/L (fecal 
D-lactate threshold), to reach a measurable serum concentration (Figure 18). In case of 
calves, the severity of diarrhea may have resulted to produce more lactates (~23 mmol/L) 
in colon hence high levels (~13 mmol/L) in serum (Ewaschuk et al. 2003; Ewaschuk et al. 
2004).  The calf fecal D-lactate threshold was calculated using our laboratory data from 
2000 to 2004 and was shown in Appendix D.  Lactate transporters (monocarboxylic, MCT) 
in the gut allow the stereoselective uptake of D-lactate to a greater extent than L-lactate 
(Ogihara et al. 2000).  Once the lumen D-lactate concentration increases, MCT may start 
transport of D-lactate into the circulation.  This gut-originated D-lactate would then appear 
as increased serum concentration resulting in D-lactatemia (Ewaschuk et al. 2005; Hove 
and Mortensen 1995).  However, the excretion of D-lactate from blood may be rapid if the 
kidneys are healthy and functionally efficient (Jørgensen and Sheikh 1984; Ullrich et al. 
1982b).  Our lambs were in the early stages of diarrhea; D-lactatemia was low, probably 
because of reduced production and more efficient renal clearance than in severely 
compromised calves (Ewaschuk et al. 2003; Ewaschuk et al. 2004).  Serum L-lactate 
concentrations were higher in diarrheic lambs.  Even in healthy lambs values were high, 
possibly due to acute stress and exercise from the process of catching and restraining for 
sampling (Arola et al. 1980).  
Intestinal infection, which may be the primary cause of diarrhea, has a negative 
impact on enzymatic digestion in the affected portion of the intestines (Field 2002; Tzipori 
et al. 1981) and passage of excess nutrients to the colon may transpire (Bongaerts et al. 
1997; Field 2002; Luckey 1987; Meier et al. 2003).  Escherichia coli and cryptosporidium 
greatly reduced lactase enzymatic activity with severe intestinal lesions in the infected 
lamb (Tzipori et al. 1981).  Lactose tolerance in diarrheic lambs infected with rotavirus was 
not affected (Ferguson et al. 1981) in contrast to calves infected with reo-like virus 
(Pearson et al. 1978).  Therefore, we assume that colonic bacterial over growth may occur 
secondary to lamb diarrhea (Ewaschuk et al. 2004; Hove and Mortensen 1995). 
Urine D-lactate concentrations were high.  However, these values were not 
comparable with the concentrations in clinical DLA cases reported by previous authors 
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(Haschke-Becher et al. 2000; Inoue et al. 2007; Petersen 2005).  Urine D-lactate content, 
expressed as a creatinine ratio (27 mmol/mol of creatinine) appeared moderate.  Since the 
majority of our lambs had moderate diarrhea and were undergoing only a mild metabolic 
acidosis (Omole et al. 2001), it is likely that absorbed D-lactate was being effectively 
excreted by the kidneys (Jørgensen and Sheikh 1984; Ullrich et al. 1982b). 
The correlation between serum total lactate and blood pH indicated that lactate 
contributed to metabolic acidosis.  However, serum D-lactate concentration, were often too 
low to measure and so did not correlate with blood pH.  Loss of Na+ with diarrhea may be 
the reason for the negative correlation between fecal score and blood Na+ concentration.  
We did not find a linear correlation between anion gap and serum D-lactate concentration.  
Again, this is likely because the majority of lambs had little measurable D-lactate.  Overall, 
our data shows that short term diarrhea rarely causes severe metabolic acidosis in lambs. 
In general environment, feeding and nutrition management have an impact on 
diarrhea syndromes (Meier et al. 2003).  Over 80% of cases in this study had mild to 
moderate diarrhea which may not have been pathologically severe enough to extensively 
increase production and membrane permeability to intestinal (lumen) D-lactic acid.  The 
barn where these lambs were raised was comparatively clean and routine management 
practices such as feeding, watering, and cleaning were well maintained.  Therefore, these 
diarrheic lambs had less chance of having cross contamination, dehydration and 
malnutrition.  This situation would minimize the severity of disease.  In addition, the stage 
of diarrhea of these lambs was early.  Under worse sanitary conditions and persistent 
diarrhea, the colonic response might be different and bacterial overgrowth in colon with the 
production of more D-lactate might be possible (Hove and Mortensen 1995; Vella and 
Farrugia 1998).  
We conclude that DLA may not arise secondary to lamb diarrhea as commonly as 
in calf diarrhea, although diarrheic lambs had mesurable fecal D-lactate concentrations.  
Our discovery of lumen threshold for D-lactate absorption in lambs would contribute in 
achieving the prevention of DLA in general.  These results may reflect the mild stage of 
diarrhea in these lambs as well as the sanitary environment of the experimental barn.  
Therefore, further investigations on a broader scale are suggested. 
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4.2 Use of malate to prevent D-lactic acidosis 
4.2.1 Introduction 
D-lactic acidosis is a common problem in humans and animals.  In diarrheic 
calves, DLA is correlated with neurological depression and mortality (Ewaschuk et al. 
2003; Ewaschuk et al. 2004; Omole et al. 2001).  Similarly, DLA has been blamed for 
neurological impairments in humans secondary to short bowel syndrome, propylene glycol 
ingestion and other digestive disorders (Hudson et al. 1990; Jorens et al. 2004; Uribarri et 
al. 1998).  A common feature of these cases is that D-lactic acid originates from the gut and 
is absorbed into the blood circulation and other body compartments (Bongaerts et al. 1997; 
Ding and Xu 2003; Hove and Mortensen 1995; Jorens et al. 2004; Omole et al. 2001; 
Packer et al. 2005; Petersen 2005).  Intestinal bacterial over growth (dysbiosis) and 
decrease in the gut pH play a major role to increase D-lactic acid producing bacteria 
(Ewaschuk et al. 2005; Hove and Mortensen 1995; Hudson et al. 1990; Uribarri et al. 
1998).  The persistence of dysbiosis further amplifies rapid fermentation of simple 
carbohydrates and over growth of lactic acid forming bacteria, which subsequently leads to 
an excessive and overwhelming production of D- and L-lactic acid.  Both D- and L-lactic 
acids may be rapidly absorbed in to the circulation (Ewaschuk et al. 2005; Ogihara et al. 
2000; Poole and Halestrap 1993; Uribarri et al. 1998).  Prevention of DLA involves 
modulating the gut environment and targeting gut bacteria to minimize D-lactic acid 
production.  Probiotics (such as Lactobacillus strains) (Ewaschuk et al. 2004) and 
prebiotics (such as malate) could be used in the treatment / prevention of DLA.  
Malic acid has been used as a common food flavor (Elkins and Heuser 1994; 
Nielsen and Richelieu 1999).  Malic acid is a major pH modulator in many commonly 
consumed fruits and vegetables (Lobit et al. 2006; Romero Rodriguez et al. 1992; Velterop 
and Vos 2001; Vorarat et al. 2002); it has also been used in the fermentation of wine and 
pickles (Passos et al. 2003).  Malate in the form of oral medicinal tablets is a proven 
treatment (Abraham and Flechas 1992; Russell et al. 1995) for some systemic diseases 
(fibromyalgia).  Malate has the ability to modulate pH (Passos et al. 2003; Piva et al. 2002; 
Russell and Rychlik 2001), and promotes the growth of gut bacteria that can convert lactate 
to propionate (Evans and Martin 1977; Martin 1998).  Malate has been used to reduce 
rumen D-lactic acid production in cattle (Martin 1998; Nisbet and Martin 1991; Nisbet and 
Martin 1994; Russell and Rychlik 2001).  Therefore, malate may be a potential candidate in 
the prevention of DLA.  We hypothesized that malate has the ability to reduce body D-
lactate by converting lactate to propionate, hence reducing gut pH, and eventually 
promoting a gut environment for favorable bacteria.  The primary objective of the present 
study was to determine the ability of oral malate to reduce D-lactate concentrations in fecal, 
urine and blood matrices.  Additional objectives were to determine an appropriate oral dose 
and regimen for this beneficial response in calves. 
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4.2.2 Materials and methods 
Use of calves in this study was approved by the Animal Research Ethics Board of 
the University of Saskatchewan, and was carried out in accordance with the guidelines 
specified by the Canadian Council on Animal Care (Canadian Council on Animal Care 
1993).  The calves for this study were obtained from the Dairy Barn, Department of Animal 
and Poultry Sciences, University of Saskatchewan, Canada.  Calves were selected on the 
basis of breed (Holstein), age (1-6 weeks), and good health in order to assure a uniform 
sample. 
 
4.2.2.1 Experimental design and treatment regimen 
Sixteen healthy calves (27 ± 2 days of age, 61 ± 2 kg) were randomly (n = 4) fed 
4 different doses of sodium malate (NaC4H6O5; Fuso Chemicals Company Limited, Osaka, 
Japan); 1000, 500, 50 and 0 (control) mg/kg body weight (BW) daily in milk for a 5 day 
period.  The calf weight was measured (Norac Instaweigh™ Instrumentation Animal Scale; 
Norac Weighing and Control Systems, Norac International Inc., Saskatoon, Saskatchewan, 
Canada) a day prior to the start of treatment. 
 
4.2.2.2 Calf care 
The calves were housed in the Stone-Barn Calf Unit of Dairy Barn, Department of 
Animal and Poultry Sciences, University of Saskatchewan, Canada; this environment 
provided 20 ± 5 °C room temperature, 65 ± 5% relative humidity throughout day, and 
automated light system from 06.00 to 20.00 h.  Each calf was housed in a pen which was 
made up of wood and concrete with approximate dimensions of 2.0 × 1.5 m2.  The floor of 
these pens was bedded with 10 cm thick layer of straw.  Clean water was provided to these 
calves in 4 L plastic buckets fixed to the pen wall.  Animal technicians performed regular 
pen cleaning at 08.00 and 17.00 h.  The calves were fed after pen cleaning with fresh milk 
and alfalfa hay.  The calves received a bucket of milk (2.5-3.0 L) depending on the body 
weight.  Approximately 1 kg of second cut alfalfa hay was provided on feeder in the pen 
for consumption by the calves per day.  Once calves were moved into this calf unit, the pre-
experimental supervisory period was 5 days where the calves were monitored every day for 
ailments. 
 
4.2.2.3 Sample collection 
Feces, urine and jugular blood samples were collected pre-prandially at 08.00 on 
0, 3, 5 and 7 days.  Venous blood (4 mL) was aspirated for serum separation in order to 
conduct analysis of lactate isomers and 1 mL of blood was drawn to heparinized syringes 
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and kept in ice (less than 1 h) until used for blood gas analyses.  Serum separation was 
performed allowing non-heparinized venous blood to coagulate for 20 min, and spinning in 
a refrigerated centrifuge (IEC Centra-7R Refrigerated Centrifuge; International Equipment 
Company, Needham Heights, Massachusetts, USA) at 1000 RCF for 30 min.  Serum and 
urine samples were stored in a freezer (-20 °C) until analyzed for lactate.  Feces were 
dissolved 1 to 1 in 1% sodium ethylmercuric thiosalicylate (thiomerosal; ICN Biomedicals 
Inc., Aurora, Ohio, USA) solution to minimize bacterial growth and stored at -20 °C. 
 
4.2.2.4 Laboratory analyses 
Heparinized blood samples were analyzed for pH, HCO3- (mmol/L), base excess, 
(mmol/L), gasses (PCO2 and PO2 , mm Hg), hemoglobin (Hb, g/L), Na+ (mmol/L), Ca++ 
(mmol/L), Cl- (mmol/L) and glucose (mmol/L) using an ABLTM 5 Blood Gas Analyzer 
(Severinghaus 2002) (Radiometer Medical A/S, Copenhagen, Denmark) and an OSM3 
Hemoximeter (Haughton and Radcliff 1987; Zwart et al. 1987) (Radiometer Medical A/S, 
Copenhagen, Denmark). 
Fecal, urinary and serum lactate (D and L isomer) concentrations were measured 
using an HPLC system with a Waters 600 HPLC pump (see the sections 3.1.2.8 and 
4.1.2.2). 
 
4.2.2.5 Statistical analysis 
Preliminary data on calf characteristics (health, body weight and age), blood gas 
values and HPLC readings were managed, and graphs and Figures were created using a 
spreadsheet (Microsoft Excel, Microsoft Corporation, Redmond, Washington, USA).  
Lactates and blood gas data were analyzed using a statistical analytical software package 
(SPSS v13, 2005; SPSS Inc., Chicago, Illinois, USA).  General Linear Model ANOVA and 
repeated measures analysis and Student-Newman-Keul’s (SNK) test (Steel and Torrie 
1980) were performed to differentiate the treatment as well as time effects.  Calf body 
weight was accommodated as the covariate for Repeated Measures analysis.  A P < 0.05 
was considered as evidence of statistical difference.  Results were reported as mean and 
standard error (mean ± se). 
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4.2.3 Results 
4.2.3.1 Fecal and serum lactates 
Malate had a significant influence in reducing fecal and serum lactate 
concentrations after 5 days of treatment.  Malate doses from low to high respectively 
caused a 55, 80 and 60% decrease in fecal D-lactate concentrations (~36 to ~11 mmol/L on 
average, Figure 20, P < 0.05) at 7 days.  Fecal L-lactate concentration was decreased by 
20–60% (Figure 21, P < 0.05) over the same period. At 7 days, serum total lactate declined 
by 45–59% (Figure 22, P < 0.05), D-lactate by 40–62% (~0.5 to ~0.3 on average, Figure 
20, P < 0.05) and L-lactate by 45-60% (Figure 21, P < 0.05).  Urinary D-lactate (27 ± 19 
mmol/L, Figure 22) and L-lactate (11 ± 15 mmol/L) were not affected by malate, however, 
values varied with treatment and time. 
D-lactate reduction correlated with malate dosage (r = 0.63).   Although malate 
was fed only for 5 days, the greatest drop in lactate (fecal and serum) was reported on the 
7th day.  None of the doses caused major adverse clinical reactions; however, a drop in milk 
palatability was apparent at the 1000 mg/kg BW dose.  The 500 mg/kg BW dose provided 
the most consistent decrease in serum D-lactate over time with no feeding difficulties. 
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Figure 20. Fecal [graph A] and serum [graph B] D-lactate concentrations (mmol/L) as 
affected by Na malate doses; 1000 mg/kg BW , 500 mg/kg BW , 50 mg/kg BW  
and 0 mg/kg BW   (control).  Values that do not share a common subscript (a or b) in a 
day (time point) are statistically significant at P < 0.05 by Student-Newman-Keul’s test.  
Treatment, time, and treatment versus time effects indicated by Repeated Measures 
ANOVA were statistically significant at P < 0.05 (n = 4 per treatment group). 
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Figure 21. Fecal [graph A] and serum [graph B] L-lactate concentrations (mmol/L) as 
affected by Na malate doses; 1000 mg/kg BW , 500 mg/kg BW , 50 mg/kg BW  
and 0 mg/kg BW   (control).  Values that do not share a common subscript (a or b) in a 
day (time point) are statistically significant at P < 0.05 by Student-Newman-Keul’s test.  
Treatment, time, and treatment versus time effects indicated by Repeated Measures 
ANOVA were statistically significant at P < 0.05 (n = 4 per treatment group). 
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Figure 22. Serum DL-lactate [graph A] concentration (mmol/L) and urine D-lactate [graph 
B] concentration (mmol/mol of creatinine) as affected by Na malate doses; 1000 mg/kg 
BW , 500 mg/kg BW , 50 mg/kg BW  and 0 mg/kg BW   (control).  Values that 
do not share a common subscript (a or b) in a day (time point) are statistically significant at 
P < 0.05 by Student-Newman-Keul’s test.  Treatment, time, and treatment versus time 
effects indicated by Repeated Measures ANOVA were statistically significant at P < 0.05 
(n = 4 per treatment group). 
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4.2.3.2 Bicarbonate, base excess and other blood values 
Blood glucose (4.8 ± 0.3), pH (7.35 ± 0.06), Hb (108 ± 9), Na+ (133 ± 4), Ca++ 
(1.2 ± 0.2) and Cl- (99 ± 4) were not affected by malate.  A marginal drop in bicarbonate 
and noticeable drop in BE occurred (Figure 23, P < 0.05) at the 1000 mg/kg dose after 5 
days of treatment.  However, bicarbonate concentrations never dropped below 24 ± 1 
mmol/L value (Figure 23).  Venous blood gases (PCO2 and PO2, mm Hg) were not changed 
statistically although PCO2 ranged 50-53 mm Hg and PO2 ranged 20-35 mm Hg among 
calves along the course regardless of the treatment. 
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Figure 23. Blood bicarbonate concentration [graph A] and base excess [graph B] as 
affected by Na malate doses; 1000 mg/kg BW , 500 mg/kg BW , 50 mg/kg BW  
and 0 mg/kg BW   (control).  Values that do not share a common subscript (a or b) in a 
day (time point) are statistically significant at P < 0.05 by Student-Newman-Keul’s test.  
Treatment, time, and treatment versus time effects indicated by Repeated Measures 
ANOVA were statistically significant at P < 0.05 (n = 4 per treatment group). 
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4.2.4 Discussion 
Serum D-lactate concentrations were in measurable quantities (> 0.05 mmol/L) 
and fecal D-lactates were high in healthy calves at the start of malate treatment.  Milk 
(bucket) feeding may be a reason for these high concentrations of D-lactate.  The milk 
(bucket) fed calves usually retain high colonic fermentation.  Colonic lactate production is 
high even in healthy young calves (Shimomura and Sato 2006) thus both D- and L- isomers 
are high in feces.  Therefore, using healthy calves to understand the effect of malate on 
lactate reduction is justifiable. 
Previously reported DLA cases had serum D-lactate concentration over 2 mmol/L 
(Ewaschuk et al. 2005; Uribarri et al. 1998).  This study showed the effectiveness of Na 
malate in reducing fecal and serum D-lactate concentrations (clinically non-significant 
concentrations).  Similar effectiveness of malic acid on plasma D-lactate levels was 
reported by Montano et al. 1999 (Montano et al. 1999) in high-concentrate fed healthy 
steers after 13 days of malic acid treatment.  In an intra ruminal challenge with a high dose 
of glucose, malic acid did not reduce either ruminal or plasma lactates within 7 h of the 
challenge.  However, malic acid promoted a higher rumenal pH than that in control calves 
(Montano et al. 1999).  In comparison, we evaluated the effectiveness of malate for a 
longer period (0 to 7 days).  We found malate was effective in reducing lactates after 5 
days of treatment. 
Possible reasons for serum D-lactate reduction include low production of lactates 
in the intestinal lumen.  As affected by malate, fecal D-lactate concentration reduced (from 
~36 mmol/L) to ~11 mmol/L.  This concentration is closer to our previous finding of lumen 
(fecal) D-lactate threshold 10 mmol/L for lambs (Section 4.1.3.2) and 9 mmol/L for calves 
(Apendix C, Ewaschuk et al. 2004).  Therfore, D-lactate absorption to the circulation may 
be minimal.  Alternatively, malate may enhance D-lactate utilization in the body tissue.  
Hepatic uptake of lactate is the major route of serum lactate removal (Ewaschuk et al. 
2005; Naylor et al. 1984; Poole and Halestrap 1993; Prior 1983).  According to De Beri et 
al. 2002, rat liver mitochondria can uptake D-lactate rapidly via D-lactate-malate antipoter 
and D-lactate may be metabolized by D-lactate dehydrogenase present in the inner 
mitochondrial respiratory chain (De Bari et al. 2002).  Vmax of D-lactate dehydrogenase 
was reported 15±17 nmol/min per mg (De Bari et al. 2002).  Modulation of pH by malate is 
also a possible benefit for D-lactate transport across plasma membranes (De Bari et al. 
2002; Poole and Halestrap 1993).  Figure 24 summarizes the possible pathways in serum 
D-lactate reduction in the gut and the liver. 
The decrease in serum bicarbonate in this experiment may not be clinically 
harmful because the lowest values (24 ± 1 mmol/L) did not drop below clinically critical 
levels (Robinson and Huffman 1925; Stocker et al. 1999).  However, this slight decrease in 
bicarbonate may be important to follow up in the clinical setting.  The drop in base excess 
caused by high doses of malate may be due the direct absorption and systemic metabolism 
of malate during the treatment period (5 days).  It may also indicate a prebiotic activity 
with changes in the gut flora and production of different loads of organic acids (Shimomura 
and Sato 2006).  Although venous blood gasses (PCO2 and PO2, mm Hg) were not changed 
statistically, there were fluctuations in PCO2 within a range of 50-53 mm Hg, and PO2 within 
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a range of 20−35 mm Hg among.  This indicates the buffering ability in healthy calves and 
the possible production of different organic acids instead of D-lactic acid in the 
gastrointestinal tract with malate effect (Graf et al. 1986; Shimomura and Sato 2006; 
Stocker et al. 1999).  
Since malate treatment was more effective after 5 days, prolonged use of malate 
in potential DLA cases may yield better results.  Furthermore, it is reasonable to expect that 
Na malate may be effective in calves with clinically significant serum D-lactate 
concentrations (> 2 mmol/L).  Malate has been used in monogastric nutrition to improve 
digestive efficacy and growth promotion by being a buffer or modulator (Partanen and 
Mroz 1999; Piva et al. 2002).  In our experiment, a moderate dose of malate (500 mg/kg 
BW) was more consistently effective.  Dosages used by other workers (Martin et al. 1999; 
Montano et al. 1999; Vicini et al. 2003) for digestive efficacy and growth promotions 
ranged from 40 or 80 g per day which is approximately 50 or 100 mg/kg BW.  
The use of probiotics and nutraceuticals in clinical diseases has given mixed 
results (Chermesh and Eliakim 2006).  Probiotics played a positive role in rotavirus 
diarrhea, post antibiotic diarrhea and pouchitis (Chermesh and Eliakim 2006).  Probiotics 
also reduced fecal water content in diarrheic calves (Ewaschuk et al. 2004).  Similarly, 
there was a long debate in the use of organic acids as feed additives (Callaway and Martin 
1996; Martin 1998; Partanen and Mroz 1999; Piva et al. 2002) in both monogastric and 
ruminant nutrition.  It is not different when it comes to the use of malate or malic acid 
(Evans and Martin 1977; Martin and Streeter 1995; Martin and Streeter 1995; Martin et al. 
1999; Montano et al. 1999; Russell et al. 1995; Vicini et al. 2003).  Therefore, the 
effectiveness of Na malate in clinical cases needed to be investigated because even the 
probiotic (Lactobacillus GG) did not reduce D-lactate in diarrheic calves in a clinical 
setting (Ewaschuk et al. 2006).  Feeding lower doses of Na malate twice a day may resolve 
the problem of low palatability that we experienced with higher doses.  
We conclude that oral administration of Na malate dissolved in milk at a rate of 
50-500 mg/kg BW daily for more than a period of 5 days has the ability to reduce fecal and 
serum D-lactate.  Use of malate dissolved in milk would be readily applicable for on-farm 
scenarios.  However, based on these findings, clinical research investigating the 
preventative and treatment potential of malate in metabolic acidosis is obligatory.  
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Figure 24. Possible pathways involved in D-lactate reduction with the support of malate in 
the gut lumen and in the liver cells (De Bari et al. 2002; Evans and Martin 1977; Poole and 
Halestrap 1993).  
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5 GENERAL DISCUSSION AND CONCLUSIONS 
DLA is associated with gastrointestinal diseases complicated by neurological 
signs (Jorens et al. 2004; Packer et al. 2005; Petersen 2005; Uribarri et al. 1998).  Billions 
of cases of gastrointestinal diseases, usually including diarrhea occur worldwide, in humans 
and other species (Bhan et al. 1989; Ewaschuk et al. 2005; Field 2002; Katelaris 1996; 
Ruuska and Vesikari 1991).  The reported neurological signs associated with DLA in 
humans and animals include slurred speech, loss of reflexes (impairment of palpebral and 
menace reflexes), abnormal gate, ataxia, paresis and coma (Lorenz et al. 2005; Packer et al. 
2005; Petersen 2005; Uribarri et al. 1998).  Although clinical studies have consistently 
shown an association between D-lactate concentration and neurological signs (Hudson et 
al. 1990; Jorens et al. 2004; Packer et al. 2005; Petersen 2005; Uribarri et al. 1998; Zhang 
et al. 2003) this thesis is the first to establish a causal link.  In many previous clinical 
studies, understanding the pathophysiology was complicated because other parameters, 
such as acidemia, deficiencies and dehydration were also associated with neurological 
impairment.  In the controlled studies reported in this thesis severe acidemia and mild 
impairments of neurological function were induced by HCl infusion alone.  DL-LA 
infusion produced severe neurological dysfunction or disturbance with signs identical to 
those clinically observed in cases of DLA.  This neurotoxicity is independent of acidosis. 
Toxicity is also unrelated to L-lactatemia.  Our studies also rule out hypertonicity as the 
pathological mechanism for neurological signs, as was proposed recently (Lorenz et al. 
2005; Stampfli 2005).  Thus, D-lactate is a neurotoxic agent.  Since D-lactate can move 
into neurons with either sodium or hydrogen ions via Na+- or H+-monocarboxylate 
transporters (Martin et al. 2006; Shimozono et al. 1998) either D-lactate or D-lactic acid 
may be the toxic agent in intracellular environment.  The intracellular or interneuronal 
mechanism that underlies this toxicity needs to be investigated.  
The absence of neurological effects following oral administration of DL-LA in a 
previous experiment (De Vrese et al. 1990) can be explained by the relatively smaller 
amounts of DL-LA administered per day, and possibly reduced oral absorption, in those 
experiments with lower serum D-lactate concentrations (< 1 mmol/L).  In comparison, 
eight times higher quantities were delivered by IV infusion to the body in our research 
study.  Therefore, a peak serum concentration of around 36 mmol/L was reached.  It is 
commonly understood that serum D-lactate concentrations have to be at least 3 mmol/L 
before clinical signs are observed (Uribarri et al. 1998). 
In agreement with Lorenz’s findings in 2004 we noted that ataxia and loss of the 
palpebral reflex are correlated with D-lactate concentrations whereas the strength of the 
suck reflex is correlated with acidemia (Lorenz 2004b).  Therefore, we conclude that 
acidemia depresses the suck reflex but is not responsible for ataxia or changes in the 
palpebral reflex. 
Previous studies in our laboratory established that diarrheic calves with 
neurological depression have serum D-lactate concentrations as high as 26 mmol/L 
(Ewaschuk et al. 2004; Omole et al. 2001).  The serum D-lactate concentrations (36 
mmol/L) in this infusion study are well below the serum value (110 mmol/L) reported in a 
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patient intoxicated after over-ingestion of propylene glycol (Jorens et al. 2004).  
Furthermore, these data show that it takes time for D-lactate to diffuse into the CSF.  A 
more gradual and slower infusion could result in greater equilibration between CSF and 
blood D-lactate concentrations and clinical signs at lower venous serum D-lactate 
concentrations. 
In the nervous tissue, astrocytes are net producers of L-lactate, because their thin 
processes are too small to accommodate mitochondria (Hertz et al. 2007; Hyder et al. 
2006).  Neurons metabolize L-lactate (Aubert et al. 2005; Bouzier-Sore et al. 2006; Hyder 
et al. 2006; Medina and Tabernero 2005; Schurr 2006).  The majority (75%) of neuronal 
oxygen consumption is accounted for by L-lactate metabolism and only 25% by glucose 
metabolism (Bouzier-Sore et al. 2006).   Lactate utilization may be particularly important 
during acidemia, since low pH can inhibit phospofructokinase activity, a key glycolytic 
regulatory enzyme (Kreisberg 1980).  In neurons, uptake of L-lactate is close to saturation 
at physiologic L-lactate concentrations (Hertz and Dienel 2005).  D-lactate inhibits the 
ability of isolated optic nerves to generate an action potential, probably by competitively 
blocking L-lactate entry into neurons and limiting neuronal metabolism (Tekkök et al. 
2003; Tekkök et al. 2005).  L-lactate can act as an energy substance during ischemia / 
reperfusion injury and reduces cerebral injury (Cassady et al. 2001; Ros et al. 2001).  In 
contrast, D-lactate enhances neuronal injury in ischemia-reperfusion models (Cassady et al. 
2001).  D-lactate dehydrogenase is poorly expressed in mammalian nervous tissue, 
although it is found in mitochondria, particularly in liver and kidney (Flick and Konieczny 
2002).  We speculate that the D-lactate neurotoxicity observed in this study is the result of 
reduced L-lactate availability within neurons and energy deficit.  In support of this, the 
serum-CSF L-lactate difference was slightly greater during DL-LA infusion; this may 
reflect reduced neuronal removal of astrocyte produced L-lactate.  Similarly, others have 
shown that blockade of neuronal monocarboxylate transporters responsible for L-lactate 
entry results in increased neuronal cell death in the developing brain (Adle-Biassette et al. 
2007). 
Ethanol also has early effects on energy metabolism (Adle-Biassette et al. 2007; 
Juhlin-Dannfelt 1977; Volkow et al. 2006) which may be similar to some of the actions of 
D-lactate.  However, in acute ethanol consumption, neurological depression is perhaps 
caused by low concentrations of circulating tryptophan (Badawy et al. 1995) or interactions 
with the GABAA receptor complex and facilitation of GABA action (Gonzales and 
Hoffman 1991; Starke 1991). 
L-lactate can be transported across the blood brain barrier by mono-carboxylic 
acid transporters (Gladden 2004; Hertz and Dienel 2005; Schurr 2006) which are stereo 
specific (Tekkök et al. 2003; Tekkök et al. 2005).  However, lactate is mainly transported 
across the blood brain barrier by lipid mediated penetration (Oldendorf et al. 1979).  
During DL-LA infusion, CSF L-lactate concentrations increased steadily and were higher 
than serum concentrations by a similar amount in all infusions.  L-lactate was probably 
being formed within nervous tissue by metabolism of glucose and this likely contributes to 
the higher concentrations in CSF (Aubert et al. 2005; Gladden 2004).  In this study D-
lactate rapidly crossed the blood brain barrier. 
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Following the cessation of infusion, serum D-lactate exhibited an exponential 
decay in this study, and also in previous work (Lorenz et al. 2005).  However, CSF D-
lactate removal was constant over the period studied suggesting that the metabolic process 
involved in removal was saturated. Mono-carboxylic transporters may remove D-lactate 
from CSF (Tekkök et al. 2003; Tekkök et al. 2005).  In contrast, D-lactate elimination from 
blood occurs at least in part through renal clearance (Connor et al. 1983; Ewaschuk et al. 
2004; Ewaschuk et al. 2005; Jørgensen and Sheikh 1984; Oh et al. 1985; Ullrich et al. 
1982b).  Slow elimination of CSF D-lactate would prolong the effects of neurological 
disturbance and encephalopathy observed in many clinical DLA cases even after treatment 
has been initiated (Petersen 2005; Puwanant et al. 2005; Uribarri et al. 1998).  Serum L-
lactate decline was not exponential and the relatively lower concentrations may be partially 
accountable for our finding of slow removal.  Previous studies show that serum L-lactate is 
cleared through two independent processes, hepatic removal follows second order kinetics 
while extrasplanchnic removal is linearly related to serum concentration (Naylor et al. 
1984).  D-lactate may also be up taken by hepatic and extrahepatic tissue (De Bari et al. 
2002; Naylor et al. 1984), although some is excreted in urine (Connor et al. 1983; 
Ewaschuk et al. 2004; Ewaschuk et al. 2005; Jørgensen and Sheikh 1984; Oh et al. 1985; 
Ullrich et al. 1982b).  
D-lactate is a potent neurotoxic agent.  According to these findings the 
neurological disturbance is strongly related to D-lactate accumulation in CSF rather than in 
blood or to acidosis in CSF.  The D-lactate isomer is neurotoxic and may deplete cellular 
energy metabolism in the nervous tissue.  D-lactate accumulation causes the majority of 
clinical signs of depression and loss of function in a variety of diseases including neonatal 
calf diarrhea and other animal and human syndromes characterized by DLA.  Research 
needs to be undertaken to determine the precise mechanism of neurological depression 
caused by D-lactate. 
In our second research study IV NaHCO3 therapy eased neurological 
disturbances.  NaHCO3 infusion did not produce paradoxical CSF acidosis in calves made 
acidotic with DL-lactic acid.  Rapid NaHCO3 infusion exhibited a trend for more rapidly 
correcting CSF acidosis.  In agreement with the first infusion study, DL-LA infusion 
caused neurological dysfunction with severe ataxia.  The onset of neurological signs was 
delayed, however, signs appeared at lower (~40%) serum and CSF D-lactate 
concentrations.  These lower values are compatible with natural DLA found in 
gastrointestinal diseases (Ewaschuk et al. 2004; Uribarri et al. 1998).  However, our study 
values are higher than the serum D-lactate concentrations of about 3 mmol/L reported in 
some clinical cases (Uribarri et al. 1998).  The suck reflex correlated with acidemia and 
recovered quickly with NaHCO3 therapy (Kasari and Naylor 1986; Lofstedt et al. 1999; 
Lorenz 2004b). 
The slight acidic tide in the CSF during first few hours of NaHCO3 therapy had 
no clinical impact in the paradoxic acidosis experiment.  The rapid increase in blood pH 
may have allowed a rapid flow of CO2 across blood brain barrier from the blood and a 
paradoxical CSF pH decrease (Herrera and Kazemi 1980; Javaheri et al. 1979; Javaheri et 
al. 1983; Kraut and Kurtz 2001).  
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An important finding in the paradoxic acidosis study is that the elimination of D-
lactate from CSF and blood was promoted by rapid NaHCO3 therapy.  Therefore, the value 
of NaHCO3 therapy is confirmed as a quick remedy for DLA (Lorenz and Vogt 2006; 
Lorenz 2007; Petersen 2005; Puwanant et al. 2005).  The mechanism that enhances serum 
D-lactate decrease by NaHCO3 is not well understood.  In a previous study hepatic lactate 
uptake in rat liver (100 μmol/kg . min-1) was increased by 1 mol/L NaHCO3 infusions 
(Beech et al. 1993).  Although D-lactate may not be metabolized by the same enzymes, 
permeation across transporters and membranes may be enhanced (De Bari et al. 2002; 
Hertz and Dienel 2005; Poole and Halestrap 1993; Ullrich et al. 1982b).  Increasing the 
alkalinity of blood with bicarbonate does not modulate D-lactate transport via kidneys, 
however, Na+ and PCO2 have a positive effect on D-lactate transport (Ullrich et al. 1982b). 
Long term exposure (24 h plus) of cells to D-lactate is more comparable to natural 
DLA than short term exposure.  Long term elevations of D-lactate concentrations in blood 
may allow greater penetration of D-lactate into cells and explain the onset of signs of 
neurological disturbance at lower serum D-lactate concentrations than in our more acute 
experiments (Lorenz 2007; Petersen 2005).   
In conclusion for the second research study, in the models of severe prolonged 
acidosis that we used, there appears to be no danger of inducing paradoxical CSF acidosis 
with IV NaHCO3 therapy at commonly used therapeutic infusion rates.  Rapid correction of 
DL-LA-induced acidosis was exceptional in that DL-lactate concentrations decreased fast 
with rapid NaHCO3 therapy and this is presumably the explanation for the absence of 
paradoxical CSF acidosis in this group.  However, our results certainly do not exclude the 
possibility that the effect of NaHCO3 therapy on cellular pH in other critical organs such as 
the heart exist.  Further research studies in animals and humans will be necessary with 
therapies focused to the type and cause of acidosis.   
In our third (clinical research) study diarrheic lambs did not experience DLA 
within the first few days of onset of diarrhea.  Calf diarrhea has resulted in fecal and serum 
D-lactate concentrations of 25 and 14 mmol/L respectively (Ewaschuk et al. 2003; 
Ewaschuk et al. 2004).  In contrast our diarrheic lamb data showed increased serum D-
lactate concentrations but the mean concentrations did not exceed 0.5 mmol/L though fecal 
D-lactate concentrations averaged 14 mmol/L.  Therefore, serum D-lactate concentrations 
were clinically non-significant (< 2 mmol/L) in those lambs.  This may be due to a 
pathophysiological difference (Field 2002) in the process of D-lactate absorption in upper 
intestines of sheep (Ding and Xu 2003).  Lactic acid absorption (~0.1 µmol/cm2.min) in 
sheep intestine was affected by pH, osmotic pressure and lactic acid concentration (Ding 
and Xu 2003).  We found that the threshold level of fecal D-lactate for absorption appeared 
~10 mmol/L or above to reach a measurable serum concentration.  Lactate transporters 
(~MCT) in the gut allow the stereoselective uptake of D-lactate greater than L-lactate 
(Ogihara et al. 2000).  Once the lumen D-lactate concentration increases, MCT may start to 
transport D-lactate into the circulation.  This gut-originated D-lactate would produce 
measurable serum D-lactate concentrations (Ewaschuk et al. 2005; Hove and Mortensen 
1995).  According to current understanding, the excretion of D-lactate from blood may be 
fairly rapid if kidneys are healthy and functionally efficient (Jørgensen and Sheikh 1984; 
Ullrich et al. 1982b).  During the early stages of diarrhea D-lactatemia may not arise as fast 
as in chronic and profound diarrhea cases (Ewaschuk et al. 2003; Ewaschuk et al. 2004) 
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because of efficient urinary excretion (Jørgensen and Sheikh 1984; Ullrich et al. 1982b).  
Serum L-lactate concentrations were high in both healthy and diarrheic lambs.  The reason 
may be acute stress and muscular activity resulting from restraint and sampling (Arola et al. 
1980); the higher values and greater variability in diarrheic lambs may be the result of 
dehydration and poor tissue perfusion in some lambs. 
Lamb diarrhea primarily caused by intestinal infections negatively affects 
enzymatic digestion in the affected portion of the intestines (Field 2002; Tzipori et al. 
1981).  Depending on the type of infection the degree of indigestion and passage of 
nutrients to the colon is altered (Bongaerts et al. 1997; Field 2002; Luckey 1987; Meier et 
al. 2003).  Therefore, we assume that colonic bacterial over-growth may occur secondary to 
lamb diarrhea as observed in calves (Ewaschuk et al. 2004; Hove and Mortensen 1995). 
Urine D-lactate increase in diarrheic lambs does not indicate DLA and is a weak 
marker for clinical DLA as reported by previous authors (Haschke-Becher et al. 2000; 
Inoue et al. 2007; Petersen 2005).  The majority of lambs had moderate diarrhea with only 
minor pathological consequences such as mild metabolic acidosis (Omole et al. 2001).  
Therefore, D-lactate excretion via the kidneys was sufficient to avoid onset of DLA 
(Jørgensen and Sheikh 1984; Ullrich et al. 1982b). 
A linear correlation between anion gap and serum D-lactate concentration was not 
found as in calf diarrhea (Ewaschuk et al. 2004; Omole et al. 1999) hence in early stages of 
lamb diarrhea, D-lactate is not an important contributor to the anion gap in diarrheic lambs.  
Short term or acute lamb diarrhea may be insufficient to cause severe metabolic acidosis.  
Farm management practices have an impact on diarrhea syndromes (Meier et al. 2003).  
Many cases in this study had mild to moderate diarrhea because of better farm conditions.  
Good management was likely the explanation for the mild to moderate diarrhea.  Mild 
enteritis is probably insufficient for marked intestinal D-lactic acid production.  This 
situation would minimize weight loss and the severity of disease consequences.  Therefore, 
further research is needed using lambs with severe and chronic diarrhea to determine if 
DLA exists under these circumstances. 
Our last DLA prevention study with malate supported the effectiveness of Na 
malate to reduce fecal and serum D-lactate concentrations.  In a previous study an effect of 
malic acid to decrease plasma D-lactate was reported (Montano et al. 1999).  We also 
found malate was effective in reducing lactates after 5 days of treatment in a standardized 
setup.  Therefore, malate administration may be an effective long term method of 
preventing DLA.   
Decreased production of lactates in the gut lumen may explain the serum D-
lactate decrease.  Other mechanisms, which enhance D-lactate utilization in the body tissue 
in the presence of malate, may also be responsible.  Hepatic uptake of lactate is the major 
route of serum lactate removal (Ewaschuk et al. 2005; Naylor et al. 1984; Poole and 
Halestrap 1993; Prior 1983).  Rat liver mitochondria can uptake D-lactate rapidly via D-
lactate-malate antipoter and D-lactate may metabolized by D-lactate dehydrogenase present 
in the inner mitochondrial respiratory chain (De Bari et al. 2002).  Modulation of pH is an 
inherent property of malate which is also supportive for D-lactate transport via plasma 
membranes (De Bari et al. 2002; Poole and Halestrap 1993).  
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Colonic lactate production is high even in healthy young calves (Shimomura and 
Sato 2006) thus both D- and L- isomers are high in feces.  Therefore, this study using 
healthy calves to understand the effect of malate on lactate reduction is justified. 
We suggest that prolonged use of malate may be more effective in control of 
potential DLA cases.  Malate can effectively reduce lumen (fecal) D-lactate concentration 
to the threshold (~10 mmol/L) needed for absorption.  This may be possible because malate 
has been used effectively in monogastric nutrition to increase digestive efficacy and 
promote growth through its actions as a buffer or pH modulator (Partanen and Mroz 1999; 
Piva et al. 2002).  In our studies, a moderate malate dose (500 mg/kg BW) was more 
appropriate and consistent than higher or lower dosages.  This dosage is consistent with 
previous work which describes digestive efficacy and growth promotion properties of 
malate (Martin et al. 1999; Montano et al. 1999; Vicini et al. 2003)  
The use of probiotics in calf diarrhea is controversial.  In other species they have a 
positive impact on relieving rotavirus diarrhea, post antibiotic diarrhea and pouchitis 
(Chermesh and Eliakim 2006).  Probiotics are also effective on diarrhea in calves by 
reducing fecal water content (Ewaschuk et al. 2004).  A long debate on the use of organic 
acids as feed additives was also common in nutrition literature (Callaway and Martin 1996; 
Martin 1998; Partanen and Mroz 1999; Piva et al. 2002).  A similar debate surrounds the 
use of malate or malic acid (Evans and Martin 1977; Martin and Streeter 1995; Martin and 
Streeter 1995; Martin et al. 1999; Montano et al. 1999; Russell et al. 1995; Vicini et al. 
2003) in different nutritional or clinical perspectives.  The effectiveness of Na malate in 
clinical cases needed to be further investigated.  
We conclude that oral administration of Na malate dissolved in milk at a rate of 
0.05−0.5 g/kg BW daily for more than a period of 5 days has the ability to reduce fecal and 
serum D-lactate.  Use of malate dissolved in milk would be a worthy, preventive measure 
for on-farm practice.  However, based on our findings, clinical research investigating the 
preventative and treatment potential of malate in metabolic acidosis is obligatory.  
In conclusion, we proved that D-lactate is a potent neurotoxic agent and that 
clinical signs occur experimentally at concentrations similar to these seen in disease.  The 
common alkali treatment, NaHCO3 infusion therapy is safe and effective in the treatment of 
DLA and metabolic acidosis.  Mild to moderately diarrheic lambs do not develop DLA.  
Malate can be used as a prebiotic (or premixer with animal feed) to prevent the onset of 
DLA.  Our research studies shed a new light on understanding DLA and D-lactate 
metabolism and address the prevention, control and treatment of acidosis.  
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APPENDICES 
A: Measurement of high and low concentrations of D-lactate: An 
alternate quantification (analytical) method 
D- and L-lactate concentrations in biological samples (matrices) were measured 
using an HPLC system (see the section 3.1.2.8 Laboratory analyses). 
   
A1: Measurement of high D-lactate concentrations 
Samples could be analyzed without dilution when concentrations are expected to 
be within 0.5-40 mmol/L in order to achieve accurate measurement within our (normal 
standard curve) detection range (0.5–10 mmol/L).  Otherwise, samples are appropriately 
diluted after identifying they contain higher concentrations (> 40 mmol/L) to gain accurate 
detection (Buglass and Lee 2003; Ohmori and Iwamoto 1988; Okubo et al. 2000; Tormo 
and Izco 2004).  In our model experiments we applied this dilution procedure.  All dilutions 
are performed using deionized water from a Milli-Q synthesis A10 (Millipore Corporation, 
Bedford, Massachusetts, USA). 
  
A2: Measurement of low D-lactate concentrations 
Low lactate concentrations (<0.5 mmol/L) are run with a low concentration linear 
standard curve (0.05-1.0 mmol/L).  By this way we can eliminate curving error effect of 
very low to very high concentrations (large range).  
We also workout to use high sample volume (> 100 μL) in sample preparation 
(substituting water volume) or high injection volume (> 10 μL) in the autosampler for 
dispatching higher D-lactate quantity to the column for a countable separation to achieve a 
visible and quantifiable detection (Buglass and Lee 2003; Ohmori and Iwamoto 1988; 
Okubo et al. 2000; Tormo and Izco 2004).  A standard curve equation (y = mx + c) 
supports quantifiable concentrations > 0.05 mmol/L.  However, values < 0.04 mmol/L is 
not used in statistical calculations and 0.04 mmol/L was used as the lowest limit for 
statistical purposes. 
   
  
 
 
 II 
  
 
 
 
Figure 25 (Appendix A). Appearance of D- and L- isomer peaks at the concentration of 
0.05 mmol/L DL-lactic acid in a volume of 100 μL sample following an injection of 10 μL 
to HPLC system. D-isomer appears at 11.115 min and L-isomer appears at 13.267 min. L-
isomer is taller than D-isomer because of the interference of L-lactates from adding 
standard (healthy) serum. 
 
 
 
Figure 26 (Appendix A). After increasing injection volume to 20 μL, D- and L- isomer 
peaks at the concentration of 0.05 mmol/L DL-lactic acid in a volume of 100 μL sample 
appeared taller. D-isomer appears at 13.091 min and L-isomer appears at 15.874 min. L-
isomer is taller than D-isomer because of the interference of standard serum L-lactates. 
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B: Surgical procedures; a calf model for repeated sampling of CSF and 
blood 
B1: Introduction 
Repeated sampling of CSF is a requirement in many neurological research 
studies.  However, in common practice the placement and existence of CSF catheter in 
many species are not satisfactorily attainable or successful.  A main constraint with CSF 
epidural catheter, reported by many authors is the rapid development of fibrous tissue 
around the catheter, which quickly limits the usefulness of the epidural catheter (Iwase et 
al. 2002). 
The main sites of CSF sampling were the lumba-sacral and atlanto-occipital 
(Dyce et al. 1996).  The atlanto-occipital site reaches cisterna magna (cerebellomedullary 
cistern) which seems to be a more convenient site for calves and other animals such as 
rodents.  A prerequisite for accurate studies on cisternal CSF is that its composition is not 
significantly influenced by the sampling technique per se (Huang et al. 1995).  
It is important to perform the experiment under least injurious conditions 
(atraumatic or normal and undistorted) a much as possible (Cox and Littledike 1978; De 
Craene et al. 1997).  In order to over come those mishap, we develop a calf model with 
indwelling CSF catheter, two venous catheters, and arterial catheter to ensure frequent 
sampling (every 1-2 h), and infusions to last more than two weeks.  In the process of 
developing a surgically catheterized model, 24 calves were subjected.  Calves are fixed 
with atlanto-occipital CSF catheter, 2 jugular (left and right) venous catheters and ear 
arterial catheter, infusing stressful acids and repeatedly sampling CSF, venous and arterial 
blood for 2 weeks. 
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B2: Materials and Methods 
B2.1: Surgery 
The surgery is performed in the Department of Large Animal Clinical Science, 
Western College of Veterinary Medicine, University of Saskatchewan.  The calves were 
premedicated with intravenous hydromophone at 0.1 mg/kg, sometimes in combination 
with metatomidine at 7 μg/kg or medetomidine at 4 μg/kg, induced with a combination of 
ketamine at 2 to 6 mg/kg and diazepam at 0.1 to 0.5 mg/kg, intubated and maintained under 
gaseous isoflurane anesthesia.  Strict aseptic technique was followed throughout the 
catheter placement procedure. 
 
B2.1.1: Atlantooccipital catheter 
The calf is appropriately anesthetized and kept in lateral recumbence.  A 12 by 12 
cm area of the skin, centered on the atlanto-occipital space is surgically prepared (Bouman 
and Van Wimersma Greidanus, T.B. 1979; Cox and Littledike 1978; Gordh and Wiklund 
1986; Jones and Robinson 1981).  The calf head is flexed in 90 degree angle by the 
assistant.  A stab incision 3 mm wide and 7 mm deep is made with a #15 scalpel blade 
through the skin over the atlanto-occipital space (2/3 from the posterior end of atlas 
towards the level of lateral ridges of occipital vertebra).  A spinal (Tuohy) needle (18 G, 9 
cm) from a freshly opened epidural kit (Mila International Inc., Kentucky, USA) is inserted 
(controlled jabbing, 3-5 cm from the skin depending on the body size of the calf) into the 
subarachnoid space (cisterna magna, site confirmed by needle ‘pop’ and aspiration / flow 
of CSF fluid; several 'pops' may be felt as the needle passes through various tissue planes; 
Figure 27 and Figure 28).  It is vital to ensure that the needle is parallel to the floor (or 
surgery table) and is being advanced perpendicularly to the patient's spine exactly on the 
patient's midline and that the open bevel of the needle tip is facing caudally.  The stylet of 
the Tuohy needle is then removed and carefully wiped on a sterile portion of the gloved 
hand to ensure no cerebrospinal fluid is visible.  Accurate placement of the needle into the 
epidural / subarachnoid space is then verified using the loss of resistance, and free flow of 
clear cerebrospinal fluid.  The catheter (20G, 9203 wire reinforced, closed end) is threaded 
10 to 15 cm into the space, the needle withdrawn, a sampling adaptor and 0.22 µ bacterial 
filter device attached to the open end of the tube.  A clean tape butterfly or clamp style 
rubber butterfly from the kit fixed the catheter near the skin-catheter interface is sutured to 
ensure that the catheter is rigid, but, flexible and unlikely to kink.  The sampling tip 
(infusion cap) of CSF catheter is placed in a sterile plastic bag with an antiseptic such as 
hibitane.  
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Figure 27 (Appendix B). CSF / epidural needle (Tuohy) is inserted through atlanto 
occipital junction of a calf. 
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Figure 28 (Appendix B). CSF catheter placement through atlanto-occipital joint: 1, 
calvaria; 2, occipital; 3, atlas; 4, cerebellum + colliculus + medulla oblongata area; 5, 
Tuohy needle pointed to duramater + epidural space + subarachnoid space in 
cerebellomedullary cistern (adopted from Dyce et al.1996). 
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B2.1.2: Intravenous catheter 
An incision is made with a #15 scalpel blade on a side of the calves’ neck adjacent to the 
jugular vein after this area has been shaved and appropriately disinfected (surgically 
prepared).  A catheter is made using clean vinyl tube (Dural Plastics & Engineering, 
Auburn, Australia) with an inner diameter of 1 mm and a length of 45 cm.  The catheter is 
placed through a needle into the jugular veins. The catheter is placed 25-30 cm into the 
vein (depending on the calf body weight), and tunneled subcutaneously (5-6 cm) to 
maximize the durability.  Then it is sutured to the skin with sutures using a piece of tape 
folded in butterfly shape.  Both jugulars are catheterized; one catheter will be used for 
infusion and the other for blood sampling. 
 
B2.1.3: Arterial catheter 
Dorsal surfaces of ears are shaved and surgically prepared.  A freshly opened arterial 
catheter (BD InsyteTM, Becton Dickinson, Infusion Systems Inc., Sandy, Utah, USA) was 
placed in (22 G [0.9 mm] × 25 mm of length) ear (auricular) artery on the dorsal surface of 
one of the ears.  The catheter is fixed and glued or sutured with a clean tape.  The entire 
neck is covered with sterile dressing to protect the three catheters.  Pockets are designed in 
the dressing to allow easy access to the catheters, and endured maximum security to all 
catheters from later animal accidents and aberrations. 
Calves are clinically evaluated everyday for change in body temperature or other 
discomforts.  Daily body temperature is recorded.  
B2.2: Justification 
Catheterization of the atlantooccipital space is chosen as it was deemed more successful 
than catheterization of the lumbosacral space in previous attempts. Compared to the 
lumbosacral space, catheters in the atlantooccipital space were placed easier and lasted 
longer.  The reason may be the space in cisterna magna being larger. An iso-osmotic 
infusate is used, as it is least likely to cause hemolysis or other complications. 
 
B2.3: Statistical analysis 
Data were analyzed using SPSS v13, 2003. SNK (mean comparison) and Pearson 
correlation procedures were also performed.  A P < 0.05 was considered as evidence of 
statistical difference.  
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Table 6 (Appendix B). Viability of catheters placed in calves 
Calf 
CSF 
catheter CSF quality (1 wk) 
Venous 
catheter 
Arterial 
catheter 
> 1 or 2 
wk color Protein g/L 
RBC 
10_6/L 
Nucleated cells 
10_6/L 
> 1 or 2 
wk 
> 1 or 2 
wk 
        
488 1 c 0.2 1000 3 2 1 
498 1 c 0.3 10 16 2 1 
499 2 c 0.2 1 3 2 1 
501 1 c 0.3 1 5 2 1 
502 2 c 0.2 1 1 1 1 
504 1 c 0.2 1 8 2 2 
526 2 c 0.3 1 10 2 1 
527 2 c 0.2 10 6 1 1 
530 2 c 4 99 187 2 2 
534 2 t 5 1 7000 2 2 
560 2 c 0.2 74 1 2 1 
572 1 t 5 1 7000 2 1 
610 2 c 0.3 44 16 2 1 
660 2 c    2 2 
528 2 c    2 1 
541 2 c    2 2 
546 2 c    2 2 
319 1 t    1 1 
489 2 c    2 2 
536 2 c    2 1 
573 2 c    2 1 
580 2 c    2 2 
529 2 c 2 1 
556 2 c 2 1 
549 2 c 2 2 
Visual quality of CSF (color): c for clear and t for turbid. 
RBC, red blood cells 
wk, weeks. 
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Figure 29 (Appendix B). X-ray picture after surgery; Ci, catheter inside portion in 
subarachnoid space; Co, catheter outside portion on skin; red arrow showed the site of 
insertion. 
 
 
 
Figure 30 (Appendix B). Post surgical rapping around cervical area is applied for securing 
the site of catheter. CSF sample (~0.7 mL) is carefully aspirated after removing a 0.2 mL 
dead volume.
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Figure 31 (Appendix B).  Calf’s body weight correlates with CSF catheter needle insertion 
length (skin to epidura).  The needle insertion length (y) can be calculated using the 
equation, y = 0.5x + 0.5 where x is calf’s body weight (kg). Correlation coefficient (r) is 
0.9 (P > 0.05). 
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B3: Results and discussion 
B3.1: CSF catheter 
Accurate placement of CSF catheter radio-graphically confirmed (Figure 3).  Safe 
sampling could be carried out (Figure 30) with minimal animal restraining by a single 
technician.  There as no any noticeable discomfort either to animal or sampler.  The 
existence of indwelling CSF catheter over 2 weeks was successful (90%, Table 6) with 
stressful infusions.  Free CSF flow and clear fluid were found (> 75%) over 2 week period.  
However, CSF quality was deteriorating with time (50%) indicating higher cell counts and 
protein content.  The difficulty in maintaining an entirely aseptic environment around the 
catheter seemed to be a main reason to provoke signs of cell reaction (infection and 
inflammation).  No microbes were found except single case (> 5%) in the CSF samples.  
There was a strong correlation (r = 0.9) between calf body weight and the length of CSF 
catheter needed to penetrate into cisterna magna for free flow of CSF (Figure 31).  This 
relationship which could be estimated with this simple formula, y = 0.05x + 0.5, may torch 
guidance in future CSF catheterizations. 
 
B3.2: Implications 
This cauterization model would be useful to future neuro-metabolism studies.  
These procedures may be applicable to other species such as canine, feline and caprine. 
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C: Diarrheic calf fecal D-lactate threshold 
Data from diarrheic calves collected in 2001 to 2004 by our research group was 
analyzed to find fecal D-lactate threshold. 
 
 
Figure 32 (Appendix C). Break Point Analysis showing a threshold concentration for 
absorption when fecal D-lactate exceeded 8.82 mmol/L (↑) in diarrheic calves.  The 
regression equation for Break Point Analysis consists of serum D-lactate concentration (y), 
fecal D-lactate concentration (x) and a dummy variable (z), n = 23.  The equation for the 
estimated thresh hold is shown below. 
Equation 5. y = -9.45119 + 0.80199 x + 9.70740 z - 0.56156 (x*z)  
This equation definitions indicate, z = 0 for the fist line and z = 1 for the second line.  First 
regresssion line (—, strait) was associated with square shape ( ) data points and the 
second regression line (----, broken) was associated with triangular ( ) data points.  Linear 
Correlation between fecal and serum D-lactate concentrations (r = 0.75).  Pease see the 
section 4.1.3.2.1 (Figure 18) for diarrheic lamb’s fecal D-lactate threshold. 
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D: Ethics certificates 
Copies of Ethics Certificates for both model and clinical experiments are shown 
below.   
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E: Study Protocols 
Protocols and Tables for both model and clinical experiments are shown below. 
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Table 7 (Appendix E).  Infusate composition; pre versus post autoclaved DL-lactic acid, 
L-lactic acid and HCl. 
 
* Hitachi blood gas machine 
† Digital chloride meter 
nq, not quantified (concentrations were lower than our detection limit, 0.05 mmol/L). 
 
 
Infusate Measurement   Pre-autoclaved         Post-autoclaved 
DL-lactic acid Weight, % 100 99.93 ± 0.02 
 Total lactate, mmol/L 292.9 ± 4.2 302.7 ± 4.6 
 D-lactate, mmol/L 141.5 ± 1.4 144.7 ± 1.1 
 L-lactate, mmol/L 146.5 ± 2.0 150.6 ± 1.4 
L-lactic acid Weight, % 100 99.92 ± 0.02 
 Total lactate, mmol/L 295.5 ± 3.9 299.8 ± 4.1 
 D-lactate, mmol/L nq nq 
 L-lactate, mmol/L 293.6 ± 3.7 299.1 ± 4.3 
HCl Weight (%) 100 99.92 ± 0.03 
 Chloride*, mmol/L 358.6 ± 5.7 364.7 ± 4.1 
 Chloride†, mmol/L 304.5 ± 2.0 313.1 ± 2.6 
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A sample Table for recording basic information on infusions and calves is shown 
below. 
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A sample Table used for recording blood gas results during the experiment (24 h) is 
shown below. 
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A sample Table for recording neurological examination results and body temperature 
during the experiment (24 h) is shown below. 
 
   
  
 
 
 XXVI 
  
 
A sample Table for recording acid infusion information and progress during the 
experiment (24 h) is shown below. 
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A sample Table for recording blood gas results during the experiment (48 h) is shown 
below 
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A sample Table for recording changes of neurological signs and body temperature 
during the experiment period (48 h) is shown below. 
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A sample Table for recording acid infusion or bicarbonate therapy information and 
progress is shown below. 
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Protocol for Lamb Diarrhea and Acidosis Trial 
·  
·Investigators 
 
Principal Investigator: Dr. Jonathan M. Naylor  
    Western College of Veterinary Medicine 
 
Co-investigator : Dr. Gordon A. Zello 
    College of Pharmacy and Nutrition 
 
Grad student  : Saman Abeysekara (Sam) 
    College of Pharmacy and Nutrition 
 
Contact  : 966-5831/6913 or 373-4107 (Sam) 
    Saman.abeysekara@usask.ca 
 
Title:  D-lactic acid levels in diarrheic lambs 
 
Objective 
 
1. To determine if D-lactic acid contents increase in diarrheic lambs, and supports 
acidosis.  
 
Methodology 
Study Design 
 
 Sampling (serum, feces and urine) of diarrheic lambs the University sheep barn 
will be conducted throughout the year.  We hope to ensure the coverage of at least 
15 cases per year.  
 Blood (10 mL), fecal (100 g) and urine (10 mL) samples will be collected from 
scouring lambs.  In order to have a control, whenever samples are collected from 
diarrheic cases, a sample will be taken from a healthy lamb.  All samples will be 
stored at -20°C until analysis.  Blood serum will be analyzed for lactate, other 
organic acids, electrolytes and blood gases. Feces will be analyzed for lactates.  
Urine will be analyzed for lactates, other organic acids and electrolytes.  Data will 
be statistically analyzed by Proc t-test with unequal variance using SAS. 
 
Sample Collection  
 
1. Blood 
 A blood (5 mL) sample will be collected from anerobically from the jugular 
vain of lambs in a preheparinized plastic syringe (Smooth; Radiometer America, 
Westlake, Ohio, USA) for blood gas measurements.  A second blood sample (5 
mL) for the determination of serum organic acid concentration will also be collected 
into a tube containing no anticoagulant (Vacutainer; Becton Dickinson, Rutherford, 
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New Jersey, USA).  Blood sampling would be conducted with the help of the 
Department of Large Animal Clinical Sciences. 
 
2. Feces 
 Fecal samples (50 g) will be collected into a cream color plastic container which 
contains a preservative (thiomersal).  Thiomersal is a toxic substance, containing a 
small amount of mercury.  Therefore, you should not spill or contact thiomersal 
bear hand.  Always use gloves when you are sampling or handling. 
Scouring/diarrhea will be determined in lambs depending on fecal scoring for 
clinical diarrhea. 
***Fecal score is based on the consistency and volume of faces. 
• Volume:  filling of tray (rank 1-4) 
• Consistency   Rank 
1. Firm   0 
2. Pasty   1 
3. Loose   2 
4. Watery   3  
• Fecal score will be the sum of these two ranks  
(Volume + consistency = 0Æ7), Maximum fecal score is 7.  
• Clinical diarrhea (scouring) is defined as a score over 2.5. 
 
3. Urine 
 Urine (5-10 ml) will be collected into a urine collecting tube.  Urine collection will 
be performed at micturition or using a urinary catheter. 
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Procedure: 
• When you find a scouring lamb: 
1. Record the lamb number, body (rectal) temperature and 
the scouring number on the given record sheet 
2. Take initial samples from the lamb  
9 Feces – cream color containers  
9 Blood – red top tubes and green top tubes 
9 Urine – given tubes 
3. Take samples from a healthy lamb, record lamb number, 
and body temperature as a control 
4. All the collected samples should be well covered in the 
containers, (should be refrigerated within a half an hour of collection) 
5. Avoid sampling the same lamb next time (either a 
scouring or a control) 
 
Regularly / everyday we may visit the barn to look for new scouring 
lambs. Or you can call us (Sam) at anytime.  
Tel  – day time/office :  966-5831  
       -  cell   : 261-0248 
        – night/home : 373-4107  
 E-mail   : saman.abeysekara@usask.ca 
 
   
  
 
 
 XXXV 
  
 
 
A sample Table for recording lamb information. 
 
Lamb Diarrhea and Acidosis Trial 
 
Lamb Information      Date: 
      
ID Number Date of Birth Sex Remarks 
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Protocol for Prebiotic (Malate) Trial 
 
· Investigators 
 
Principal Investigator: Dr. Jonathan M. Naylor  
    Western College of Veterinary Medicine 
 
Co-investigator : Dr. Gordon A. Zello 
    College of Pharmacy and Nutrition 
 
Grad student  : Saman Abeysekara 
    College of Pharmacy and Nutrition 
 
Contact  : 966-5831/6913 or 373-4107 (Sam) 
 
 
· Project Title 
  
Oral use of malate, as a prebiotic, to manipulate gut flora and to reduce lactic 
acid production in calves 
 
 
· Project Outline 
 
Objectives 
 
4. To determine the effective dose of malate (a prebiotic) to observe a 
biological response in calves. 
5. To determine if malate reduces lactic acid production in calves’ colon. 
 
 
 
Methodology 
Study Design 
Twelve Holstein calves (age below 2 months) from the Dairy Barn, University of 
Saskatchewan will be selected and randomly allocated in to 3 groups; G1, G2, G3 
where 4 calves would be in each group.  After an adaptation period of 5 days for a 
relatively uniform diet these calves will be given sodium malate in three different 
dosages for consecutive 5 days.  The groups; G1, G2 and G3 will receive daily 
dose of 50, 500 and 1000 mg kg-1 respectively.  Malate can be mixed with feed / 
milk given to calves in the morning.  Malate daily treatment doses would be pre-
weighed for each calf, labeled and made available accordingly.  The guidelines of 
the Canadian Council on Animal Care (CCAC, 1993) will be followed in dealing 
with the calves.  
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 Sample Collection  
 
Fecal and jugular blood (serum) samples will be taken at the date of start (day 0), 
day 4 and day 7 (at 8.00–9.00 h just prior to feeding).  Blood sampling would be 
conducted with help of the Dept. of Large Animal Clinical Sciences. 
  
 Sample Analysis 
  
Serum will be analyzed for  
 
i. Organic acids (D-lactic acid and L-lactic acid) 
ii. Electrolytes (HCO3-, Cl-, Na+, K+, Ca++) 
iii. Blood gases (base excess, bicarbonate, pCO2, pO2)  
iv. pH, anion gap 
v.  Hemoglobin 
vi.  Glucose 
 
Feces will be analyzed for organic acids.  The high performance liquid 
chromatography (HPLC) would be preferred methods of sample analysis as 
required.  
 
 
Data Analysis 
 
Values for the samples of day 0 will be the control for each variable.  Data will be 
statistically analyzed using appropriate statistical techniques. 
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A sample Table for recording information on calf and treatment in malate prebiotic 
experiment is shown below. 
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A sample Table for recording laboratory results of blood samples in malate prebiotic 
experiment is shown below. 
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A sample Table for recording the detailed laboratory results of malate experiment is 
shown below.  
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F: Program for SAS 
SAS for Windows v.8 was used to perform repeated measures / polynomial 
analysis, MANOVA and contrast of experimental model studies data.  Breakpoint 
regression analysis of clinical studies data were performed using SAS. 
F1: A sample SAS program for repeated measures analysis used in experimental 
model studies 
data VenpO2; 
input CalfNo Aged Treatment$ t1-t12; 
cards; 
504 36 D-Lactic 30 33 31 37 38 42 47 40
 51 35 34 32 
504 35 L-Lactic 28 31 28 49 31 30 31 30
 34 25 36 34 
502 45 D-Lactic 33 34 43 34 38 39 41 41
 41 39 44 30 
502 44 L-Lactic 29 36 33 38 35 34 37 39
 32 32 36 34 
502 42 HCL 29 33 34 37 38 41 38 41 40
 41 34 33 
502 41 Saline 34 31 37 36 35 33 34 33
 33 32 30 32 
501 34 HCL 35 35 51 52 50 49 31 39 35
 31 33 32 
499 52 Saline 44 35 35 40 34 37 56 35
 38 39 43 36 
499 50 L-Lactic 42 32 36 44 41 35 36 38
 34 41 41 92 
499 48 HCL 30 38 40 49 48 51 60 49 56
 44 45 37 
499 47 D-Lactic 40 36 93 36 31 46 52 59
 45 41 51 40 
498 39 Saline 32 35 33 34 36 35 31 36
 31 35 38 36 
498 37 L-Lactic 30 38 40 41 33 53 45 31
 38 46 88 32 
660 40 HCL 37 41 40 43 46 41 39 40 40
 28 46 49 
660 38 L-Lactic 37 38 35 38 35 36 57 34
 133 37 34 39 
660 32 Saline 38 38 46 43 39 40 41 39
 38 39 39 41 
660 30 D-Lactic 40 41 46 35 40 39 48 44
 53 37 53 43 
489 27 HCL      31 27 29 38 35 28 33
 33 42 29 67 37 
489 25 L-Lactic 33 41 36 35 42 40 58 37
 35 40 36 36 
489 23 Saline  65 31 37 35 38 31 32
 40 56 37 35 42 
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489 17 D-Lactic 27 45 33 44 39 34 93 36
 36 45 26 34 
488 17 Saline  35 32 40 45 42 33 60
 32 27 37 31 39 
488 15 D-Lactic 31 34 40 47 38 43 47 46
 52 56 45 42 
; 
run; 
proc print data=VenpO2; 
run; 
 
 
proc sort data=VenpO2; 
by Treatment; 
run; 
 
proc means data=VenpO2 mean std stderr LCLM UCLM;  
var t1-t12; 
by Treatment; 
run; 
 
 
proc glm; 
class Treatment; 
model t1-t12=Treatment; 
repeated time 12(-1 0 1 2 3 4 5 6 7 8 10 24) polynomial/ summary; 
means Treatment/SNK; 
run; 
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F2: A SAS program for breakpoint regression analysis  
data ex; 
input Fecal_DL Serum_DL; 
cards; 
4.1  0 
5.6  0 
10.2 0 
8.7  0 
12.3 0 
7.4  0 
11.5 0.04 
14.3 0.37 
9.7  0 
6.8  0 
5.7  0 
8.2  0 
5.8  0 
18.2 0.61 
15.7 0.39 
13.7 0 
9.5  0 
6.7  0 
12.1 0 
7.5  0 
5.7  0 
4.7  0 
7.8  0 
13.7 0.11 
7.4  0 
12.6 0.42 
11.7 0.4 
4.2  0 
3.3  0 
3.6  0 
2.4  0 
; 
run; 
proc sort; 
by Fecal_DL; 
run; 
data ex1; 
set ex; 
D=0; 
if Fecal_DL <10 then D=1; 
FD=Fecal_DL*D;  
run; 
proc reg data=ex1; 
model Serum_DL=Fecal_DL D FD; 
run;  
 
